

?d s1/3/1-12

Display 1/3/1

08504054 93214054

Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor.

Neben S; Marcus K; Mauch P

Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.

Blood (UNITED STATES) Apr 1 1993, 81 (7) p1960-7, ISSN 0006-4971

Journal Code: A8G

Languages: ENGLISH

Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/2

08453069 93163069

Peripheral blood stem cell mobilization by cytokines.

Ahmed T; Wuest D; Ciavarella D

New York Medical College, Valhalla 10595.

J Clin Apheresis (UNITED STATES) 1992, 7 (3) p129-31, ISSN 0733-2459

Journal Code: HID

Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

- end of record -

?

Display 1/3/3

08392390 93102390

Peripheral blood stem cell mobilization after stem cell factor or G-CSF treatment: rapid enrichment for stem and progenitor cells using the CEPRATE immunoaffinity separation system.

Heimfeld S; Fogarty B; McGuire K; Williams S; Berenson RJ

CellPro, Incorporated, Bothell, Washington 98021.

Transplant Proc (UNITED STATES) Dec 1992, 24 (6) p2818, ISSN

0041-1345 Journal Code: WE9

Languages: ENGLISH

Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/4

08095168 92233168

[The role of stem cell mobilization in the scope of autologous blood stem cell transplantation]

Die Rolle der Stammzell-Mobilisation im Rahmen der Autologen Blutstammzell-Transplantation (ABSZT).

Korbling M

M. D. Anderson Cancer Center, University of Texas, Houston.

Beitr Infusionther 1991, 28 p233-41, ISSN 1011-6974 Journal Code:

BZI

Languages: GERMAN Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL English Abstract

- end of record -

?

Display 1/3/5

07865980 92003980

~~6/17~~

Medline

6/17-93

Transplantation with blood stem cells.
Zander AR; Lyding J; Bielack S
Department of Hematology-Oncology, Universitätskrankenhaus Eppendorf,
Hamburg, FRG.
Blood Cells 1991, 17 (2) p301-9, ISSN 0340-4684 Journal Code: A8H
Languages: ENGLISH
Document type: JOURNAL ARTICLE; REVIEW; REVIEW, TUTORIAL

- end of record -

?

Display 1/3/6

07765556 91284556
Mobilization of haemopoietic stem cells by cyclophosphamide into the
peripheral blood of patients with haematological malignancies.
Shepherd KM; Charles P; Sage RE; Dale BM; Norman JE; Kotasek D; Gregg A;
Futter J
Department Haematology/Oncology, Queen Elizabeth Hospital, Woodville,
Australia.
Clin Lab Haematol 1991, 13 (1) p25-32, ISSN 0141-9854
Journal Code: DKF
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/7

07408512 90315512
The median daily increment of leukocytes during hematopoietic recovery
reflects the myeloid progenitor cell yield during leukapheresis in
children.
Emminger W; Emminger-Schmidmeier W; Hocker P; Gerhartl C; Kundi M; Gadner
H
St. Anna Children's Hospital, Vienna, Austria.
Bone Marrow Transplant Jun 1990, 5 (6) p419-24, ISSN 0268-3369
Journal Code: BON
Languages: ENGLISH
Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/8

07292259 90199259
Therapeutic efficacy of autologous blood stem cell transplantation
(AB SCT): the role of cytotoxic/cytokine stem cell mobilization.
Korbling M; Haas R; Knauf W; Holle R; Hunstein W
Institut f. Medizinische Biometrie, Heidelberg University, FRG.
Bone Marrow Transplant Jan 1990, 5 Suppl 1 p39-40, ISSN 0268-3369
Journal Code: BON
Languages: ENGLISH
Document type: CLINICAL TRIAL; JOURNAL ARTICLE

- end of record -

?

Display 1/3/9

06054168 87028168
Complement split product C5a mediates the lipopolysaccharide-induced
mobilization of CFU-s and haemopoietic progenitor cells, but not the
mobilization induced by proteolytic enzymes.
Molendijk WJ; van Oudenaren A; van Dijk H; Daha MR; Benner R
Cell Tissue Kinet Jul 1986, 19 (4) p407-17, ISSN 0008-8730
Journal Code: CQA
Languages: ENGLISH

- end of record -

?

Display 1/3/10

04259195 81087195

Pyran copolymer: effect of molecular weight on stem cell mobilization in mice.

Zander AR; Spitzer G; Verma DS; Ginzburg S; Dicke KA

Biomedicine May 1980, 33 (3) p69-72, ISSN 0300-0893 Journal Code:

ASP

Contract/Grant No.: CA-24770; CA-23077

Languages: ENGLISH

Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/11

03321676 77223676

Mobilization of B and T lymphocytes and haemopoietic stem cells by polymethacrylic acid and dextran sulphate.

van der Ham AC; Benner R; Vos O

Cell Tissue Kinet Jul 1977, 10 (4) p387-97, ISSN 0008-8730

Journal Code: CQA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

- end of record -

?

Display 1/3/12

02860675 76041675

Polymethacrylic acid: induction of lymphocytosis and tissue distribution.

Ross WM; Martens AC; van Bekkum DW

Cell Tissue Kinet Sep 1975, 8 (5) p467-77, ISSN 0008-8730

Journal Code: CQA

Languages: ENGLISH

Document type: JOURNAL ARTICLE

| Set | Items | Description |
|-----|-------|---|
| S1 | 12 | STEM(W)CELL(W)(MOBILIZ? OR PERIPHERALIZ?) |
| S2 | 22 | VERY(W)LATE(W)ANTIGEN(W)4 |
| S3 | 0 | S2 AND STEM(W)CELL |
| S4 | 183 | VASCULAR(W)CELL(W)ADHESION(W)MOLECULE |
| S5 | 1 | S4 AND STEM(W)CELL |

?

Display 5/3/1

00217769 92355769

Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma.

Teixido J; Hemler ME; Greenberger JS; Anklesaria P

Department of Tumor Virology, Dana Farber Cancer Institute, Boston, Massachusetts 02115.

J Clin Invest Aug 1992, 90 (2) p358-67, ISSN 0021-9738

Journal Code: HS7

Contract/Grant No.: CA-39851; DE-08798; CA42368

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Display 1/3/3 (Item 3 from file: 5)

BROSIS
+

9805466 BIOSIS Number: 44055466

PERIPHERAL BLOOD STEM CELL MOBILIZATION AFTER STEM CELL FACTOR OR G-CSF
TREATMENT RAPID ENRICHMENT FOR STEM AND PROGENITOR CELLS USING THE CEPRATE
IMMUNOAFFINITY SEPARATION SYSTEM

HEIMFELD S; FOGARTY B; MCGUIRE K; WILLIAMS S; BERENSON R J

CELLPRO INC., 22322 20TH AVE. SE, SUITE 100, BOTHELL, WASH. 98021.

FIRST INTERNATIONAL CONGRESS OF THE CELL TRANSPLANT SOCIETY, PITTSBURGH,
PENNSYLVANIA, USA, MAY 31-JUNE 3, 1992. TRANSPLANT PROC 24 (6). 1992.

2818. CODEN: TRPPA

Language: ENGLISH

Document Type: CONFERENCE PAPER

- end of record -

?

Display 1/3/5 (Item 5 from file: 5)

9769786 BIOSIS Number: 44019786

COMPARISON OF PERIPHERAL BLOOD STEM CELL MOBILIZATION BY THREE REGIMENS

JANSSEN W E; ELFENBEIN G J; LEE C; SMILEE R; CARTER R; PACH M; LEPARC G F
; SINALDI E; MASSARO P; ET AL

H. LEE MOFFITT CANCER CENT., UNIV. SOUTH FLA. COLL. MED., TAMPA, FLA.

45TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF BLOOD BANKS, SAN
FRANCISCO, CALIFORNIA, USA, NOVEMBER 7-12, 1992. TRANSFUSION (ARLINGT) 32

(8 SUPPL.). 1992. 43S. CODEN: TRANA

Language: ENGLISH

Document Type: CONFERENCE PAPER

- end of record -

?

Display 1/3/6 (Item 6 from file: 5)

9347558 BIOSIS Number: 43092558

PERIPHERAL BLOOD STEM CELL MOBILIZATION AFTER STEM CELL FACTOR SCF ON
G-CSF TREATMENT RAPID ENRICHMENT FOR STEM AND PROGENITOR CELLS USING THE
CEPRATE IMMUNOAFFINITY SEPARATION SYSTEM

HEIMFELD S; ANDREWS R; ZSEBO K; FOGARTY B; MCGUIRE K; WILLIAMS S;
BERENSON R

CELLPRO INC., BOTHELL, WASH.

XXI ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR EXPERIMENTAL
HEMATOLOGY, PROVIDENCE, RHODE ISLAND, USA, JULY 26-30, 1992. EXP HEMATOL (N
Y) 20 (6). 1992. 748. CODEN: EXHMA

Language: ENGLISH

Document Type: CONFERENCE PAPER

- end of record -

?

Display 1/3/7 (Item 7 from file: 5)

8884735 BIOSIS Number: 42109735

PERIPHERAL BLOOD STEM CELL MOBILIZATION RAPID ENRICHMENT OF PROGENITOR
CELLS USING A UNIQUE BIOTIN-AVIDIN IMMUNOAFFINITY SEPARATION SYSTEM

HEIMFELD S; BENSINGER W; FOGARTY B; MCGUIRE K; WILLIAMS S; ZSEBO K;
BERENSON R

CELLPRO INC., BOTHELL, WASH. 98021.

KEYSTONE SYMPOSIUM ON HEMATOPOIESIS, TAMARRON, COLORADO, USA, FEBRUARY
27-MARCH 5, 1992. J CELL BIOCHEM SUPPL 0 (16 PART C). 1992. 65. CODEN:
JCBSD

Language: ENGLISH

Document Type: CONFERENCE PAPER

- end of record -

?

Display 1/3/8 (Item 8 from file: 5)

8871887 BIOSIS Number: 42096887

PERIPHERAL BLOOD STEM CELL MOBILIZATION RAPID ENRICHMENT OF PROGENITOR

CELLS USING A UNIQUE BIOTIN AVIDIN IMMUNOAFFINITY SEPARATION SYSTEM
 BERENSON R; ANDREWS R; BENSINGER W; FOGARTY B; MCGUIRE K; WILLIAMS S;
 HEIMFELD S
 CELLPRO INC., BOTHELL, WASHINGTON 98021, USA.
 KEYSTONE SYMPOSIUM ON BONE MARROW TRANSPLANTATION, KEYSTONE, COLORADO,
 USA, JANUARY 19-26, 1992. J CELL BIOCHEM SUPPL 0 (16 PART A). 1992. 189.
 CODEN: JCBSD
 Language: ENGLISH
 Document Type: CONFERENCE PAPER

- end of record -

?
 Display 1/3/12 (Item 12 from file: 5)

7329393 BIOSIS Number: 38109914
 THERAPEUTIC EFFICACY OF AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION ABSC
 THE ROLE OF CYTOTOXIC-CYTOKINE STEM CELL MOBILIZATION
 KOERBLING M; HAAS R; KNAUF W; HOLLE R; HUNSTEIN W
 MED. KLINIK POLIKLINIK V, INST. F. MED. BIOMETRIC, HEIDELBERG UNIV., FRG.
 INTERNATIONAL SYMPOSIUM ON PERIPHERAL BLOOD STEM CELL AUTOGRAFTS,
 MULHOUSE, FRANCE, OCTOBER 15-17, 1989. BONE MARROW TRANSPLANT 5 (SUPPL. 1).
 1990. 39-40. CODEN: BMTRE
 Language: ENGLISH
 Document Type: CONFERENCE PAPER

- end of record -

?
 Display 1/3/13 (Item 13 from file: 5)

7329385 BIOSIS Number: 38109906
 APPROACHES TO BLOOD STEM CELL MOBILIZATION INITIAL AUSTRALIAN CLINICAL
 RESULTS
 JUTTNER C A; TO L B; HAYLOCK D N; DYSON P G; BRADSTOCK K F; DALE B M;
 ENNO A; SAGE R E; SZER J; TOOGOOD I R G
 LEUKAEMIA RES. UNIT, IMVS, FROME RD., ADELAIDE, SOUTH AUSTRALIA, AUST.
 5000.
 INTERNATIONAL SYMPOSIUM ON PERIPHERAL BLOOD STEM CELL AUTOGRAFTS,
 MULHOUSE, FRANCE, OCTOBER 15-17, 1989. BONE MARROW TRANSPLANT 5 (SUPPL. 1).
 1990. 22-24. CODEN: BMTRE
 Language: ENGLISH
 Document Type: CONFERENCE PAPER

- end of record -

?
 Display 1/3/16 (Item 16 from file: 5)

2965749 BIOSIS Number: 69003156
 THE MECHANISM OF HEMOPOIETIC STEM CELL MOBILIZATION A ROLE OF THE
 COMPLEMENT SYSTEM
 WILSCHUT I J C; ERKENS-VERSLUIS M E; PLOEMACHER R E; BENNER R; VOS O
 DEP. CELL BIOL. GENET., ERASMUS UNIV., P.O. BOX 1738, ROTTERDAM, NETH.
 CELL TISSUE KINET 12 (3). 1979. 299-312. CODEN: CTKIA
 Full Journal Title: Cell and Tissue Kinetics
 Language: ENGLISH

- end of display -

?ds

| Set | Items | Description |
|-----|-------|--|
| S1 | 19 | STEM(W)CELL(W) (MOBILIZ? OR PERIPHERALIZ?) |
| S2 | 38 | VERY(W)LATE(W)ANTIGEN(W)4 |
| S3 | 0 | S2 AND STEM(W)CELL |
| S4 | 252 | VASCULAR(W)CELL(W)ADHESION(W)MOLECULE |
| S5 | 0 | S4 AND STEM(W)CELL |
| S6 | 0 | S1 AND S2 |
| S7 | 0 | S1 AND S4 |

7754915 BIOSIS Number: 90122915

VASCULAR CELL ADHESION MOLECULE-1 MEDIATES LYMPHOCYTE ADHERENCE TO
CYTOKINE-ACTIVATED CULTURED HUMAN ENDOTHELIAL CELLS

CARLOS T M; SCHWARTZ B R; KOVACH N L; YEE E; ROSSO M; OSBORN L; CHI-ROSSO
G; NEWMAN B; LOBB R; HARLAN J M

DIV. HEMATOL., ZA-34, HARBORVIEW MED. CENT., 325 9TH AVE., SEATTLE, WASH.
98104.

BLOOD 76 (5). 1990. 965-970. CODEN: BLOOA

Full Journal Title: Blood

Language: ENGLISH

L6

5 L1 AND L4 AND L5

APS

=> d 1-5

1. 5,188,959, Feb. 23, 1993, Extracellular matrix protein adherent T cells; Allan B. Haberman, 435/240.243, 4, 240.2 [IMAGE AVAILABLE]
2. 5,187,193, Feb. 16, 1993, Method for stimulating transplanted bone marrow cells; Richard F. Borch, et al., 514/476 [IMAGE AVAILABLE]
3. 5,169,765, Dec. 8, 1992, Method for stimulating production of bone marrow cell growth factors using dithiocarbamates; Richard F. Borch, et al., 435/70.4, 69.5, 69.52 [IMAGE AVAILABLE]
4. 4,965,195, Oct. 23, 1990, Interleukin-7; Anthony E. Namen, et al., 435/69.52, 91, 172.1, 172.3, 320.1; 530/350, 351; 536/24.3, 24.31 [IMAGE AVAILABLE]
5. 4,808,402, Feb. 28, 1989, Method and compositions for modulating neovascularization; Samuel J. Leibovich, et al., 424/78.06, 423, 618; 514/2 [IMAGE AVAILABLE]

=>

(FILE 'USPAT' ENTERED AT 11:27:00 ON 17 JUN 93)

L1 58124 S BLOOD
L2 0 S STEM(W)CELL#(W)(MOBILIZ? OR PERIPHERALIZ?)
L3 0 S STEM(W)CELL#(W)(MOBILIZ?)
L4 145 S STEM(W)CELL
L5 154 S CYTOKINE
L6 5 S L1 AND L4 AND L5

=>

d 18 1-3

1. 5,188,959, Feb. 23, 1993, Extracellular matrix protein adherent T cells; Allan B. Haberman, 435/240.243, 4, 240.2 [IMAGE AVAILABLE]
2. 4,965,195, Oct. 23, 1990, Interleukin-7; Anthony E. Namen, et al., 435/69.52, 91, 172.1, 172.3, 320.1; 530/350, 351; 536/24.3, 24.31 [IMAGE AVAILABLE]
3. 4,808,402, Feb. 28, 1989, Method and compositions for modulating neovascularization; Samuel J. Leibovich, et al., 424/78.06, 423, 618; 514/2 [IMAGE AVAILABLE]

=>

Teng, S
977702
Seqs. 1#2

Seq. 1

> 0 <
0| 0 IntelliGenetics
> 0 <

FastDB - Fast Pairwise Comparison of Sequences
Release 5.4

Results file us-07-977-702-1-ngs.res made by shears on Tue 15 Jun 93 11:23:42-PDT.

Query sequence being compared:US-07-977-702-1 (1-360)
Number of sequences searched: 25646
Number of scores above cutoff: 4455

Results of the initial comparison of US-07-977-702-1 (1-360) with:
Data bank : N-GeneSeq 10, all entries

10000-#
-
N -
U 5000- *
M -
B -
E - **
R - **
- *
D -
F 1000- *
-
S *
E 500- *
Q - *
U -
E -
N - *
C - *
E -
S 100-
-
-
50- *
-
-
- *
- **
- *
- *
- *
- *
10- *
- *
- *
- **
5- *
- ***
- ** *
- *

| | | | | | | |
|---|-------------------------------|------|-----|-----|-------|---|
| 11. Q21100 | ScFvB18 construct. | 770 | 236 | 280 | 16.05 | 0 |
| **** 15 standard deviations above mean **** | | | | | | |
| 12. Q23858 | ScFvB18 construct mutant #1. | 770 | 234 | 279 | 15.90 | 0 |
| 13. Q15164 | VH186 region of anti-nitrophe | 458 | 233 | 277 | 15.83 | 0 |
| 14. Q06227 | VH domain of antibody C again | 345 | 229 | 245 | 15.53 | 0 |
| 15. N91482 | Genomic to cDNA junction (V47 | 349 | 228 | 269 | 15.46 | 0 |
| 16. Q12013 | Sequence encoding mouse MAb 2 | 477 | 226 | 259 | 15.31 | 0 |
| 17. Q12057 | Sequence encoding heavy chain | 477 | 226 | 259 | 15.31 | 0 |
| 18. Q27141 | ICAM-1 inhibiting peptide 2. | 387 | 225 | 263 | 15.24 | 0 |
| 19. Q06957 | Genomic sequence encoding hea | 2675 | 225 | 260 | 15.24 | 0 |
| 20. N91820 | DNA sequence of the V and J r | 443 | 224 | 262 | 15.17 | 0 |
| 21. Q28263 | Fv(FRP51)-ETA fusion gene. | 2012 | 223 | 270 | 15.09 | 0 |
| 22. Q28260 | FWP51 fusion gene. | 748 | 222 | 269 | 15.02 | 0 |
| 23. Q12637 | Monoclonal antibody OK3T heav | 1570 | 222 | 268 | 15.02 | 0 |
| **** 14 standard deviations above mean **** | | | | | | |
| 24. Q28258 | FWP51 heavy chain variable do | 342 | 218 | 259 | 14.73 | 0 |
| 25. N91146 | 2H7 Vh sequence. | 458 | 218 | 266 | 14.73 | 0 |
| 26. N70968 | Sequence of the anti-hepatiti | 420 | 217 | 264 | 14.65 | 0 |
| 27. N70967 | Sequence of the anti-hepatiti | 420 | 217 | 264 | 14.65 | 0 |
| 28. Q04261 | Encodes Colon Cancer monoclon | 456 | 217 | 239 | 14.65 | 0 |
| 29. N70971 | 2H7 VH sequence which contain | 459 | 217 | 265 | 14.65 | 0 |
| 30. Q23342 | Murine heavy chain variable r | 354 | 216 | 261 | 14.58 | 0 |
| 31. N91645 | Heavy chain of monoclonal ant | 540 | 216 | 270 | 14.58 | 0 |
| 32. Q04040 | Anti-Leu 3a heavy chain varia | 765 | 216 | 262 | 14.58 | 0 |
| 33. Q04262 | Encodes Colon Cancer monoclon | 416 | 215 | 239 | 14.51 | 0 |
| 34. Q08609 | ME4 Heavy Chain V Region (mou | 492 | 215 | 261 | 14.51 | 0 |
| 35. Q04463 | Heavy chain variable region o | 361 | 214 | 238 | 14.43 | 0 |
| 36. Q04258 | Sequence homologous to TAG72 | 982 | 214 | 252 | 14.43 | 0 |
| 37. Q28522 | Hypercalcaemia agent cDNA por | 356 | 213 | 251 | 14.36 | 0 |
| 38. Q24790 | Anti-Tac antibody heavy chain | 433 | 213 | 247 | 14.36 | 0 |
| 39. Q05600 | Anti-Tac heavy chain variable | 433 | 213 | 247 | 14.36 | 0 |
| 40. Q05554 | Sequence encoding variable re | 446 | 213 | 233 | 14.36 | 0 |

1. US-07-977-702-1 (1-360)

Q11098 Encodes gamma heavy chain of T84.66 monoclonal ant

ID Q11098 standard; DNA; 861 BP.
AC Q11098;
DT 08-MAY-1991 (first entry)
DE Encodes gamma heavy chain of T84.66 monoclonal antibody.
KW MAb T84.66; gamma heavy chain; carcinoembryonic antigen; CEA;
KW human adenocarcinoma; mouse-human chimaeric antibody; ss.
OS Mus musculus.
FH Key Location/Qualifiers
FT exon 272..317
FT /*tag= a
FT intron 318..395
FT /*tag= b
FT exon 396..770
FT /*tag= c
FT promoter 109..118
FT /*tag= d
FT /note= "putative"
FT promoter 121..127
FT /*tag= e
FT /note= "putative"
FT promoter 160..166
FT /*tag= f
FT /note= "putative"
FT promoter 169..176
FT /*tag= g
FT /note= "putative"
PN W09101990-A.
PD 21-FEB-1991.
PF 19-JUL-1990; U04049.

PA (CITY) CITY OF HOPE.
 PI Shively JE, Riggs AD, Neumaier M;
 DR WPI: 91-073486/10.
 DR P-PSDB; R11384.
 PT Novel anti-CEA antibody - comparable to ATCC Accession No. BH
 PT 8747, produced by recombinant DNA, used in diagnosis of tumours
 PS Claim 4; Page 18; 24pp; English.
 CC The heavy chain variable region of murine MAb 84.66 was cloned and
 CC sequenced as follows: Hybridoma DNA was extracted, completely
 CC restricted with EcoRI and run on a gel. Fragments were extracted and
 CC ligated in the EcoRI site of Lambda-ZAP. Phage were packaged and plated.
 CC Plaque screening was with a 991bp XbaI fragment from the mouse
 CC enhancer region, a 1.5kb cDNA fragment from the heavy chain
 CC constant region gene of hybridoma CEA.66-E3 and a 5.4kb EcoRI
 CC fragment containing an aberrantly rearranged heavy chain from
 CC Sp2/0. Positive clones were further characterised by hybridisation
 CC to J-region oligonucleotides (see Q10842-Q10846) and sequenced. The
 CC murine gamma variable region gene was used to produce mouse V-human C
 CC antibodies with high affinity for CEA. Chimaeric murine-human anti-
 CC CEA Abs are used to diagnose human colon adenocarcinomas.
 CC See also Q10834-Q10841 and Q10847-8.
 SQ Sequence 861 BP; 213 A; 208 C; 203 G; 237 T;

Initial Score = 309 Optimized Score = 316 Significance = 21.40
 Residue Identity = 88% Matches = 322 Mismatches = 33
 Gaps = 10 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GTGACAGTGGCAATCACTTTGCCTTTCTTTCTACAGGGGTCAATTCAGAGTTTCAGCTGCAGCAGTCTGGGG
360      370      380      390      400      410      420      430

      30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGGAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
440      450      460      470      480      490      500

      100      110      120      130      140      150      160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAATGGATTGGAAGGATTGATCCTGCGAATGGTA
510      520      530      540      550      560      570

      170      180      190      200      210      220      230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATAGTAAATATGTCCCGAAGTTCAGGGCAAGGCCACTATAACAGCAGACACATCTCCAACACAGCCTACC
580      590      600      610      620      630      640

      240      250      260      270      280      290      300
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGGAATGTGGGTATCAACG-
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGCAGCTCACCAGCCTGACATCTGAGGACACTGCCGTCTATTATTGTGC-TCCG---TTTGGTTA-CTACGT
650      660      670      680      690      700      710

      310      320      330      340      350      X
----GGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
| ||||| ||| || ||||| ||||| ||| | ||||| ||||| |||||
GTCTGACTATGCTATGGCCTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGGTAAGAATGGCCTCTC
720      730      740      750      760      770      780

CAGGTCTTTATTTTAAACCTTTGTATGGACTTT
790      800      810

```

2. US-07-977-702-1 (1-360)

Q10381 Chimeric MAb 9.2.27 heavy chain variable region DN

ID Q10381 standard; DNA; 363 BP.
 AC Q10381;
 DT 15-APR-1991 (first entry)
 DE Chimeric MAb 9.2.27 heavy chain variable region DNA sequence.
 KW Chimeric antibodies; human glycoprotein antigen; melanoma; cancer;
 KW ss.
 OS Mus musculus.
 FH Key Location/Qualifiers
 FT CDS 1..363
 FT /*tag= a
 FT /product= H-chain V-region of MAb 9.2.27
 PN EP-411893-A.
 PD 06-FEB-1991.
 PF 31-JUL-1990; 308402.
 PR 31-JUL-1989; US-387665.
 PA (ELIL) ELI LILLY & CO.
 PI Beavers LS, Bumol TF, Gadski RA;
 DR WPI: 91-038771/06.
 DR P-PSDB; R10541.
 PT Monoclonal antibody contg. recombinant DNA - binds to human
 PT chondroitin sulphate proteoglycan on melanoma cells for melanoma
 PT treatment and diagnosis
 PS Claim 11; page 18; 33pp; English.
 CC This sequence, contained in vector pG4G21, is ligated to a DNA
 CC sequence encoding a human heavy (H) chain constant (C) region, in
 CC the construction of pN9.2.27G1. This vector is used to transform
 CC host cells, in conjunction with vector pG9.2.27K contg. murine
 CC light (L) chain variable (V) region and human L- chain C- region.
 CC The resulting host cell expresses the chimeric antibody 9.2.27
 CC which is directed against proteoglycans of human melanoma cells.
 CC This chimeric monoclonal antibody (MAb) is useful in the diagnosis
 CC and treatment of melanoma. The use of human C-regions avoids the
 CC problems associated with murine monoclonals e.g. rapid clearance
 CC from the bloodstream due to anti-self recognition.
 CC See also Q10379-81 and Q10382-84.
 SQ Sequence 363 BP; 88 A; 87 C; 105 G; 83 T;

Initial Score = 270 Optimized Score = 279 Significance = 18.54
 Residue Identity = 78% Matches = 285 Mismatches = 72
 Gaps = 6 Conservative Substitutions = 0

```

X      10      20      30      40      50      60
GTCAAAGTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGCCTCAGTCAAGTTGTCTGCACAGCT
||| | ||||| ||||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAAGATTTCTGCAAAGCT
X      10      20      30      40      50      60      70

```

```

70      80      90     100     110     120     130     140
TCTGGCTTCAACATTAAGA-CACCTATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGAT
||||| | |||| | | | ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TCTGGCTAC-GCATTAGTGGTCTTGGATGAAGTGGGTGAAGCAGAGGCCTGGACAGGGTCTTGAGTGGAT
80      90     100     110     120     130     140

```

```

150     160     170     180     190     200     210
TGGAAGGATTGATCCTGCGAG-TGGCGATACTAAATATGACCCGAAGTTCCAGGTCAAGGCCACTATTACAG
|||| | |||| | |||| | |||| | |||| | |||| | |||| | |||| | |||| | |||| |
TGGACGGATTTATCTG-GAGATGGAGATACTAACTACAATGGGAAGTTCAAGGGCAAGGCCACTGACTG
150     160     170     180     190     200     210

```

```

220     230     240     250     260     270     280
CGGACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACT

```

CAGACAAATCCTCCAGCACAGCCTACATGCAGGTGAGCAGCCTGACCTCTGTGGACTCTGCGGTCTATTTC

220 230 240 250 260 270 280

360
TCCTCA
|||||
TCCTCA
360 X

```

70      80      90      100     110     120     130
30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAA--AGACAC
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CTGAGCTGGTAAAGCCTGGGGCTTCAAGTGAAGATGTCCTGCAAGGCTTCTGGATAC-ACATTACTAGCTAT
140      150      160      170      180      190      200

100      110      120      130      140      150      160
CTATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGG
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
GT-TATGCACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATTAATCCTTACAATGA
210      220      230      240      250      260      270

170      180      190      200      210      220      230
CGATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTG
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
TGGTACTAGTTACAATGAGCCCTTCAAAGGCAAGGCCACACTGACTTCAGACAAATCCTCCAGCACAGCCTA
280      290      300      310      320      330      340

240      250      260      270      280      290      300
GCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGC-AGACGGA---ATGTGGGTAT
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CATGGAGCTCAGCAGCCTGACCTCTGAGGACTCTGCGGTCTATTACTGTGCAAGGAGGATCTACTTTGATTA
350      360      370      380      390      400      410

310      320      330      340      350      X
CAACGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCTCTCA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
CTCC----TATGTTATGGACTACTGGGGTCAAGGAACCTCGGTACACGTCTCTCTCA
420      430      440      450      460      470

```

4. US-07-977-702-1 (1-360)

Q22736 RSV19 VH.

ID Q22736 standard; DNA; 348 BP.
AC Q22736;
DT 13-AUG-1992 (first entry)
DE RSV19 VH.
KW VH; VK; donor; antibody; CDR; epitope; NEW; REI;
KW fusion protein; F protein; ss.
OS Mus musculus.
FH Key Location/Qualifiers
FT misc_feature 91..105
FT /*tag= a
FT /label= CDR1
FT misc_feature 149..199
FT /*tag= b
FT /label= CDR2
FT misc_feature 296..316
FT /*tag= c
FT /label= CDR3
FT primer_bind 2..23
FT /*tag= d
FT /note= "corresponds to primer sequence used"
FT primer_bind 316..349
FT /*tag= e
FT /note= "corresponds to primer sequence used"
PN W09204381-A.
PD 19-MAR-1992.
PF 11-SEP-1991; G01554.
PR 11-SEP-1990; GB-019812.
PA (SCOT-) SCOTGEN LTD.
PI Harris WJ, Tempest PR, Taylor G;
DR WPI; 92-114306/14.

DR P-F508: R24807.

PT New altered antibodies with donor MAb binding specificity for RSV
PT - for treatment and prevention of human respiratory syncytial
PT virus infection
PS Disclosure; Fig 1; 72pp; English.
CC The sequences of RSV19 VH and VK are represented in 022736 and 022737
CC respectively. The donor antibody RSV19 is directed against epitope
CC 417-438 of the fusion protein (F). The CDRs were identified (see
CC features), then the murine CDRs transferred to human frameworks by
CC site-directed mutagenesis, using as DNA templates human framework
CC regions of the NEW (heavy) and REI (light) proteins.
CC The altered antibodies are used to prevent or treat RSV infections
CC in humans, e.g. for prevention they are given (each 6 weeks during
CC the RSV season) at 1-20 mg/kg parenterally or 0.2-2 mg/kg
CC intranasally. Since the antibodies are predominantly
CC human, they are unlikely to cause much immune response.
SQ Sequence 348 BP; 84 A; 91 C; 95 G; 76 T;
SQ 2 Others;

Initial Score = 256 Optimized Score = 299 Significance = 17.51
Residue Identity = 84% Matches = 305 Mismatches = 40
Gaps = 15 Conservative Substitutions = 0

```

      X      10      20      30      40      50      60
      GTCAAAGTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCT
      ||| | ||||| ||||| ||||| ||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGGTCCAGCTGCAGSAGTCWGGGACAGAGCTTGAGAGGTGAGGGGCTCAGTCAAGTTGTCCTGCACAGCT
      X      10      20      30      40      50      60      70

70      80      90      100     110     120     130     140
TCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TCTGGCTTCAACATTAAAGACTACTATATGCACTGGATGAAGCAGAGGCCTGACCAGGGCCTGGAGTGGATT
      80      90      100     110     120     130     140

      150     160     170     180     190     200     210
GGAAGGATTGATCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCCAGGTCAAGGCCACTATTACAGCG
||| ||||| ||||| ||| ||| ||| | ||||| ||||| ||||| ||||| ||||| ||| |||
GGATGGATTGATCTGAGAATGATGATGTTCAATATGCCCGAAGTTCCAGGGCAAGGCCACTATGACTGCA
      150     160     170     180     190     200     210

      220     230     240     250     260     270     280
GACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GACACGTCCTCCAACACAGCCTACCTGCAGCTCACCAGCCTGACATTTGAGGACACTGCCGTCTATTTCTGT
      220     230     240     250     260     270     280

      290     300     310     320     330     340     350
GCAGACGGAATGTGGGTATCAACGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCC
||| ||| ||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
-----AAT-----TCATGGGGAGTGACTTTGACCACTGGGGCCAAGGGACCACGGTCACCGTCTCC
      290           300           310           320           330           340

360
TCA
|||
TCA
X
```

5. US-07-977-702-1 (1-360)

028739 cDNA of VH425 antibody cloned into pUC18.

ID 028739 standard; DNA; 501 BP.
AC 028739;
DT 01-MAR-1993 (first entry)

DE cDNA of VH425 antibody cloned into pUC18.
KW Monoclonal antibody; complementarity determining region; framework;
KW antigens; tumour; melanoma; carcinoma; glioma; variable; heavy;
KW light; chain; ss.
OS Synthetic.
FH Key Location/Qualifiers
FT CDS 30..450
FT /*tag= a
FT sig_peptide 30..87
FT /*tag= b
FT mat_peptide 88..450
FT /*tag= c
FT primer_bind 10..32
FT /*tag= d
FT /note= "3'-5' PCR primer binding site"
FT primer_bind 12..32
FT /*tag= e
FT /note= "PCR primer binding site"
FT primer_bind 436..465
FT /*tag= f
FT /note= "3'-5' PCR primer binding site"
PN M09215683-A.
PD 17-SEP-1992.
PF 04-MAR-1992; E00480.
PR 06-MAR-1991; EP-103389.
PA (MERE) MERCK PATENT GMBH.
PI Bendig MM, Kettleborough CA, Saldanha J;
DR WPI; 92-331729/40.
DR P-PSBD; R27049.
PT Human monoclonal antibodies binding to human receptors - for
PT treatment and diagnosis of tumours, e.g. melanoma and carcinoma
PS Disclosure; Fig 2; 89pp; English.
CC The cDNA sequence encoding the variable heavy chain of monoclonal
CC antibody 425 was prepd. synthetically and mutations made to the 5'
CC and 3' ends to allow for cloning into HCMV expression vectors.
CC Donor splice sites were recreated in the 3' flanking regions to
CC allow correct splicing of the variable and constant regions. The
CC 5' sequence was altered to introduce an initiation codon. These
CC mutations were carried out using the PCR primers shown in the
CC features table. The cloned chimeric antibody contg. 425 VL and
CC 425 VH regions were cotransfected into COS cells to confirm cloning
CC of the correct mouse base variable sequence. The cloned antibody
CC may be used int the prodn. of reshaped or humanised antibodies which
CC are less immunogenic than native antibodies and may be used to combat
CC e.g. glioma, melanoma or carcinoma.
CC See also Q27040-1.
SQ Sequence 501 BP; 127 A; 146 C; 124 G; 104 T;

Initial Score = 256 Optimized Score = 269 Significance = 17.51
Residue Identity = 75% Matches = 275 Mismatches = 82
Gaps = 6 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                ||| | |||| | | |||||
GCTATATCATCCTCTTTTGGTAGCAACAGCTACAGATGTCCACTCCCAGGTCCAGCTGCAACAACCTGGGG
   50      60      70      80      90      100     110

   30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTA-AAGACACC
| | | | ||||| | ||| | ||||| ||||| |||| | | | | | | | | | | | | | | | | | | |
CTGAACTGGTGAAGCCTGGGGCTTCAAGTGAAGTTGTCCTGCAAGGCTTCCGGCTACACCTTACCAGCCA-C
   120     130     140     150     160     170     180

   100     110     120     130     140     150     160
TATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCCAGTGGC

```


TGGATGCACTGGGTGAAGCAGAGGGCTGGACAAGGCCCTTGAGTGGATCGGAGAGTTTAATCCCAGCAACGGC
190 200 210 220 230 240 250

GATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGG
||||| || | |||| || || |||||||| | || | |||| ||||||| ||||||
CGTACTA ACTACAATGAGAAATTCAAGAGCAAAGGCCACACTGACTGTAGACAAATCCTCCAGCACAGCCTAC
260 270 280 290 300 310 320

CTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGCTACTACTGTG-CAGAC-GGAATGTGGGTATCAA
||||| |||||||||||||||||||| |||| |||| |||||| ||| | ||| | | || |
ATGCAACTCAGCAGCCTGACATCTGAGGACTCTGCCGCTATTACTGTGCCAGTCGGGACTATGATTA- CGA
330 340 350 360 370 380 390

CGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
||| | || | |||| |||||||||| |||| |||| ||||||
CGGACGGTACT-TTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACAACACCCCATC
400 410 420 430 440 450 460

GGTCTATCCACTGGATTCTCTAGAGTCGAC
470 480 490 500

CC Construct, which was then ligated into the fd gene III contg. vec-
 CC tor, fdCAT2, derived from fdTPs/Xh. (See Q21095). The clone having
 CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
 CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
 CC into fdDOGkan (fdCAT2 with the tet gene replaced by a kanamycin
 CC resistance gene) to give fdDOGkanscFvB18, or into the phagemid
 CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
 CC the effect of using mutator strains to increase the diversity of
 CC the cloned genes. The strains NR9046mutD5: NR9046 mutD5::Tn10 and
 CC NR9046mutT1: NR9046mutT1::Tn10 were constructed by P1 transduction.
 CC After 4 rounds of mutation and screening, 40 phage inserts were
 CC sequenced. They each displayed single mutations in 6 different
 CC positions, five being in the light chain region. More than 70% of
 CC the mutations occurred at positions 724 and 725 changing the first
 CC Gly in the J segment (framework 4) to Ser (in 21 cases here) or
 CC Asp (in 3 cases). The mutant shown here (see feature table for
 CC details of the mutation) occurred once. The mutant fragments had
 CC affinities for NP which were comparable to the wild-type scFv
 CC fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
 CC See also Q21092-100, 103-116, 126-131; Q23463, 465-495, 693-719,
 CC 736-738, and 793-862.

SQ Sequence 770 BP; 188 A; 196 C; 214 G; 172 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
 Residue Identity = 79% Matches = 288 Mismatches = 65
 Gaps = 11 Conservative Substitutions = 0

```

          X      10      20      30      40      50
          GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTC
          ||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
TTCTATTCTCACAGTGCACAGGTCCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTG
      10      20 X      30      40      50      60      70

      60      70      80      90      100     110     120
AAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAA
||| ||||| ||||| ||||| ||| ||| | ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGCTGTCCTGCAAGGCTTCTGGCTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGA
      80      90      100     110     120     130     140

      130     140     150     160     170     180     190
CAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCCAGTGGCGATACTAAATATGACCCGAAGTTCAGGTC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CGAGGCCTTGAGTGGATTGGAAGGATTGATCCTAATAGTGGTGGTACTAAGTACAATGAGAAGTTCAGAGC
      150     160     170     180     190     200     210

      200     210     220     230     240     250     260
AAGGCCACTATTACAGCGGACAGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGAC
||||||| ||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGGCCACACTGACTGTAGACAAACCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC
      220     230     240     250     260     270     280

      270     280     290     300     310     320     330
ACTGCCGTCTACTACTGTGC-AGA-CGGAATGTGG--GTATCAACGGGATATGCTCTGGACTTCTGGGGCCA
||||| ||||| || ||||| ||| ||| ||| ||| ||| ||| ||| ||||| ||||| ||||| |||||
TCTGCGGTCTATTATTGTGCAAGATACGACTACGGTAGTAGCTAC----TA--CT-TTGACTACTGGGGCCA
      290     300     310     320     330     340     350

      340     350      X
AGGGACCACGGTCACCGTCTCCTCA
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTAGGCGGAGGTGGCTCTGGCGGTGGCGGATCCCA
      360     370     380     390     400     410     420

```

GGC

7. US-07-977-702-1 (1-360)

Q23862 ScFvB18 construct mutant #5.

ID Q23862 standard; DNA; 770 BP.
AC Q23862;
DT 21-MAY-1992 (first entry)
DE ScFvB18 construct mutant #5.
KW Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat;
KW pilus; g3p; binding; adsorption; gene VIII; diverse repertoire;
KW specific binding pairs; replicable genetic display package; ds.
OS Synthetic.
FH Key Location/Qualifiers
FT CDS 1..770
FT /*tag= a
FT /product= scFvB18
FT mutation 725
FT /*tag= b
FT /note= "g -> a; Gly -> Asp (VL FR4)"
PN W09201047-A.
PD 23-JAN-1992.
PF 10-JUL-1991; G01134.
PR 10-JUL-1990; GB-015198.
PR 19-OCT-1990; GB-022845.
PR 12-NOV-1990; GB-024503.
PR 06-MAR-1991; GB-004744.
PR 15-MAY-1991; GB-010549.
PA (CAMB-) CAMBRIDGE ANTIBODY.
PA (MEDI-) MED RES COUNCIL.
PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
PI Winter GP, Bonner TP;
DR WPI; 92-056862/07.
DR P-PSDB; R22586.
PT Producing members of specific binding pairs - by expression in
PT recombinant host cells with a secreting replicable genetic
PT display package.
PS Example 38; Fig 44; 209pp; English.
CC The sequence encodes an antibody scFv fragment directed against 4-
CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAb
CC against NP were separately amplified and reassembled to form the
CC construct, which was then ligated into the fd gene III contg. vec-
CC tor, fdCAT2, derived from fdTPs/Xh.(See Q21095). The clone having
CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
CC into fdDOGkan (fdCAT2 with the tet gene replaced by a kanamycin
CC resistance gene) to give fdDOGkanscFvB18, or into the phagemid
CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
CC the effect of using mutator strains to increase the diversity of
CC the cloned genes. The strains NR9046mutD5: NR9046 mutD5::Tn10 and
CC NR9046mutT1: NR9046mutT1::Tn10 were constructed by P1 transduction.
CC After 4 rounds of mutation and screening, 40 phage inserts were
CC sequenced. They each displayed single mutations in 6 different
CC positions, five being in the light chain region. More than 70% of
CC the mutations occurred at positions 724 and 725 changing the first
CC Gly in the J segment (framework 4) to Ser (in 21 cases), or Asp (in
CC 3 cases as shown here). The mutant fragments had affinities for
CC NP which were comparable to the wild-type scFv fragment (20nM).
CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
CC See also Q21092-100, 103-116, 126-131; Q23463, 465-495, 693-719,
CC 736-738, and 793-863.
SQ Sequence 770 BP; 189 A; 197 C; 213 G; 171 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
Residue Identity = 79% Matches = 288 Mismatches = 65

PR 06-MAR-1991; GB-004744.
 PA (CAMB-) CAMBRIDGE ANTIBODY.
 PA (MEDI-) MED RES COUNCIL.
 PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
 PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
 PI Winter GP, Bonner TP;
 DR WPI: 92-056862/07.
 DR P-PSDB; R22585.
 PT Producing members of specific binding pairs - by expression in
 PT recombinant host cells with a secreting replicable genetic
 PT display package.
 PS Example 38; Fig 44; 209pp; English.
 CC The sequence encodes an antibody scFv fragment directed against 4-
 CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAbs
 CC against NP were separately amplified and reassembled to form the
 CC construct, which was then ligated into the fd gene III contg. vec-
 CC tor, fdCAT2, derived from fdTPs/Xh. (See Q21095). The clone having
 CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
 CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
 CC into fdDQK (fdCAT2 with the tet gene replaced by a kanamycin
 CC resistance gene) to give fdDQKanscFvB18, or into the phagemid
 CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
 CC the effect of using mutator strains to increase the diversity of
 CC the cloned genes. The strains NR9046mutD5: NR9046 mutD5::Tn10 and
 CC NR9046mutT1: NR9046mutT1::Tn10 were constructed by P1 transduction.
 CC After 4 rounds of mutation and screening, 40 phage inserts were
 CC sequenced. They each displayed single mutations in 6 different
 CC positions, five being in the light chain region. More than 70% of
 CC the mutations occurred at positions 724 and 725 changing the first
 CC Gly in the J segment (framework 4) to Ser (in 21 cases, as shown
 CC here) or Asp (in 3 cases). The mutant fragments had affinities
 CC for NP which were comparable to the wild-type scFv fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DQG1 and fdDQG1.
 CC See also Q21092-100, 103-116, 126-131; Q23463, 465-495, 693-719,
 CC 736-738, and 793-863.
 SQ Sequence 770 BP; 189 A; 197 C; 213 G; 171 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
 Residue Identity = 79% Matches = 288 Mismatches = 65
 Gaps = 11 Conservative Substitutions = 0

```

      X      10      20      30      40      50
      GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTC
      ||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
TTCTATTCTCACAGTGCACAGGTCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTCAGTG
      10      20 X      30      40      50      60      70

      60      70      80      90      100     110     120
AAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAA
||| ||||| ||||| ||||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| |||||
AAGCTGTCTGCAAGGCTTCTGGTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGA
      80      90      100     110     120     130     140

      130     140     150     160     170     180     190
CAGGCGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCAGGTC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CGAGGCCTTGAGTGGATTGGAAGGATTGATCCTAATAGTGGTACTAAGTACAATGAGAAGTTCAGAGC
      150     160     170     180     190     200     210

      200     210     220     230     240     250     260
AAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGAC
||||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGGCCACACTGACTGTAGACAAACCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC
      220     230     240     250     260     270     280

```

270 280 290 300 310 320 330
 ACTGCCGTCTACTACTGTGC-AGA-CGGAATGTGG--GTATCAACGGGATATGCTCTGGACTTCTGGGGCCA
 ||||| ||||| || ||||| ||| || || ||| ||| || || ||||| |||||
 TCTGCGGTCTATTATTGTGCAAGATACGACTACGGTAGTAGCTAC----TA--CT-TTGACTACTGGGGCCA
 290 300 310 320 330 340 350

 340 350 X
 AGGGACCACGGTCACCGTCTCCTCA
 |||||
 AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTGAGGCGGAGGTGGCTCTGGCGGTGGCGGATCCCA
 360 370 380 390 400 410 420

GGC

9. US-07-977-702-1 (1-360)

Q23860 ScFvB18 construct mutant #3.

ID Q23860 standard; DNA; 770 BP.
 AC Q23860;
 DT 21-MAY-1992 (first entry)
 DE ScFvB18 construct mutant #3.
 KW Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat;
 KW pilus; g3p; binding; adsorption; gene VIII; diverse repertoire;
 KW specific binding pairs; replicable genetic display package; ds.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT CDS 1..770
 FT /*tag= a
 FT /product= scFvB18
 FT mutation 706
 FT /*tag= b
 FT /note= "a -> g; Ser -> Gly (VL CDR3)"
 PN W09201047-A.
 PD 23-JAN-1992.
 PF 10-JUL-1991; G01134.
 PR 10-JUL-1990; GB-015198.
 PR 19-OCT-1990; GB-022845.
 PR 12-NOV-1990; GB-024503.
 PR 06-MAR-1991; GB-004744.
 PR 15-MAY-1991; GB-010549.
 PA (CAMB-) CAMBRIDGE ANTIBODY.
 PA (MEDI-) MED RES COUNCIL.
 PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
 PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
 PI Winter GP, Bonner TP;
 DR WPI; 92-056862/07.
 DR P-PSDB; R22584.
 PT Producing members of specific binding pairs - by expression in
 PT recombinant host cells with a secreting replicable genetic
 PT display package.
 PS Example 38; Fig 44; 209pp; English.
 CC The sequence encodes an antibody scFv fragment directed against 4-
 CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAB
 CC against NP were separately amplified and reassembled to form the
 CC construct, which was then ligated into the fd gene III contg. vec-
 CC tor, fdCAT2, derived from fdTPs/Xh.(See Q21095). The clone having
 CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
 CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
 CC into fdDOGkan (fdCAT2 with the tet gene replaced by a kanamycin
 CC resistance gene) to give fdDOGkanscFvB18, or into the phagemid
 CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
 CC the effect of using mutator strains to increase the diversity of
 CC the cloned genes. The strains NR9046mutD5; NR9046 mutD5::Tn10 and
 CC NR9046mutT1; NR9046mutT1::Tn10 were constructed by P1 transduction.

CC After 4 rounds of mutation and screening, 40 phage inserts were
 CC sequenced. They each displayed single mutations in 6 different
 CC positions, five being in the light chain region. More than 70% of
 CC the mutations occurred at positions 724 and 725 changing the first
 CC Gly in the J segment (framework 4) to Ser (in 21 cases) or Asp (in
 CC 3 cases). The mutant shown here (see feature table for details of
 CC mutation) occurred once. The mutant fragments had affinities for
 CC NP which were comparable to the wild-type scFv fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
 CC See also 021092-100, 103-116, 126-131; 023463, 465-495, 693-719,
 CC 736-738, and 793-863.
 SB Sequence 770 BP; 187 A; 197 C; 215 G; 171 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
 Residue Identity = 79% Matches = 288 Mismatches = 65
 Gaps = 11 Conservative Substitutions = 0

```

      X      10      20      30      40      50
      GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTC
      ||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
TTCTATTCTCACAGTGCACAGGTCCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTG
      10      20 X      30      40      50      60      70

      60      70      80      90      100     110     120
AAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAA
||| ||||| ||||| ||||| ||| | | | | | ||| ||||| ||||| ||||| ||||| ||||| |||||
AAGTGTCTCTGCAAGGCTTCTGGTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGA
      80      90      100     110     120     130     140

      130     140     150     160     170     180     190
CAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCAGGTC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CGAGGCCTTGAGTGGATTGGAAGGATTGATCCTAATAGTGGTGGTACTAAGTACAATGAGAAGTTCAGAGC
      150     160     170     180     190     200     210

      200     210     220     230     240     250     260
AAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGAC
||||||| ||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGGCCACACTGACTGTAGACAAACCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC
      220     230     240     250     260     270     280

      270     280     290     300     310     320     330
ACTGCCGTCTACTACTGTGC-AGA-CGGAATGTGG--GTATCAACGGGATATGCTCTGGACTTCTGGGGCCA
||| ||||| || ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||||| ||||| ||||| |||||
TCTGCGGTCTATTATTGTGCAAGATACGACTACGGTAGTAGCTAC----TA--CT-TTGACTACTGGGGCCA
      270     300     310     320     330     340     350

      340     350      X
AGGGACCACGGTCACCGTCTCCTCA
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCCCA
      360     370     380     390     400     410     420
  
```

GGC

10. US-07-977-702-1 (1-360)

023859 ScFvB18 construct mutant #2.

ID 023859 standard; DNA; 770 BP.
 AC 023859;
 DT 21-MAY-1992 (first entry)
 DE ScFvB18 construct mutant #2.
 KW Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat;
 KW pilus; g3p; binding; adsorption; gene VIII; diverse repertoire;

specific binding pairs; replicable genetic display package; ds.
 OS Synthetic.
 FH Key Location/Qualifiers
 FT CDS 1..770
 FT /*tag= a
 FT /product= scFvB18
 FT mutation 703
 FT /*tag= b
 FT /note= "t -> g; Tyr -> Asp (VL CDR3)"
 PN W09201047-A.
 PD 23-JAN-1992.
 PF 10-JUL-1991; G01134.
 PR 10-JUL-1990; GB-015198.
 PR 19-OCT-1990; GB-022845.
 PR 12-NOV-1990; GB-024503.
 PR 06-MAR-1991; GB-004744.
 PR 15-MAY-1991; GB-010549.
 PA (CAMB-) CAMBRIDGE ANTIBODY.
 PA (MEDI-) MED RES COUNCIL.
 PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
 PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
 PI Winter GP, Bonner TP;
 DR WPI; 92-056862/07.
 DR P-PSDB; R22583.
 PT Producing members of specific binding pairs - by expression in
 PT recombinant host cells with a secreting replicable genetic
 PT display package.
 PS Example 38; Fig 44; 209pp; English.
 CC The sequence encodes an antibody scFv fragment directed against 4-
 CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAb
 CC against NP were separately amplified and reassembled to form the
 CC construct, which was then ligated into the fd gene III contg. vec-
 CC tor, fdCAT2, derived from fdTPs/Xh. (See Q21095). The clone having
 CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
 CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
 CC into fdDOGkan (fdCAT2 with the tet gene replaced by a kanamycin
 CC resistance gene) to give fdDOGkanscFvB18, or into the phagemid
 CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
 CC the effect of using mutator strains to increase the diversity of
 CC the cloned genes. The strains NR9046mutD5: NR9046 mutD5::Tn10 and
 CC NR9046mutT1: NR9046mutT1::Tn10 were constructed by P1 transduction.
 CC After 4 rounds of mutation and screening, 40 phage inserts were
 CC sequenced. They each displayed single mutations in 6 different
 CC positions, five being in the light chain region. More than 70% of
 CC the mutations occurred at positions 724 and 725 changing the first
 CC Gly in the J segment (framework 4) to Ser (in 21 cases) or Asp (in
 CC 3 cases). The mutant shown here (see feature table for details of
 CC mutation) occurred once. The mutation shown on the fig., of t -> c
 CC would result in the Tyr being replaced by His, contrary to the data
 CC in Table 9 of the specification which indicates that the substn. is
 CC with Asp (i.e. t -> g). The mutant fragments had affinities for NP
 CC which were comparable to the wild-type scFv fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
 CC See also Q21092-100, 103-116, 126-131; Q23463, 465-495, 693-719,
 CC 736-738, and 793-863.
 SQ Sequence 770 BP; 188 A; 197 C; 215 G; 170 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
 Residue Identity = 79% Matches = 288 Mismatches = 65
 Gaps = 11 Conservative Substitutions = 0

X 10 20 30 40 50
 GTCAAAGTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTC
 ||| | ||||| ||||| ||||| ||||| ||||| |||||
 TTCTATTCTCAGAGTGCACAGGTCCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTG
 10 20 X 30 40 50 60 70

FT /note= "c -> t; Thr -> Ile (VL FR4); Q23863"
 PN WD9201047-A.
 PD 23-JAN-1992.
 PF 10-JUL-1991; G01134.
 PR 10-JUL-1990; GB-015198.
 PR 19-OCT-1990; GB-022845.
 PR 12-NOV-1990; GB-024503.
 PR 06-MAR-1991; GB-004744.
 PR 15-MAY-1991; GB-010549.
 PA (CAMB-) CAMBRIDGE ANTIBODY.
 PA (MEDI-) MED RES COUNCIL.
 PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
 PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
 PI Winter GP, Bonner TP;
 DR WPI: 92-056862/07.
 DR P-PSDB: R22568.
 PT Producing members of specific binding pairs - by expression in
 PT recombinant host cells with a secreting replicable genetic
 PT display package.
 PS Example 38; Fig 44; 209pp; English.
 CC The sequence encodes an antibody scFv fragment directed against 4-
 CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAb
 CC against NP were separately amplified and reassembled to form the
 CC construct, which was then ligated into the fd gene III contg. vec-
 CC tor, fdCAT2, derived from fdTPs/Xh. (See Q21095). The clone having
 CC the scFvB18 sequence fused in frame to gene III was designated
 CC fdCAT2scFvB18. Alternatively the fragment was cloned into fdDOGkan
 CC (fdCAT2 with the tet gene replaced by a kanamycin resistance gene)
 CC to give fdDOGkanscFvB18, or into the phagemid pHEN1 to create pHEN1-
 CC scFvB18. The constructs were used to test the effect of using muta-
 CC tor strains to increase the diversity of the cloned genes. The
 CC strains NR9046mutD5: NR9046 mutD5::Tn10 and NR9046mutT1: NR9046
 CC mutT1::Tn10 were constructed by P1 transduction. After 4 rounds of
 CC mutation and screening, 40 phage inserts were sequenced. They each
 CC displayed single mutations in 6 different positions, five being in
 CC the light chain region. More than 70% of the mutations occurred at
 CC positions 724 and 725 changing the first Gly in the J segment
 CC (framework 4) to Ser (in 21 cases) or Asp (in 3 cases). The
 CC mutant fragments had affinities for NP which were comparable to the
 CC wild-type scFv fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
 CC See also Q21092-99, 103-116, 126-131; Q23463, 465-495, 693-719,
 CC 736-738, and 793-863.
 SQ Sequence 770 BP; 188 A; 197 C; 214 G; 171 T;

Initial Score = 236 Optimized Score = 280 Significance = 16.05
 Residue Identity = 79% Matches = 288 Mismatches = 65
 Gaps = 11 Conservative Substitutions = 0

```

          X      10      20      30      40      50
          GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCCTCAGTC
          ||| | ||||| ||||| ||||| ||||| ||||| |||||
TTCTATTCTCACAGTGCACAGGTCCAGCTGCAGCAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTG
      10      20 X      30      40      50      60      70

      60      70      80      90     100     110     120
AAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAA
||| ||||| ||||| ||| | | | | ||||| ||||| ||||| ||||| ||||| |||||
AAGCTGTCCTGCAAGGCTTCTGGTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGA
      80      90      100      110      120      130      140

     130     140     150     160     170     180     190
CAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCCAGTGGCGATACTAAATATGACCCGAAGTTCAGGTC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CGAGGCCTTGAGTGGATTGGAAGGATTGATCCTAAATAGTGGTGGTACTAAGTACAATGAGAAGTTCAGAGC
  
```

```

150      160      170      180      190      200      210
200      210      220      230      240      250      260
AAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGAC
||||||| | | | |||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| |
AAGGCCACACTGACTGTAGACAAACCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC
220      230      240      250      260      270      280

270      280      290      300      310      320      330
ACTGCCGTCTACTACTGTGC-AGA-CGGAATGTGG--GTATCAACGGGATATGCTCTGGACTTCTGGGGCCA
|||| | |||| | | |||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
TCTGCCGTCTATTATTGTGCAAGATACGACTACGGTAGTAGCTAC---TA--CT-TTGACTACTGGGGCCA
290      300      310      320      330      340      350

340      350      X
AGGGACCACGGTCACCGTCTCCTCA
||||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | ||||| | |||||
AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTGAGGCGGAGGTGGCTCTGGCGGTGGCGGATCCCA
360      370      380      390      400      410      420

GGC

```

12. US-07-977-702-1 (1-360)

Q23858 ScFvB18 construct mutant #1.

ID Q23858 standard; DNA; 770 BP.
AC Q23858;
DT 21-MAY-1992 (first entry)
DE ScFvB18 construct mutant #1.
KW Fd; bacteriophage; gene III; filamentous; phagemid; capsid; coat;
KW pilus; g3p; binding; adsorption; gene VIII; diverse repertoire;
KW specific binding pairs; replicable genetic display package; ds.
OS Synthetic.
FH Key Location/Qualifiers
FT CDS 1..770
FT /*tag= a
FT /product= scFvB18
FT mutation 308
FT /*tag= b
FT /note= "c -> t; Ala -> Val (VH FR3)"
PN W09201047-A.
PD 23-JAN-1992.
PF 10-JUL-1991; G01134.
PR 10-JUL-1990; GB-015198.
PR 19-OCT-1990; GB-022845.
PR 12-NOV-1990; GB-024503.
PR 06-MAR-1991; GB-004744.
PR 15-MAY-1991; GB-010549.
PA (CAMB-) CAMBRIDGE ANTIBODY.
PA (MEDI-) MED RES COUNCIL.
PI McCafferty J, Pope AR, Johnson KS, Hoogenboom HRJ, Griffiths AD;
PI Jackson RH, Holliger KP, Marks JD, Clackson TP, Chiswell DJ;
PI Winter GP, Bonner TP;
DR MPI; 92-056862/07.
DR P-PSDB; R22582.
PT Producing members of specific binding pairs - by expression in
PT recombinant host cells with a secreting replicable genetic
PT display package.
PS Example 38; Fig 44; 209pp; English.
CC The sequence encodes an antibody scFv fragment directed against 4-
CC hydroxy-3-nitrophenylacetic acid (NP). HV and LV chains of an MAb
CC against NP were separately amplified and reassembled to form the
CC construct, which was then ligated into the fd gene III contg. vec-
CC tor, fdCAT2, derived from fdTPs/Xh.(See Q21095). The clone having

CC the scFvB18 sequence (see Q21100) fused in frame to gene III was
 CC designated fdCAT2scFvB18. Alternatively the fragment was cloned
 CC into fdDOGkan (fdCAT2 with the tet gene replaced by a kanamycin
 CC resistance gene) to give fdDOGKanscFvB18, or into the phagemid
 CC pHEN1 to create pHEN1-scFvB18. The constructs were used to test
 CC the effect of using mutator strains to increase the diversity of
 CC the cloned genes. The strains NR9046mutD5: NR9046 mutD5::Tn10 and
 CC NR9046mutT1: NR9046mutT1::Tn10 were constructed by P1 transduction.
 CC After 4 rounds of mutation and screening, 40 phage inserts were
 CC sequenced. They each displayed single mutations in 6 different
 CC positions, five being in the light chain region. More than 70% of
 CC the mutations occurred at positions 724 and 725 changing the first
 CC Gly in the J segment (framework 4) to Ser (in 21 cases) or Asp (in
 CC 3 cases). The mutant shown here (see feature table for details of
 CC mutation) occurred three times. The mutant fragments had affinities
 CC for NP which were comparable to the wild-type scFv fragment (20nM).
 CC N.B. fdCAT2 is also referred to as fd-tet-DOG1 and fdDOG1.
 CC See also Q21092-100, 103-116, 126-131; Q23463, 465-495, 693-719,
 CC 736-738, and 793-863.
 SQ Sequence 770 BP; 188 A; 196 C; 214 G; 172 T;

Initial Score = 234 Optimized Score = 279 Significance = 15.90
 Residue Identity = 78% Matches = 287 Mismatches = 66
 Gaps = 11 Conservative Substitutions = 0

```

      X      10      20      30      40      50
      GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTC
      ||| | ||||| ||||| ||||| ||||| ||||| ||||| |||||
TTCTATTCTCACAGTGCACAGGTCACAGTCTGGGGCTGAGCTTGTGAAGCCTGGGGCTCAGTG
      10      20 X      30      40      50      60      70

      60      70      80      90      100     110     120
AAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCTGAA
||| ||||| ||||| ||||| ||| ||| ||| ||||| ||||| ||||| ||||| ||||| |||||
AAGCTGTCCTGCAAGGCTTCTGGTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCTGGA
      80      90      100     110     120     130     140

      130     140     150     160     170     180     190
CAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCAGGTC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CGAGGCCTTGAGTGGATTGGAAGGATTGATCCTAATAGTGGTGGTACTAAGTACAATGAGAAGTTCAGAGC
      150     160     170     180     190     200     210

      200     210     220     230     240     250     260
AAGGCCACTATTACAGCGGACACGTCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGAC
||||||| ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAGGCCACACTGACTGTAGACAAACCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC
      220     230     240     250     260     270     280

      270     280     290     300     310     320     330
ACTGCCGTCTACTACTGTG-CAGA-CGGAATGTGG--GTATCAACGGGATATGCTCTGGACTTCTGGGGCCA
||| ||||| || |||| ||| ||| ||| ||| ||| ||| ||| ||||| ||||| ||||| |||||
TCTGCGGTCTATTATTGTGTAAGATACGACTACGGTAGTAGCTAC----TA--CT-TTGACTACTGGGGCCA
      290     300     310     320     330     340     350

      340     350      X
AGGGACCACGGTCACCGTCTCCTCA
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGGACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTTCAGCGGAGGTGGCTCTGGCGGTGGCGGATCCCA
      360     370     380     390     400     410     420

```

GGC

ID Q15164 standard; DNA; 458 BP.
 AC Q15164;
 DT 16-MAR-1992 (first entry)
 DE VH186 region of anti-nitrophenylacetyl heavy chain Ab gene.
 KW mouse; murine; antibody; heavy chain; variable region;
 KW polymerase chain reaction; ss.
 OS Mus musculus.
 PN J03247283-A.
 PD 05-NOV-1991.
 PF 29-DEC-1989; 340628.
 PR 29-DEC-1989; JP-340628.
 PA (MATU) MATSUSHITA ELEC IND KK.
 DR WPI; 91-366330/50.
 PT DNA binding to termini of anti-nitrophenyl:acetyl antibody gene
 PT - allows specific amplification of variable region in gene by PCR
 PS Disclosure; Page 2; 3pp; Japanese.
 CC This sequence corresponds to the region of the heavy chain variable
 CC region of the murine anti-nitrophenylacetyl IgG antibody which is
 CC amplified by PCR primers HA and HS.
 CC See Q15159-Q15163.
 SQ Sequence 458 BP; 112 A; 124 C; 120 G; 102 T;

Initial Score = 233 Optimized Score = 277 Significance = 15.83
 Residue Identity = 78% Matches = 283 Mismatches = 72
 Gaps = 7 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAACTGCAGCAGTCTGGGG
                                ||| ||||| ||||| |||||
GCTGTATCATGCTCTTCTTGGCAGCAACAGCTACAGGTGTCCACTCCCAGGTCCAAGTGCAGCAGCCTGGGG
  20      30      40      50      60      70      80

  30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGAGCTTGTGAAGCCTGGGGCTTCAAGTGAAGCTGTCTGCAAGGCTTCTGGCTACACCTTACCAGCTACT
  90      100     110     120     130     140     150

  100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GGATGCACTGGGTGAAGCAGAGGCTGGACGAGGCTTGAAGTGGATTGGAAGGATTGATCCTAATAGTGGTG
  160     170     180     190     200     210     220

  170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GTACTAAGTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTAGACAAACCCTCCAGCACAGCCTACA
  230     240     250     260     270     280     290

  240     250     260     270     280     290     300     310
TGCAGCTCAGCAGCCTGACATCTGAGGACTGCGGTCTACTACTGTGCAGACGGAATGTGGGTATCAACGG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGCAGCTCAGCAGCCTGACATCTGAGGACTGCGGTCTATTATTGTGCA---AGA-TACGATTA-CTACGG
  300     310     320     330     340     350     360

  320     330     340     350      X
GATATGCT-CT-GGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
| ||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TAGTAGCTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGCCAAAACAACAGCCCCATC
  370     380     390     400     410     420     430

GGTCTATCCACTGGCCCCTGT
  440     450

```

14. US-07-977-702-1 (1-360)
006227 VH domain of antibody C against tumour-associated

ID 006227 standard; DNA; 345 BP.
AC 006227;
DT 22-JAN-1991 (first entry)
DE VH domain of antibody C against tumour-associated antigens.
KW Tumour-associated antigen; murine monoclonal antibody C;
KW pancreatic carcinoma; metastases; diagnosis; ss.
OS Mus musculus.
PN EP-388914-A.
PD 26-SEP-1990.
PF 21-MAR-1990; 105322.
PR 24-MAR-1989; DE-909799.
PA (BEHW) BEHRINGWERKE AG.
PI Bosslet K, Seemann G, Sedlacek HH;
DR MPI; 90-291873/39.
DR P-PSDB; R07320.
PT Monoclonal antibodies to tumour associated antigens - used for
PT diagnosis of malignant tumours etc.
PS Disclosure; Page 13; 18pp; German.
CC Antibody C is produced as described in EP-141079 and binds to
CC pancreatic carcinoma primary tumours and metastases.
CC They are useful in tumour diagnosis and therapy.
CC See also 006228 for VK of MAb C, 007312-15 for MAb A and B and
CC 006229-30 for MAb D.
SQ Sequence 345 BP; 87 A; 87 C; 93 G; 78 T;

Initial Score = 229 Optimized Score = 245 Significance = 15.53
Residue Identity = 71% Matches = 255 Mismatches = 86
Gaps = 15 Conservative Substitutions = 0

```

X      10      20      30      40      50      60
GTCAAAGTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCT
||| ||||| ||||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGGTCCAAGTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAAGTGAAGATGTCCTGCAAGGCT
X      10      20      30      40      50      60      70
```

```

70      80      90     100     110     120     130     140
TCTGGCTTCAACATT-AAAGACACCTATATGCACTGGGTGAAGCAGAGGCTGAACAGGGGCTGGAGTGGAT
||||| ||| ||||| || ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TCTGGATAC-ACATTCACTTACTATGTTATTCAGTGGGTGAAACAGAAGCCTGGGCAGGGGCTTGAGTGGAT
      80      90     100     110     120     130     140
```

```

      150     160     170     180     190     200     210
TGGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCCAGGTCAAGGCCACTATTACAGC
||||| ||| ||||| || ||| ||||| || ||| ||||| ||| ||||| ||||| ||||| |||||
TGGATACATTATCCTTACAATGCTGGTACTGAGTACAATGAGAAGTTCAAAGGCAAGGCCACACTGACTTC
      150     160     170     180     190     200     210
```

```

      220     230     240     250     260     270     280
GGACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTG
||||| ||||| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGCCTGACCTCTGAGGACTCTGCCGTCTATTACTG
      220     230     240     250     260     270     280
```

```

      290     300     310     320     330     340     350   X
TGCAGACGGAATGTGGGTATCAACGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTC
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
TTCA-ATGGGACGAGGGGT-----GACTA--CTGGGGCC--AAGGGACCACGG--TCACCGTCTCC-TCA
      290     300     310     320     330     340     350   X
```

360
CTCA

N91482 Genomic to cDNA junction (V47 to VB1-8) DNA

Initial Score = 228 Optimized Score = 269 Significance = 15.46
Residue Identity = 77% Matches = 275 Mismatches = 71
Gaps = 7 Conservative Substitutions = 0

290 300 310 320 330 340 350
GACGGAATGTGGGTATCAACGGGATATGCT-CT-GGACTTCTGGGGCCAAGGACCACGGTCACCGTCTCCT
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
---AGA-TACGATT-CTACGGTAGTAGCTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCT
280 290 300 310 320 330 340

360
CA
II
CAG
X

> 0 <
0| 0 IntelliGenetics
> 0 <


FastDB - Fast Pairwise Comparison of Sequences
Release 5.4


Results file us-07-977-702-1.res made by shears on Tue 15 Jun 93 12:27:44-PDT.

Query sequence being compared:US-07-977-702-1 (1-360)
Number of sequences searched: 125798
Number of scores above cutoff: 4369

Results of the initial comparison of US-07-977-702-1 (1-360) with:

Data bank : EMBL-NEW 3, all entries
Data bank : GenBank 75, all entries
Data bank : GenBank-NEW 3, all entries
Data bank : UEMBL 34_75, all entries





PARAMETERS

| | | | |
|--------------------------|---------|--------------------|----|
| Similarity matrix | Unitary | K-tuple | 4 |
| Mismatch penalty | 1 | Joining penalty | 30 |
| Gap penalty | 1.00 | Window size | 32 |
| Gap size penalty | 0.33 | | |
| Cutoff score | 0 | | |
| Randomization group | 0 | | |
| Initial scores to save | 40 | Alignments to save | 15 |
| Optimized scores to save | 0 | Display context | 50 |

SEARCH STATISTICS

| Scores: | Mean | Median | Standard Deviation |
|---------|------|--------|--------------------|
| | 28 | 28 | 13.45 |

| Times: | CPU | Total Elapsed |
|--------|-------------|---------------|
| | 00:30:37.12 | 01:03:42.00 |

| | |
|--------------------------------|-----------|
| Number of residues: | 150464018 |
| Number of sequences searched: | 125798 |
| Number of scores above cutoff: | 4369 |

Cut-off raised to 22.
 Cut-off raised to 26.
 Cut-off raised to 30.
 Cut-off raised to 33.
 Cut-off raised to 36.
 Cut-off raised to 39.
 Cut-off raised to 41.
 Cut-off raised to 44.
 Cut-off raised to 46.
 Cut-off raised to 49.
 Cut-off raised to 53.
 Cut-off raised to 58.
 Cut-off raised to 64.

The scores below are sorted by initial score.
 Significance is calculated based on initial score.

A 100% identical sequence to the query sequence was not found.

The list of best scores is:

| Sequence Name | Description | Length | Score | Init. Opt. | Score | Sig. | Frame |
|---|-------------------------------|--------|-------|------------|-------|------|-------|
| **** 20 standard deviations above mean **** | | | | | | | |
| 1. MMIGGNP2 | Mouse mRNA for idiotypic anti | 420 | 310 | 318 | 20.97 | 0 | |
| 2. MMCEAHCH | M.musculus gene for anti-CEA | 861 | 309 | 316 | 20.89 | 0 | |
| 3. MUSIGHNPA | Mouse Ig active H-chain mRNA, | 421 | 305 | 318 | 20.60 | 0 | |
| **** 18 standard deviations above mean **** | | | | | | | |
| 4. MUSIGHNP | Mouse Ig active H-chain mRNA, | 414 | 281 | 314 | 18.81 | 0 | |
| 5. MMIGGNP1 | Mouse mRNA for idiotypic anti | 414 | 281 | 314 | 18.81 | 0 | |
| 6. MMV20292B | M.musculus mRNA for VH-gen se | 363 | 276 | 282 | 18.44 | 0 | |
| 7. S114902 | immunoglobulin heavy chain (n | 452 | 276 | 281 | 18.44 | 0 | |
| 8. MMIGVDJAA | M.musculus immunoglobulin hea | 452 | 276 | 281 | 18.44 | 0 | |
| 9. MUSIGHNPG | Mouse Ig active H-chain mRNA, | 414 | 273 | 309 | 18.22 | 0 | |
| 10. MMIGGNP8 | Mouse mRNA for idiotypic anti | 414 | 273 | 307 | 18.22 | 0 | |
| 11. MUSIGHNPB | Mouse Ig active H-chain mRNA, | 414 | 272 | 307 | 18.14 | 0 | |
| 12. MMIGGNP3 | Mouse mRNA for idiotypic anti | 414 | 272 | 308 | 18.14 | 0 | |
| 13. MMIGG1HCV | M.musculus rearranged mRNA fo | 351 | 271 | 316 | 18.07 | 0 | |
| 14. MUSIGMU4G | Mouse monoclonal antiidiotypi | 354 | 271 | 307 | 18.07 | 0 | |
| 15. MUSIGHBB | Mouse Ig active mu-chain VDJ- | 390 | 271 | 326 | 18.07 | 0 | |
| 16. MUSIGHBH | Mouse Ig active H-chain: anti | 501 | 271 | 324 | 18.07 | 0 | |
| 17. MMIGVK1 | Mouse mRNA for anti-GAT VH an | 501 | 271 | 324 | 18.07 | 0 | |
| 18. MUSIGHXO | Mouse Ig germline H-chain gen | 970 | 271 | 305 | 18.07 | 0 | |
| 19. MMIG10VH | Mouse (GAT-specific) subgroup | 970 | 271 | 305 | 18.07 | 0 | |
| 20. MMIGHVXA | Mouse (hybridoma 3A112) immun | 1069 | 271 | 277 | 18.07 | 0 | |
| 21. MUSIGHVXA | Mouse (hybridoma 3A112) immun | 1069 | 271 | 277 | 18.07 | 0 | |
| **** 17 standard deviations above mean **** | | | | | | | |
| 22. MMV20311 | M.musculus mRNA for VH-gen se | 363 | 270 | 279 | 17.99 | 0 | |
| 23. MUSIGHADE | Mouse Ig rearranged H-chain g | 404 | 270 | 275 | 17.99 | 0 | |
| 24. MUSIGHEA | Mouse Ig mu-chain active V-re | 444 | 269 | 322 | 17.92 | 0 | |
| 25. MUSIGHDZ | Mouse Ig mu-chain active V-re | 444 | 269 | 322 | 17.92 | 0 | |
| 26. MUSIGHNPH | Mouse Ig active H-chain mRNA, | 417 | 268 | 321 | 17.85 | 0 | |
| 27. MUSIGHBC | Mouse Ig active H-chain a-NP | 511 | 268 | 321 | 17.85 | 0 | |
| 28. MUSIGHZTA | Mouse Ig germline H-chain gen | 294 | 267 | 272 | 17.77 | 0 | |
| 29. MUSIGHZP | Mouse Ig germline H-chain gen | 294 | 266 | 271 | 17.70 | 0 | |
| 30. MUSIGHAEM | Mouse Ig heavy-chain mRNA V r | 328 | 266 | 288 | 17.70 | 0 | |
| 31. MUSIGB1H1 | Mouse mRNA for immunoglobulin | 1544 | 266 | 271 | 17.70 | 0 | |
| 32. MMIGB1H1 | Mouse mRNA for immunoglobulin | 1544 | 266 | 271 | 17.70 | 0 | |
| 33. MUSIGHZQ | Mouse Ig germline H-chain gen | 291 | 265 | 268 | 17.62 | 0 | |
| 34. MUSIGHZN | Mouse Ig germline H-chain gen | 291 | 265 | 267 | 17.62 | 0 | |
| 35. MUSIGHDF | Mouse Ig active mu-chain V-re | 363 | 265 | 271 | 17.62 | 0 | |
| 36. MMIGNP4 | Mouse mRNA for idiotypic anti | 411 | 265 | 310 | 17.62 | 0 | |
| 37. MUSIGHNPE | Mouse Ig active H-chain mRNA, | 417 | 265 | 312 | 17.62 | 0 | |
| 38. MMIGGNP6 | Mouse mRNA for idiotypic anti | 417 | 265 | 312 | 17.62 | 0 | |
| 39. MMIGWM65B | M.musculus WM65 immunoglobuli | 536 | 265 | 317 | 17.62 | 0 | |
| 40. MMIGHVXZ | Mouse (hybridoma H1-39) immun | 1068 | 265 | 273 | 17.62 | 0 | |

1. US-07-977-702-1 (1-360)

MMIGGNP2 Mouse mRNA for idiotypic anti-NP IgG(1) heavy chain

LOCUS MMIGGNP2 420 bp RNA ROD 07-MAY-1992

DEFINITION Mouse mRNA for idiotypic anti-NP IgG(1) heavy chain V-D-J (hybridoma 18.1.16)

ACCESSION X02563 M12744

KEYWORDS gamma-immunoglobulin; Ig D-segment; Ig heavy chain; immunoglobulin; joining region; signal peptide; variable region.

SOURCE mouse

ORGANISM Mus musculus

Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.

REFERENCE 1 (bases 1 to 420)

AUTHORS Boersch-Supan,M.E., Agarwal,S., White-Scharf,M.E. and Imanishi-Kari,T.
 TITLE Heavy chain variable region: Multiple gene segments encode anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 COMMENT *source: strain=Balb/c;

Serological analysis of hybridoma proteins resulting from the immune response to the hapten NP reveals NP(a) idiotypes expressed by Balb/C mice and NP(b) idiotypes expressed by C57 BL/6 mice. The NP(b) family of antibodies consists of 6 subgroups (I-VI) with I-IV sharing more determinants than V and VI which appear quite distinct.

FEATURES Location/Qualifiers
 sig_peptide 1..57
 mat_peptide join(58..351,352..375,376..420)
 /product="idiotypic anti-NP IgG(1) heavy chain V-D-J"
 misc_feature 58..351
 /note="variable region (aa 1-98)"
 misc_feature 148..162
 /note="CDR I"
 misc_feature 205..255
 /note="CDR II"
 misc_feature 352..375
 /note="D-region (aa 99-106)"
 misc_feature 376..>420
 /note="J-region (aa 107-121)"
 CDS join(1..351,352..375,376..420)
 /product="idiotypic anti-NP IgG(1) heavy chain V-D-J"
 /codon_start=1
 /translation="MKCSWVMFFLMAVVTGVNSEVQLQSGAELVKPGASVKLSCTAS
 GFNIKDTYMHVVKRPEQGLEWIGRIDPANGNTKYDPKFQGGKATITADTSSNTAYLQL
 SSLTSEDYAVYYCARYLYYYGSSDFDYWGQGTTLTVSS"

BASE COUNT 107 a 106 c 110 g 97 t
 ORIGIN

Initial Score = 310 Optimized Score = 318 Significance = 20.97
 Residue Identity = 88% Matches = 323 Mismatches = 34
 Gaps = 6 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GCTGGGTTATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTACAGTGCAGCAGTCTGGGG
      20      30      40      50      60      70      80

      30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACGGCTTCTGGCTTCAACATTAAAGACACCT
      90      100      110      120      130      140      150

      100      110      120      130      140      150      160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTA
      160      170      180      190      200      210      220

      170      180      190      200      210      220      230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATACTAAATATGACCCGAAGTTCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC
      230      240      250      260      270      280      290

      240      250      260      270      280      290      300
  
```

TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGCTCTACTACTGTGC-AGACGGAAATGTGGGTATCAACG
 |||||
 TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGCTCTACTACTGTGCTAGA---TACCTCTATTACTACG
 300 310 320 330 340 350 360

310 320 330 340 350 X
 GGA-TA-TGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
 |||||
 GTAGTAGCGACTTTGACTACTGGGGCCAAGGGACCACTCTCACAGTCTCCTCA
 370 380 390 400 410 420

2. US-07-977-702-1 (1-360)

MMCEAHCH M.musculus gene for anti-CEA mAb T84.66 heavy chain

LOCUS MMCEAHCH 861 bp DNA ROD 03-DEC-1992
 DEFINITION M.musculus gene for anti-CEA mAb T84.66 heavy chain V-region
 ACCESSION X52769
 KEYWORDS CEA; heavy chain; tumor-associated antigen.
 SOURCE mouse
 ORGANISM Mus musculus
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
 Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 861)
 AUTHORS Neumaier, M., Shively, L., Chen, F.S., Gaida, F.J., Ilgen, C.,
 Paxton, R.J., Shively, J.E. and Riggs, A.D.
 TITLE Cloning of the genes for T86.66, an antibody that has a high
 specificity and affinity for carcinoembryonic antigen, and
 expression of chimeric human/mouse T84.66 genes in myeloma and
 Chinese hamster ovary cells
 JOURNAL Cancer Res. 50, 2128-2134 (1990)
 STANDARD full automatic
 FEATURES Location/Qualifiers
 promoter 109..118
 promoter 121..127
 promoter 160..166
 promoter 169..176
 exon 272..317
 /number=1
 exon 396..770
 /number=2
 intron 318..395
 /number=1
 CDS join(272..317,396..770)
 /partial
 /note="heavy chain"
 /product="anti-CEA mAb T84.66"
 /codon_start=1
 /translation="MKCSWVIFFLMAVVTGVNSEVQLQDSGAELVEPGASVKLSCTAS
 GFNIKDTYMHVWKQRPEQGLEWIGRIDPANGNSKYVPKFQKATITADTSSNTAYLQL
 TSLTSEDYAVYYCAPFGYYVSDYAMAYWGQGTSTVTVSS"

BASE COUNT 213 a 208 c 203 g 237 t
 ORIGIN

Initial Score = 309 Optimized Score = 316 Significance = 20.89
 Residue Identity = 88% Matches = 322 Mismatches = 33
 Gaps = 10 Conservative Substitutions = 0

X 10 20
 GTCAAAGTGCAGCAGTCTGGGG
 |||
 GTGACAGTGGCAATCACTTTGCCCTTTCTTCTACAGGGGTCAATTCAGAGGTTAGCTGCAGCAGTCTGGGG
 360 370 380 390 400 410 420 430

30 40 50 60 70 80 90
 CAGAGCTTGTAAGCCAGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAGACACCT

```

|||||
CAGAGCTTGTGGAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
440      450      460      470      480      490      500

100      110      120      130      140      150      160
ATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
|||||
ATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAATGGATTGGAAGGATTGATCCTGCGAATGGTA
510      520      530      540      550      560      570

170      180      190      200      210      220      230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
|||
ATAGTAAATATGTCCCGAAGTTCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC
580      590      600      610      620      630      640

240      250      260      270      280      290      300
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGGAATGTGGGTATCAACG-
|||||
TGCAGCTCACCAGCCTGACATCTGAGGACACTGCCGTCTATTATTGTGC-TCCG---TTTGGTTA-CTACGT
650      660      670      680      690      700      710

310      320      330      340      350      X
----GGATATGCTCTGGACTTCTGGGGCCAGGGACCACGGTCACCGTCTCCTCA
|
GTCTGACTATGCTATGGCCTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGGTAAGAATGGCCTCTC
720      730      740      750      760      770      780

CAGGTCTTTATTTTAACTTTGTATGGACTTT
790      800      810

```

3. US-07-977-702-1 (1-360)

MUSIGHNPA Mouse Ig active H-chain mRNA, V-region (VDJ) from

```

LOCUS      MUSIGHNPA      421 bp ss-mRNA      ROD      01-SEP-1988
DEFINITION Mouse Ig active H-chain mRNA, V-region (VDJ) from anti-NP hybridoma
18.1.16.
ACCESSION  M12744
KEYWORDS   immunoglobulin; immunoglobulin heavy chain; variable region.
SOURCE     Mouse (BALB/c) hybridoma 18.1.16, cDNA to mRNA.
ORGANISM   Mus musculus
            Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
            Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
REFERENCE  1 (bases 1 to 421)
AUTHORS    Boersch-Supan,M.E., Agarwal,S., White-Scharf,M.E. and
            Imanishi-Kari,T.
TITLE      Heavy chain variable region Multiple gene segments encode
            anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
JOURNAL    J. Exp. Med. 161, 1272-1292 (1985)
STANDARD   full automatic
FEATURES   Location/Qualifiers
            sig_peptide      1..57
                        /codon_start=1
                        /note="Ig H-chain V-region signal peptide"
            mat_peptide      58..421
                        /codon_start=1
                        /note="Ig H-chain V-region"
            misc_recomb      351..352
                        /note="V-region end/D-region start"
            misc_recomb      375..376
                        /note="D-region end/J-region start"
            CDS               1..421
                        /note="Ig H-chain; (VDJ-region) precursor"
                        /codon_start=1
                        /translation="MKCSWVMFFLMAVVTGVNSEVQLQSGAELVKPGASVKLSCTAS

```

GFNIRDITMHWVRPEGLWIGRIDPANGNIRYDPRFQGRATITADTSSNTAYLQL
 SSLTSEDVAVYYCARYLYYYGSSYFDYWGQGTTLTVSLX"

BASE COUNT 107 a 106 c 110 g 98 t
 ORIGIN Chromosome 12.

Initial Score = 305 Optimized Score = 318 Significance = 20.60
 Residue Identity = 89% Matches = 324 Mismatches = 33
 Gaps = 7 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAAGTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GCTGGGTTATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTGAGTGCAGCAGTCTGGGG
   20      30      40      50      60      70      80

   30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACGGCTTCTGGCTTCAACATTAAAGACACCT
   90     100     110     120     130     140     150

  100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTA
  160     170     180     190     200     210     220

  170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATACTAAATATGACCCGAAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC
  230     240     250     260     270     280     290

  240     250     260     270     280     290     300
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGC-AGACGGAATGTGGGTATCAACG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGCTAGA---TACCTCTATTACTACG
  300     310     320     330     340     350     360

  310     320     330     340     350      X
GGATATGCT-CT-GGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTC-CTCA
|| ||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GTAGTAGCTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCGCTCA
  370     380     390     400     410     420

```

4. US-07-977-702-1 (1-360)

MUSIGHNP Mouse Ig active H-chain mRNA, V-region (VDJ) from

LOCUS MUSIGHNP 414 bp ss-mRNA ROD 01-SEP-1988
 DEFINITION Mouse Ig active H-chain mRNA, V-region (VDJ) from anti-NP hybridoma 20.1.43.
 ACCESSION M12176
 KEYWORDS immunoglobulin; immunoglobulin heavy chain; variable region.
 SOURCE Mouse (BALB/c) hybridoma 20.1.43, cDNA to mRNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
 Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 414)
 AUTHORS Boersch-Supan, M.E., Agarwal, S., White-Scharf, M.E. and Inanishi-Kari, T.
 TITLE Heavy chain variable region Multiple gene segments encode anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 FEATURES Location/Qualifiers

```

sig_peptide 1..57
              /codon_start=1
              /note="Ig H-chain V-region signal peptide"
mat_peptide  58..>414
              /codon_start=1
              /note="Ig H-chain V-region"
misc_recomb  351..352
              /note="V-region end/D-region start"
misc_recomb  366..367
              /note="D-region end/J-region start"
CDS           1..>414
              /note="Ig H-chain; (VDJ-region) precursor"
              /codon_start=1
              /translation="MKCSWVMFFLMAVVTGVNSEVQLQSGAELVRPGASVKLSCTAS
              GFNIKDTYMHVVKQRPEQGLEWIGRIDPANGNTKYDPKFQGKATITADTSSNTAYLQL
              SSLTSEDTA VVYCASYRYERAWFAYWGQGLTVTSA"
BASE COUNT   101 a    98 c    118 g    97 t
ORIGIN        Chromosome 12.

```

```

Initial Score   =   281   Optimized Score   =   314   Significance   = 18.81
Residue Identity =   88%   Matches           =   321   Mismatches    =   31
Gaps            =    10   Conservative Substitutions   =    0

```

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | |||||
GCTGGGTTATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTACGCTGCAGCAGTCTGGGG
    20      30      40      50      60      70      80

    30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAGGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
    90     100     110     120     130     140     150

    100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTA
    160     170     180     190     200     210     220

    170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATACTAAATATGACCCGAAGTTCAGGGCAAGGCCACTATAACAGCAGACACATCTCCAACACAGCCTACC
    230     240     250     260     270     280     290

    240     250     260     270     280     290     300
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGC-AGACGGAATGTGGGTATCAACG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGCTAG-----TTATAGGTA-CGAGA
    300     310     320     330     340     350     360

    310     320     330     340     350     360
GGATATGCTCTGGACTT-CTGGGGCCAAGGGACCACGGTCACCGTCTCCTCA
|| || || || || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GGGCCTGGTTTG--CTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
    370     380     390     400     410   X

```

5. US-07-977-702-1 (1-360)

MMIGGNP1 Mouse mRNA for idiotypic anti-NP IgG(1) heavy chain

```

LOCUS      MMIGGNP1      414 bp      RNA      ROD      07-MAY-1992
DEFINITION Mouse mRNA for idiotypic anti-NP IgG(1) heavy chain V-J (hybridoma
20.1.43)

```

ACCESSION X02362 M12176
 KEYWORDS gamma-immunoglobulin; Ig D-segment; Ig heavy chain; immunoglobulin; joining region; signal peptide; variable region.
 SOURCE mouse
 ORGANISM Mus musculus
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 414)
 AUTHORS Boersch-Supan,M.E., Agarwal,S., White-Scharf,M.E. and Imanishi-Kari,T.
 TITLE Heavy chain variable region: Multiple gene segments encode anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 COMMENT #source: strain=Balb-c;

Serological analysis of hybridonaproteins resulting from the immune response to the hapten NP reveals NP(a) idiotypes expressed by Balb/C mice and NP(b) idiotypes expressed by C57 BL/6 mice. The NP(b) family of antibodies consists of 6 subgroups (I-VI) with I-IV sharing more determinants than V and VI which appear quite distinct.

FEATURES Location/Qualifiers
 sig_peptide 1..57
 misc_feature 58..351
 /note="variable region (aa 1-98)"
 misc_feature 148..162
 /note="CDR 1"
 misc_feature 205..255
 /note="CDR 2"
 misc_feature 352..366
 /note="D-region (aa 99-103)"
 misc_feature 367..>414
 /note="J-region (aa 104-119)"
 CDS join(58..351,352..366,367..414)
 /product="idiotypic anti-NP IgG(1) heavy chain V-J"
 /codon_start=1
 /translation="EVQLQQSGAELVRPGASVKLSCTASGFNIKDTYMHVVKQRPEQG
 LEWIGRIDPANGNTKYDPKFGKATITADTSSNTAYLQLSSLTSEDYVYYCASRYRE
 RAWFAYWGQGTLLTVTSA"
 BASE COUNT 101 a 98 c 118 g 97 t
 ORIGIN

Initial Score = 281 Optimized Score = 314 Significance = 18.81
 Residue Identity = 88% Matches = 321 Mismatches = 31
 Gaps = 10 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAAGTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GCTGGGTTATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGTTTCAGCTGCAGCAGTCTGGGG
    20      30      40      50      60      70      80

    30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAGGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
    90     100     110     120     130     140     150

    100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCCAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCCAATGGTA
    160     170     180     190     200     210     220

    170     180     190     200     210     220     230
  
```



```

70      80      90      100     110     120     130     140
TCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATT
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
TCTGGCTACACCTTACCAGCTACTGGATGCACTGGGTGAAGCAGAGGCCTGGACGAGGCCTTGAGTGGATT
      80      90      100     110     120     130     140

      150     160     170     180     190     200     210
GGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCG
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GGAAGGATTGATCCTAATAGTGGTGGTACTAAGTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTA
      150     160     170     180     190     200     210

      220     230     240     250     260     270     280
GACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGT
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GACAAACCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGACTCTGCGGTCTATTATTGT
      220     230     240     250     260     270     280

      290     300     310     320     330     340     350
GCAGACGGAATGTGGGTAT--CAA--CGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGT
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
GCA-AGAGA---TGGGTATGGTAACCTCCCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGT
290      300      310      320      330      340      350

      360
CTCCTCA
|||||
CTCCTCA
360 X

```

7. US-07-977-702-1 (1-360)

S114902 immunoglobulin heavy chain (nonfunctional VDJ comp

```

LOCUS      S114902      452 bp      DNA              ROD      30-NOV-1992
DEFINITION immunoglobulin heavy chain (nonfunctional VDJ complex) [mice, pre-B
cell line 46 transformed with ts mutant of A-MuLV, Genomic, 452 nt]
ACCESSION  S45712
KEYWORDS
SOURCE     mice pre-B cell line 46 transformed with ts mutant of A-MuLV
ORGANISM   Unclassified.
           Unclassified.
REFERENCE  1 (bases 1 to 452)
AUTHORS    Shirasawa,T., Miyazoe,I., Hagiwara,S., Kinoto,H., Shigemoto,K.,
           Taniguchi,M. and Takemori,T.
TITLE      Heavy chain variable (VH) region diversity generated by VH gene
           replacement in the progeny of a single precursor cell transformed
           with a temperature-sensitive mutant of Abelson murine leukemia
           virus.
JOURNAL    J. Exp. Med. 176, 1209-1214 (1992)
STANDARD   full automatic
COMMENT    This entry [NCBI gibbsq 114902] was created by the journal scanning
           component of NCBI/GenBank at the National Library of Medicine.
           This sequence comes from Fig. 2. The authors begin their numbering
           at -6. Zero is not present in the numbering.
FEATURES
  CDS             Location/Qualifiers
                   join(7..52,132..452)
                   /partial
                   /note="Description: immunoglobulin heavy chain"
BASE COUNT      113 a      115 c      115 g      109 t
ORIGIN

```

```

Initial Score      =      276  Optimized Score      =      281  Significance = 18.44
Residue Identity   =      91%  Matches              =      284  Mismatches   =      22
Gaps               =           3  Conservative Substitutions      =           0

```

```

X      10      20
GTCAAAGTGCAGCAGTCTGGGG
|| | |||||
GTGACAGTGGCAATCACTTTGCCTTTCTTTCTACAGGGGTCAATTCAGAGTTTCAGCTGCAGCAGTCTGGGG
100      110      120      130      140      X 150      160

30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
|||||
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
170      180      190      200      210      220      230

100      110      120      130      140      150      160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
|||||
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTA
240      250      260      270      280      290      300      310

170      180      190      200      210      220      230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
|||||
ATACTAAATATGACCCGAAGTTCAGGGCAGGCCACTATAACAGCAGACATCCTCCAACACAGCCTACC
320      330      340      350      360      370      380

240      250      260      270      280      290      300      X
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGG-AATGTGGGTATCAACG
|||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGC-TACGGTCCCTGGTA-CTTC
390      400      410      420      430      440      450 X

310      320      330      340      350
GGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCCT

```

8. US-07-977-702-1 (1-360)

MMIGVDJAA M.musculus immunoglobulin heavy chain VDJ complex

ID MMIGVDJAA standard; DNA; ROD; 452 BP.
XX
AC Z21679;
XX
DT 17-FEB-1993 (Rel. 35, Created)
DT 17-FEB-1993 (Rel. 35, Last updated, Version 1)
XX
DE M.musculus immunoglobulin heavy chain VDJ complex gene.
XX
KW immunoglobulin heavy chain; VDJ complex.
XX
OS Mus musculus (mouse)
OC Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
OC Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
XX
RN [1]
RP 1-452
RA Shirasawa T., Miyazoe I., Hagiwara S., Kimoto H., Shigemoto K.,
RA Taniguchi M., Takenori T.;
RT "Heavy Chain Variable (VH) Region Diversity Generated by VH Gene
RT Replacement in the Progeny of a Single Precursor Cell Transformed
RT with a Temperature-sensitive Mutant of Abelson Murine Leukemia
RT Virus";
RL J. Exp. Med. 176:1209-1214(1992).
XX
RN [2]
RP 1-452
RA Shirasawa T.;

RL Submitted (27-JAN-1993) on tape to the EMBL Data Library by:
RL Takuji Shirasawa, Molecular Pathology, Tokyo Metropolitan Institute
RL of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo, 173, Japan

XX
CC *source: strain=BALB/c;
CC *source: cell_line=pre-B cell;
CC *source: clone_library=pre-B cell;
CC *source: clone=VDJ;
CC *source: is_macronuclear=N;
CC *source: is_proviral=N;
CC *source: is_germline=N;

XX
FH Key Location/Qualifiers
FH
FT exon 7..52
FT /number=1
FT intron 53..131
FT exon 132..452
FT /number=2
FT CDS join(7..52,132..>452)
FT /product="VDJ complex"
FT misc_feature 432..439
FT /note="D region"
FT misc_feature 440..442
FT /note="N sequence"
FT misc_feature 443..452
FT /note="J region"

XX
SQ Sequence 452 BP; 113 A; 115 C; 115 G; 109 T; 0 other;

Initial Score = 276 Optimized Score = 281 Significance = 18.44
Residue Identity = 91% Matches = 284 Mismatches = 22
Gaps = 3 Conservative Substitutions = 0

X 10 20
GTCAAAGTGCAGCAGTCTGGGG
||| |

GTGACAGTGGCAATCACTTTGCCTTTCTTTCTACAGGGGTCAATTCAGAGTTTCAGCTGCAGCAGTCTGGGG
100 110 120 130 140 X 150 160

30 40 50 60 70 80 90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
|||||
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
170 180 190 200 210 220 230

100 110 120 130 140 150 160
ATATGCACTGGGTGAAGCAGAGGCCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
|||||
ATATGCACTGGGTGAAGCAGAGGCCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTA
240 250 260 270 280 290 300 310

170 180 190 200 210 220 230
ATACTAAATATGACCCGAAGTTCAGGTCAGGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
|||||
ATACTAAATATGACCCGAAGTTCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC
320 330 340 350 360 370 380

240 250 260 270 280 290 300 X
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGG-AATGTGGGTATCAACG
|||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGC-TACGGTTCCCCTGGTA-CTTC
390 400 410 420 430 440 450 X

310 320 330 340 350

9. US-07-977-702-1 (1-360)

MUSIGHNPG Mouse Ig active H-chain mRNA, V-region (VDJ) from

LOCUS MUSIGHNPG 414 bp ss-mRNA ROD 01-SEP-1988
 DEFINITION Mouse Ig active H-chain mRNA, V-region (VDJ) from anti-NP hybridoma P3.6.5.
 ACCESSION M12750
 KEYWORDS immunoglobulin; immunoglobulin heavy chain; variable region.
 SOURCE Mouse (C57BL/6) group V hybridoma P3.6.5, cDNA to mRNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
 Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 414)
 AUTHORS Boersch-Supan,M.E., Agarwal,S., White-Scharf,M.E. and
 Imanishi-Kari,T.
 TITLE Heavy chain variable region Multiple gene segments encode
 anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 FEATURES Location/Qualifiers
 sig_peptide 1..57
 /codon_start=1
 /note="Ig H-chain V-region signal peptide"
 mat_peptide 58..414
 /codon_start=1
 /note="Ig H-chain V-region"
 misc_recomb 351..352
 /note="V-region end/D-region start"
 misc_recomb 372..373
 /note="D-region end/J-region start"
 CDS 1..414
 /note="Ig H-chain; (VDJ-region) precursor"
 /codon_start=1
 /translation="MKCSWIMFFLMAVVTGVNSEVQLQSGAELVRPGASVKLSCTAS
 GFNIKDTYMHVVKQRTQGLEWIGRIDPEDGETKYAPKFQVKATITADTSSNTAYLQL
 SSLTSEDYAVYYCARYYYGSSFFAYWGQGLVTVSA"
 BASE COUNT 103 a 99 c 113 g 99 t
 ORIGIN Chromosome 12.

Initial Score = 273 Optimized Score = 309 Significance = 18.22
 Residue Identity = 87% Matches = 317 Mismatches = 34
 Gaps = 12 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GCTGGATCATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTCACTGCAGCAGTCTGGGG
    20      30      40      50      60      70      80

    30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAGGCCAGGGGCCTCAGTCAAGTTGTCTGCACGGCTTCTGGCTTCAACATTAAAGACACCT
    90     100     110     120     130     140     150

    100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGACTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGAGGATGGTG
    160     170     180     190     200     210     220

    170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC

```


Initial Score = 273 Optimized Score = 307 Significance = 18.22
 Residue Identity = 86% Matches = 314 Mismatches = 38
 Gaps = 10 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | ||||| ||||| |||||
GCTGGATCATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTACAGTGCAGCAGTCTGGGG
   20      30      40      50      60      70      80

   30      40      50      60      70      80      90
CAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTGAGGCCAGGGGCTCAGTCAAGTGGTCTGCACGGCTTCTGGCTTCAACATTAAAGACACCT
   90     100     110     120     130     140     150

   100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGACTGAACAGGGCTGGAGTGGATTGGAAGGATTGATCCTGAGGATGGTG
   160     170     180     190     200     210     220

   170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAACTAAATATGCCCCGAAATTCAGGTCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC
   230     240     250     260     270     280     290

   240     250     260     270     280     290     300     310
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGGAATGTGGGTATCAACGG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGTGC--TAGCTAT-----TA-CTACGG
   300     310     320     330     340     350     360

   320     330     340     350     360
GA-TATGCTCTGGACTT-CTGGGGCCAAGGGACACGGTCACCGTCTCCTCA
| || ||| ||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TAGTAGCTTCTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
   370     380     390     400     410 X

```

11. US-07-977-702-1 (1-360)

MUSIGHNPB Mouse Ig active H-chain mRNA, V-region (VDJ) from

LOCUS MUSIGHNPB 414 bp ss-mRNA ROD 01-SEP-1988
 DEFINITION Mouse Ig active H-chain mRNA, V-region (VDJ) from anti-NP hybridoma P5.40.1.
 ACCESSION M12745
 KEYWORDS immunoglobulin; immunoglobulin heavy chain; variable region.
 SOURCE Mouse (C57BL/6) group VI hybridoma P5.40.1, cDNA to mRNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
 Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 414)
 AUTHORS Boersch-Supan, M.E., Agarwal, S., White-Scharf, M.E. and Imanishi-Kari, T.
 TITLE Heavy chain variable region Multiple gene segments encode anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 FEATURES Location/Qualifiers
 sig_peptide 1..57
 /codon_start=1
 /note="Ig H-chain V-region signal peptide"
 mat_peptide 58..>414

ORGANISM MUS MUSCULUS
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
 Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 414)
 AUTHORS Boersch-Supan,M.E., Agarwal,S., White-Scharf,M.E. and
 Imanishi-Kari,T.
 TITLE Heavy chain variable region: Multiple gene segments encode
 anti-4-(hydroxy-3-nitrophenyl)acetyl idiotypic antibodies
 JOURNAL J. Exp. Med. 161, 1272-1292 (1985)
 STANDARD full automatic
 COMMENT *source: strain=C57 BL/6;

Serological analysis of hybridoma proteins resulting from the immune
 response to the hapten NP reveals NP(a) idiotypes expressed by
 Balb/C mice and NP(b) idiotypes expressed by C57 BL/6 mice. The
 NP(b) family of antibodies consists of 6 subgroups (I-VI) with I-IV
 sharing more determinants than V and VI which appear quite
 distinct.

FEATURES Location/Qualifiers
 sig_peptide 1..57
 mat_peptide join(58..351,352..371,372..414)
 /product="idiotypic anti-NP IgG(1) heavy chain V-D-J"
 misc_feature 58..351
 /note="variable region"
 misc_feature 148..162
 /note="CDR I"
 misc_feature 205..255
 /note="CDR II"
 misc_feature 352..371
 /note="D-region (aa 99-105)"
 misc_feature 372..>414
 /note="J-region (aa 106-119)"
 CDS join(1..351,352..371,372..414)
 /product="idiotypic anti-NP IgG(1) heavy chain V-D-J"
 /codon_start=1
 /translation="MKFSWVMFFLMAVVTGVNSEVQLQGSVAELVRPGASVKLSCTAS
 GFNIKNTYMHVVKQRPEQGLEWIGRIDPANGSTKYAPKFQIKATITADTSSNTAYLQL
 SSLTSEDTAIYYCARYYYESSLFAYWGQGTLVTVSA"

BASE COUNT 102 a 101 c 111 g 100 t
 ORIGIN

Initial Score = 272 Optimized Score = 308 Significance = 18.14
 Residue Identity = 87% Matches = 315 Mismatches = 37
 Gaps = 10 Conservative Substitutions = 0

```

                                X      10      20
                                GTCAAACTGCAGCAGTCTGGGG
                                || | ||||| ||||| ||
GCTGGGTCATGTTCTTCTCTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTACGCTGCAGCAGTCTGTGG
    20      30      40      50      60      70      80

    30      40      50      60      70      80      90
CAGAGCTTGTAAGCCAGGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAGACACCT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAGAGCTTGTAAGCCAGGGGCCTCAGTCAAGTTGTCCTGCACAGCTTCTGGCTTCAACATTAAAAACACCT
    90     100     110     120     130     140     150

    100     110     120     130     140     150     160
ATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCCAGTGGCG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCCAATGGTA
    160     170     180     190     200     210     220

    170     180     190     200     210     220     230
ATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCGGACACGTCCTCCAACACAGCCTGGC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

```

```

      230      240      250      260      270      280      290
GTACTAAGTATGCCCCGAGGTTCCAGATCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACC

240      250      260      270      280      290      300      310
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGTGCAGACGGAATGTGGGTATCAACGG
|||||
TGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCATCTATTACTGTGC--TAGGTAT-----TA-CTACGA
300      310      320      330      340      350      360

      320      330      340      350      360
GA-TATGCTCTGGACTT-CTGGGGCCAAGGACACGGTCACCGTCTCCTCA
|| || || | |||
GAGTAGCCTGTTTGCTTACTGGGGCCAAGGACTCTGGTCACTGTCTCTGCA
370      380      390      400      410      X

```

13. US-07-977-702-1 (1-360)

MMIGG1HCV M.musculus rearranged mRNA for anti-cytochrome c i

LOCUS MMIGG1HCV 351 bp RNA ROD 21-NOV-1991
 DEFINITION M.musculus rearranged mRNA for anti-cytochrome c immunoglobulin G1 (IgG1) heavy chain variable region
 ACCESSION X60683
 KEYWORDS Anti-cytochrome c immunoglobulin G1; E8 variable heavy chain; E8 variable heavy chain D region; E8 variable heavy chain J region; E8 variable heavy chain V region; IgG1.
 SOURCE mouse
 ORGANISM Mus musculus
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 351)
 AUTHORS Mylvaganam,S.E.
 TITLE Direct Submission
 JOURNAL Submitted (05-JUL-1991) S.E. Mylvaganam, Dept of Mol Biology, MB4, The Scripps Research Inst 10666 N. Torrey Pines Rd, La Jolla, CA 92037, USA
 STANDARD full automatic
 REFERENCE 2 (bases 1 to 351)
 AUTHORS Mylvaganam,S.E., Paterson,Y., Kaiser,K., Bowdish,K. and Getzoff,E.D.
 TITLE Biochemical Implications from the Variable Gene Sequences of an Anti-cytochrome c Antibody and Crystallographic Characterization of its Antigen-binding Fragment in Free and Antigen-complexed Forms
 JOURNAL J. Mol. Biol. 221, 455-462 (1991)
 STANDARD full automatic
 COMMENT *source: strain=BAKB/c;
 *source: cell_type=myeloma;
 *source: cell_line=CA4-1;

E8 is a monoclonal antibody of the anti-cytochrome c immunoglobulin G1 (IgG1) that binds horse cytochrome c. E8 variable light chain - X60684

E8 variable heavy chain - X60683.

FEATURES Location/Qualifiers
 misc_feature 1..282
 /note="heavy variable region"
 misc_feature 91..105
 /note="first hyper-variable region"
 misc_feature 148..198
 /note="second hyper-variable region"
 misc_feature 295..318
 /note="third hyper-variable region"
 misc_feature 283..315
 /note="D region"
 misc_feature 316..352
 /note="J region"

<1.7>351
 /product="E8 variable heavy chain"
 /codon_start=1
 /translation="EVQLQQSGAELVKPGASVKLSCTASGFNIDTYMHNVKQRPEKG
 LEWIGRIDPASGNTKYDPKFQDKATITADTSSNTAYLQLSSLTSEDYAVYYCAGYDYG
 NFDYWGGGTTLVSS"

BASE COUNT 92 a 92 c 91 g 76 t
 ORIGIN

Initial Score = 271 Optimized Score = 316 Significance = 18.07
 Residue Identity = 89% Matches = 323 Mismatches = 25
 Gaps = 12 Conservative Substitutions = 0

 X 10 20 30 40 50 60
 GTCAAAGTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCT
 || | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 GAGGTTTCAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCAGGGGCTCAGTCAAGTTGTCCTGCACAGCT
 X 10 20 30 40 50 60 70

70 80 90 100 110 120 130 140
 TCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAACAGGGCCTGGAGTGGATT
 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 TCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAGCAGAGGCCTGAAAAGGGCCTGGAGTGGATT
 80 90 100 110 120 130 140

 150 160 170 180 190 200 210
 GGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCGAAGTTCAGGTCAAGGCCACTATTACAGCG
 |||||||||||||||||| |||||||||||||||||||||| |||||||||| |||||
 GGAAGGATTGATCCTGCGAGTGGTAATACTAAATATGACCCGAAGTTCAGGACAAGGCCACTATAACAGCA
 150 160 170 180 190 200 210

 220 230 240 250 260 270 280
 GACACGTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTACTACTGT
 |||| | |||||||||| |||||||||||||||||||||||||||||||||| |||||
 GACACATCCTCCAACACAGCCTACCTGCAGCTCAGCAGCCTGACATCTGAGGACACTGCCGTCTATTACTGT
 220 230 240 250 260 270 280

 290 300 310 320 330 340 350
 GCAGACGGAATGTGGGTATCAACGGGATATGCTCTGGACTTCTGGGGCCAAGGGACCACGGTCACCGTCTCC
 || | | || | || |||| | || | |||| |||||||||| ||||| ||||| |||||
 GCTG--GTTATG-----AT-TACGGCA---ACTTT-GACTACTGGGGCCAAGGGACCACTCTCACAGTCTCC
 290 300 310 320 330 340

X
 TCA
 |||
 TCA
 350

14. US-07-977-702-1 (1-360)

MUSIGMU4G Mouse monoclonal antiidiotypic antibody IgM VDJ-re

LOCUS MUSIGMU4G 354 bp ss-mRNA ROD 16-JUL-1992
 DEFINITION Mouse monoclonal antiidiotypic antibody IgM VDJ-region mRNA.
 ACCESSION M83722
 KEYWORDS diversity region; immunoglobulin heavy chain;
 immunoglobulin mu-chain; joining region;
 monoclonal antiidiotypic antibody; variable region.
 SOURCE Mus musculus hybridoma cDNA to mRNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
 Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 354)
 AUTHORS Taub,R., Hsu,J.-C., Garsky,V.M., Hill,B.L., Erlanger,B.F. and
 Kohn,L.D.

IMMUNOGLOBULIN MU-CHAIN; joining region; processed gene;
variable region.

SOURCE Mouse (Balb/c) hybridoma 87.92.6 (mu,kappa), cDNA to mRNA.

ORGANISM Mus musculus
Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
Eutheria; Rodentia; Myomorpha; Muridae; Murinae.

REFERENCE 1 (bases 1 to 390)

AUTHORS Bruck,C., Co,M.S., Slaoui,M., Gaulton,G.N., Smith,T., Fields,B.N.,
Mullins,J.I. and Greene,M.I.

TITLE Nucleic acid sequence of an internal image-bearing monoclonal
anti-idiotypic and its comparison to the sequence of the external
antigen

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83, 6578-6582 (1986)

STANDARD full automatic

FEATURES Location/Qualifiers

sig_peptide <1..30
/codon_start=1
/note="Immunoglobulin mu-chain signal peptide"

mat_peptide 31..390
/codon_start=1
/note="Immunoglobulin mu-chain"

misc_recomb 327..328
/note="V-region end/D-region start"

misc_recomb 342..343
/note="D-region end/J-region start"

CDS <1..390
/note="Immunoglobulin mu-chain precursor"
/codon_start=1
/translation="LMAVVTGVNSEVQLQSGAELVKPGASVKLSCTASGFNIKDTYH
HWVKQRPEQGLEWIGRIDPANGNTKYDPKFQKGATITADTSSNTAYLQLSSLTSEDTA
VYYCARGGLRRGYANDYWGQGTSVTVSS"

BASE COUNT 100 a 96 c 111 g 83 t

ORIGIN 44 bp upstream of PstI site; chromosome 12.

Initial Score = 271 Optimized Score = 326 Significance = 18.07
Residue Identity = 91% Matches = 330 Mismatches = 25
Gaps = 7 Conservative Substitutions = 0

```

                                X      10      20      30
                                GTCAAACTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCA
                                || | |||||
CTGATGGCAGTGGTTACAGGGGTCAATTCAGAGGTTAGCTGCAGCAGTCTGGGGCAGAGCTTGTGAAGCCA
    10      20      30 X    40      50      60      70

40      50      60      70      80      90      100     110
GGGGCCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAG
|||||
GGGGCCTCAGTCAAGTTGTCTGCACAGCTTCTGGCTTCAACATTAAAGACACCTATATGCACTGGGTGAAG
    80      90      100     110     120     130     140

    120     130     140     150     160     170     180
CAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAGTGGCGATACTAAATATGACCCG
|||||
CAGAGGCCTGAACAGGGCCTGGAGTGGATTGGAAGGATTGATCCTGCGAATGGTAATACTAAATATGACCCG
    150     160     170     180     190     200     210

    190     200     210     220     230     240     250
AAGTTCCAGGTCAAGGCCACTATTACAGCGGACAGCTCCTCCAACACAGCCTGGCTGCAGCTCAGCAGCCTG
|||||
AAGTTCCAGGGCAAGGCCACTATAACAGCAGACACATCCTCCAACACAGCCTACCTGCAGCTCAGCAGCCTG
    220     230     240     250     260     270     280

    260     270     280     290     300     310     320
ACATCTGAGGACACTGCCGTCTACTACTGTGC-AGACGGAATGTGGGTATCAAC-GGGATATGCTCTGGACT
|||||
ACATCTGAGGACACTGCCGTCTATTACTGTGCTAGAGGG-----GGATTACGACGGGGTATGCTATGGACT

```



```

-          **  *  **  *          **  *
-
-
-          *  *          **  *
-
0-----
| | | | | | | | | | | | | | |
SCORE 0 | 29 | 58 | 88 | 117 | 146 | 175 | 205 | 234 | 263
STDEV   0  1  2  3  4  5  6  7  8  9

```

PARAMETERS

```

Similarity matrix      Unitary      K-tuple      4
Mismatch penalty       1           Joining penalty 30
Gap penalty            1.00        Window size   32
Gap size penalty       0.33
Cutoff score           0
Randomization group    0

```

```

Initial scores to save 40      Alignments to save 15
Optimized scores to save 0      Display context 50

```

SEARCH STATISTICS

```

Scores:                Mean      Median      Standard Deviation
                        17        14          12.85

```

```

Times:                 CPU              Total Elapsed
                        00:03:01.00      00:06:12.00

```

```

Number of residues:      14371384
Number of sequences searched: 25646
Number of scores above cutoff: 4637

```

Cut-off raised to 8.
 Cut-off raised to 15.
 Cut-off raised to 22.
 Cut-off raised to 26.
 Cut-off raised to 29.

The scores below are sorted by initial score.
 Significance is calculated based on initial score.

A 100% identical sequence to the query sequence was not found.

The list of best scores is:

| Sequence Name | Description | Length | Init. Score | Opt. Score | Sig. | Frame |
|---------------|-------------|--------|-------------|------------|------|-------|
|---------------|-------------|--------|-------------|------------|------|-------|

```

      **** 19 standard deviations above mean ****
1. Q04265  Encodes Colon Cancer monoclon  381  263  265  19.14  0
      **** 18 standard deviations above mean ****
2. Q28254  VL FRP5. 407  260  263  18.91  0
3. Q28653  DNA encoding 1E6 kappa light 327  257  260  18.68  0
4. Q28262  Fv(FRP5)-ETA fusion gene. 2011  257  260  18.68  0
5. Q28257  Fv(FRP5)-phoA recombinant ant 2233  257  260  18.68  0
6. Q04592  Sequence encoding region of h 324  256  257  18.60  0
7. N90813  DNA encoding light chain vari 324  256  257  18.60  0
8. Q27132  Light chain variable region c 387  256  257  18.60  0
9. Q28256  Fv heavy chain/light chain va 748  256  259  18.60  0
10. Q05557  Sequence encoding variable re 411  255  259  18.52  0
11. N40022  cDNA insert of pK17G4 encodin 882  252  254  18.29  0
12. Q04264  Encodes Colon Cancer monoclon 685  250  253  18.13  0

```

| | | | | | | |
|---|-------------------------------|------|-----|-----|-------|---|
| 13. N40023 | MMNA encoding kappa anti-Larc | 882 | 249 | 253 | 18.06 | 0 |
| **** 16 standard deviations above mean **** | | | | | | |
| 14. Q25592 | Encodes 4D5 Fab IgG antibody | 2178 | 234 | 237 | 16.89 | 0 |
| 15. Q28747 | Anti-CEA specific light chain | 387 | 227 | 257 | 16.34 | 0 |
| **** 15 standard deviations above mean **** | | | | | | |
| 16. N81636 | Anti-pseudomonas aeruginosa h | 324 | 216 | 219 | 15.49 | 0 |
| 17. N81638 | Anti-pseudomonas aeruginosa h | 671 | 216 | 220 | 15.49 | 0 |
| 18. Q10946 | Feline immunoglobulin kappa c | 618 | 214 | 221 | 15.33 | 0 |
| 19. Q11191 | V region gene JP2gL411 from a | 618 | 214 | 221 | 15.33 | 0 |
| 20. Q04654 | Plasmid pBT111 encoding antib | 5238 | 213 | 214 | 15.25 | 0 |
| 21. Q29150 | WN1 222-5 antibody Light chai | 322 | 210 | 215 | 15.02 | 0 |
| **** 14 standard deviations above mean **** | | | | | | |
| 22. Q12017 | Sequence encoding mouse MAb 1 | 402 | 208 | 216 | 14.86 | 0 |
| 23. Q12061 | Sequence encoding light (kapp | 402 | 208 | 216 | 14.86 | 0 |
| 24. Q29151 | WN1 58-9 antibody Light chain | 321 | 204 | 213 | 14.55 | 0 |
| 25. Q15114 | IL-2 chimeric antibody light | 432 | 204 | 211 | 14.55 | 0 |
| 26. Q23566 | Rat CD4 antibody light chain | 620 | 204 | 209 | 14.55 | 0 |
| 27. Q05556 | Sequence encoding variable re | 419 | 200 | 210 | 14.24 | 0 |
| 28. N90672 | DNA sequence encoding uproces | 420 | 200 | 208 | 14.24 | 0 |
| 29. Q15113 | IL-2 chimeric antibody light | 432 | 200 | 207 | 14.24 | 0 |
| 30. Q08608 | ME4 Light Chain V Region (mou | 444 | 200 | 208 | 14.24 | 0 |
| 31. Q12633 | CD4-specific CDR-grafted ligh | 754 | 200 | 208 | 14.24 | 0 |
| 32. N90500 | Light chain antibody variable | 608 | 198 | 206 | 14.09 | 0 |
| 33. Q23567 | Reshaped CAMPATH-1 antibody l | 748 | 198 | 206 | 14.09 | 0 |
| 34. Q20381 | Sequence encoding the shorten | 819 | 198 | 208 | 14.09 | 0 |
| 35. Q23568 | Reshaped CD4 antibody light c | 748 | 197 | 205 | 14.01 | 0 |
| 36. N90300 | Insert coding for light chain | 1395 | 197 | 207 | 14.01 | 0 |
| **** 13 standard deviations above mean **** | | | | | | |
| 37. Q11848 | Human anti-placental alkaline | 324 | 194 | 204 | 13.77 | 0 |
| 38. Q21097 | FabD1.3 in pUC19. | 1526 | 194 | 203 | 13.77 | 0 |
| 39. Q11846 | Anti-placental alkaline phosp | 324 | 193 | 203 | 13.70 | 0 |
| 40. N30165 | Sequence encoding the leader, | 450 | 192 | 199 | 13.62 | 0 |

1. US-07-977-702-2 (1-318)

Q04265 Encodes Colon Cancer monoclonal antibody CC92 ligh

ID Q04265 standard; DNA; 381 BP.
AC Q04265;
DT 13-SEP-1990 (first entry)
DE Encodes Colon Cancer monoclonal antibody CC92 light chain variable region
KW chimeric antibodies; TAG72; light chain variable region;
KW heavy chain variable region; ss
OS synthetic.
PN EP-365997-A.
PD 02-MAY-1990.
PF 18-OCT-1989; 119361.
PR 19-OCT-1988; US-259943.
PA (DOWC) Dow Chemical Co.
PI Mezes P, Gourlie B, Rixon M;
DR WPI; 90-133521/18.
DR P-PSDB; R04388.
PT Chimeric antibodies against TAG72 and conjugate to provide imaging
PT markers and therapeutic tools
PS Disclosure; pp; English.
CC The polypeptide encoded by this sequence forms part of a chimera. The
CC other components are a heavy chain variable region and human-derived
CC constant light and heavy chain regions. The variable regions have
CC high affinity for TAG72. The constant regions reduce the side-effects
CC when administered to human patients because they are of human origin.
CC See also Q04258-64 and Q04266-9.
SQ Sequence 381 BP; 90 A; 90 C; 97 G; 104 T;

Initial Score = 263 Optimized Score = 265 Significance = 19.14
Residue Identity = 83% Matches = 266 Mismatches = 52
Gaps = 1 Conservative Substitutions = 0


```

X      10      20
AG-TATTGTGATGACCCAGACT
|| |||||
AGATCCAGGTCCTTTGTATTCTGTTCTCTGGTGTCTGGTGTGACGGAGACATTGTGATGACCCAGTCT
10      20      30      40      50      60      70

30      40      50      60      70      80      90
CCCAAATTCCTGCTGTTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAAT
| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTAGT
80      90      100      110      120      130      140      150

100      110      120      130      140      150      160
GATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTAC
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GCTGTAGGGTGGTTTCAACAGAAACCAGGACAATCTCCTAAATTACTGATTTATTCGGCATCCTACCGGTAT
160      170      180      190      200      210      220

170      180      190      200      210      220      230
ACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACCTTTCACCATCAGCACTGTGCAG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTCGGACGGATTTCACCTTTCACCATCACCAGTGTGCAG
230      240      250      260      270      280      290

240      250      260      270      280      290      300
GCTGAAGACCTGGCAGTTTATTTCTGTCAGCAGGATTATAGCTCTCCGTACACGTTTCGGAGGGGGACCAAG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GCTGAAGACCTGGCAGTTTATTTCTGTCAGCAACATTATAGTAGTCCGCTCACGTTTCGGTGTGGGACCAAG
300      310      320      330      340      350      360

310      X
CTGGAGATC
||||| |
CTGGAGCTGAAACT
370      X 380

```

2. US-07-977-702-2 (1-318)

Q28254 VL FRP5.

ID Q28254 standard; DNA; 407 BP.
AC Q28254;
DT 11-FEB-1993 (first entry)
DE VL FRP5.
KW Minigene; pMZ18/1; monoclonal antibody; kappa; light chain;
KW variable region; pMW31; ss.
OS Mus musculus.
PN EP-502812-A.
PD 09-SEP-1992.
PF 27-JAN-1992; 810056.
PR 05-FEB-1991; EP-810079.
PA (CIBA) CIBA GEIGY AG.
PI Groner B, Hardman N, Harwerth I, Hynes NE, Wels WS;
PI Zwickl M;
DR WPI; 92-302096/37.
PT Recombinant antibodies directed to growth factor receptor C-erbB-2 -
PT for diagnosing and treating tumours expressing C-erbB-2 e.g. breast
PT or ovarian tumours
PS Disclosure; Page 29; 67pp; English.
CC The sequence given a portion of the plasmid pMZ18/1 and encodes the
CC kappa light chain variable (V) domain of the monoclonal antibody FRP5.
CC The V-region was excised from this plasmid and cloned into plasmid
CC pMW31 which was used in the construction of a recombinant antibody
CC which is directed to the extracellular domain of the growth factor
CC c-erbB-2.

Sequence 407 BP; 101 A; 107 C; 94 G; 105 T;
 Initial Score = 260 Optimized Score = 263 Significance = 18.91
 Residue Identity = 82% Matches = 264 Mismatches = 54
 Gaps = 1 Conservative Substitutions = 0

```

      X      10      20      30      40
      AG-TATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGC
      || ||||| ||||| ||| ||||| |||||
TCTAGTCACTGGATGGTGGGAAGATGGAGACATTGTGATGACCCAGTCTCACAATTCCTGTCCACTTCAGT
    10      20      30      40      50      60      70

    50      60      70      80      90      100     110
AGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAA
||||| ||| ||||| ||||| ||||| ||||| ||| || ||||| |||||
AGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGTATAATGTGTTGCCTGGTATCAACAGAA
    80      90      100     110     120     130     140

    120     130     140     150     160     170     180
GCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCAC
||||| || ||||| ||||| ||| ||||| || ||||| ||||| |||||
ACCAGGACAATCTCCTAAACTTCTGATTTACTCGGCATCCTCCCGGTACACTGGAGTCCCTTCTCGCTTCAC
    150     160     170     180     190     200     210

190      200      210      220      230      240      250      260
TGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTATT
||||| ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TGGCAGTGGCTCTGGGCCGGATTTCACTTTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTATT
    220     230     240     250     260     270     280

      270      280      290      300      310      X
CTGTGAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGCTGGAGATC
||||| ||| || ||||| ||||| ||||| || ||| ||
CTGTGAGCAACATTTTCGTACTCCATTACGTTCCGGCTCGGGGACAAAATTGGAATAAACGGGCTGATGC
290      300      310      320      330      340      X 350      360

TGCACCAACTGTATCCATCTTCCACCATCCAGTGA
    370      380      390
  
```

3. US-07-977-702-2 (1-318)

Q28653 DNA encoding 1E6 kappa light chain variable region

ID Q28653 standard; DNA; 327 BP.
 AC Q28653;
 DT 17-FEB-1993 (first entry)
 DE DNA encoding 1E6 kappa light chain variable region.
 KW Chimeric; heavy chain; variable region; monoclonal antibody;
 KW lymphocyte function associated antigen-3; LFA-3; inflammation;
 KW autoimmune disease; immunomodulation; systemic lupus erythematosus;
 KW rheumatoid arthritis; thyroiditis; ss.
 OS Homo sapiens.
 PN EP-503646-A.
 PD 16-SEP-1992.
 PF 12-MAR-1992; 104318.
 PR 12-MAR-1991; US-667975.
 PA (BIOJ) BIOGEN INC.
 PI Chisholm PL, Sato VL, Wallner BP;
 DR WPI; 92-309758/38.
 DR P-PSDB; R27144.
 PT Monoclonal antibodies active against lymphocyte function
 PT associated antigen-3 - for treating inflammation and auto:immune
 PT diseases, and for detecting LFA-3 protein in a sample
 PS Claim 16; Page 14; 30pp; English.
 CC DNA sequences obt'd. from the hybridoma cell line 1E6-2C12 (ATCC HB
 CC 10693) encoding the light and heavy chain regions of 1E6 were

CC amplified for cloning and sequencing using PCR. The PCR primers for
 CC the light chain variable region were MKVP7 and 360-41, and the heavy
 CC chain primers were VH01 and VH02. The PCR prods. were
 CC electrophoresed on agarose gel and the DNA excised and inserted into
 CC plasmids. The light and heavy chain regions may be used to
 CC construct a monoclonal antibody active against LFA-3 which blocks
 CC adhesion of LFA-3 expressing cells to lymphocytes. The antibody may
 CC be used in the treatment and diagnosis of acute and chronic
 CC inflammation, autoimmune diseases and for immunomodulation including
 CC systemic lupus erythematosus, rheumatoid arthritis and thyroiditis.
 CC See also Q28654-8.

Sequence 327 BP; 89 A; 82 C; 83 G; 73 T;

Initial Score = 257 Optimized Score = 260 Significance = 18.68
 Residue Identity = 81% Matches = 260 Mismatches = 58
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AACATTGTAATGACCAATCTCCCAAATCCATGTCCATGTCTAGTAGAGAGAGGGTCACCTTGACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
||||| ||| |||| ||| |||| | |||| | ||||| ||||| ||||| ||||| ||||| |||||
GCCAGTGAGAATGTGGTTACTTATGTTTCCTGGTATCAACAGAAACCAGAGCAGTCTCCTAAACTGCTCATA
      80      90     100     110     120     130     140

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACT
||  ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TACGGGGCATCCAACCGGTACACTGGGGTCCCCGATCGCTTCACAGGCAGTGGATCTGCAACAGATTTCACT
     150     160     170     180     190     200     210

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGGATTATAGCTCTCCGTAC
|  ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGACCATCAGCAGTGTGCAGGCTGAAGACCTTGACAGATTATCACTGTGGACAGGGTTACAGCTATCCGTAC
     220     230     240     250     260     270     280

     290     300     310     X
ACGTTCGGAGGGGGGACCAAGCTGGAGATC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACGTTCGGAGGGGGGACCAAGCTGGAATAAAACGGGCT
     290     300     310     320

```

4. US-07-977-702-2 (1-318)

Q28262 Fv(FRP5)-ETA fusion gene.

ID Q28262 standard; DNA; 2011 BP.
 AC Q28262;
 DT 11-FEB-1993 (first entry)
 DE Fv(FRP5)-ETA fusion gene.
 KW Monoclonal antibody; light chain; heavy chain; tumour; c-erbB-2;
 KW variable region; ETA; ss.
 OS Pseudomonas aeruginosa PAK.
 FH Key Location/Qualifiers
 FT sig_peptide 1..63
 FT /*tag= a
 FT /label= ompA_signal_peptide
 FT misc_RNA 64..87
 FT /*tag= b
 FT /note= "FLAG peptide and enterokinase cleavage site"
 FT misc_RNA 97..453

FT /*tag= c
 FT /label= FRP5_heavy_chain_variable_domain
 FT misc_RNA 454..498
 FT /*tag= a
 FT /label= Linker
 FT misc_RNA 499..822
 FT /*tag= a
 FT /label= FRP5_light_chain_variable_domain
 FT CDS 826..1911
 FT /*tag= a
 FT /label= ETA_1574-1747
 FT 3'clip 1912..2012
 FT /*tag= a
 FT /label= ETA_3'_non-coding_region
 PN EP-502812-A.
 PD 09-SEP-1992.
 PF 27-JAN-1992; 810056.
 PR 05-FEB-1991; EP-810079.
 PA (CIBA) CIBA GEIGY AG.
 PI Groner B, Hardman N, Harwerth I, Hynes NE, Wels WS;
 PI Zwickl M;
 DR WPI: 92-302096/37.
 DR P-PSDB: R26982.
 PT Recombinant antibodies directed to growth factor receptor C-erbB-2 -
 PT for diagnosing and treating tumours expressing C-erbB-2 e.g. breast
 PT or ovarian tumours
 PS Disclosure; Page 47-52; 67pp; English.
 CC The sequences given in 028261-3 encode part of the exotoxin A (ETA)
 CC sequence corresponding to positions 1574-1747 of the full exotoxin A
 CC sequence. These sequences were used in the construction of
 CC Fv(FRP5)-ETA fusion genes. The ETA sequence was used as a marker gene
 CC so that E. coli transformed with the fusion gene could be identified.
 CC The fusion genes were expressed in E. coli and the antibody was
 CC extracted. This recombinant antibody can be used for the qualitative
 CC and quantitative determination of c-erbB-2. This can be used for
 CC monitoring or in-vivo localisation of tumours overexpressing c-erbB-2.
 SQ Sequence 2011 BP; 383 A; 653 C; 620 G; 355 T;

Initial Score = 257 Optimized Score = 260 Significance = 18.68
 Residue Identity = 81% Matches = 260 Mismatches = 58
 Gaps = 0 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                ||  | ||||| |||
CCTCTGGCGGTGGCGGTTCTGGTGGCGGTGGCTCCGGCGGTGGCGGTTCTGACATCCAGCTGACCCAGTCTC
450      460      470      480      490      500      510      520

      30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||| |||| | ||||| |||| | ||| ||||| ||||| |||| | ||||
ACAAATTCCTGTCCACTTCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGTATAATG
      530      540      550      560      570      580      590

      100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||| || |||| | ||||| |||| | ||||| |||| | ||| |||| | ||||
CTGTTGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTTCTGATTTACTCGGCATCCTCCCGGTACA
      600      610      620      630      640      650      660

      170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||| |||| | ||||| |||| | ||||| |||| | |||| | |||| | ||||
CTGGAGTCCCTTCTCGCTTCACTGGCAGTGGCTCTGGGCCGGATTTCACTTTCACCATCAGCACTGTGCAGG
      670      680      690      700      710      720      730
  
```

240 250 260 270 280 290 300 310
 CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGGACCAAGC
 |||||
 CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAACATTTTCGTACTCCATTACGTTCCGGCTCGGGGACAAAAT
 740 750 760 770 780 790 800

X
 TGGAGATC
 |||||
 TGGAGATCAAAGCTCTAGAGGGGGGCGAGCCTGGCCGCGCTGACCGCGCACCAGGCCTG
 810 X 820 830 840 850 860

5. US-07-977-702-2 (1-318)

Q28257 Fv(FRP5)-phoA recombinant antibody.

ID Q28257 standard; DNA; 2233 BP.
 AC Q28257;
 DT 11-FEB-1993 (first entry)
 DE Fv(FRP5)-phoA recombinant antibody.
 KW Monoclonal antibody; light chain; heavy chain; tumour; phoA;
 KW variable region; alkaline phosphatase; c-erbB-2; ss
 OS Synthetic.
 FH Key Location/Qualifiers
 FT CDS 23..2158
 FT /*tag= a
 FT sig_peptide 23..85
 FT /*tag= b
 FT /label= ompA_signal_peptide
 FT misc_RNA 89..445
 FT /*tag= c
 FT /label= FRP5_heavy_chain_variable_domain
 FT misc_RNA 446..490
 FT /*tag= d
 FT /label= Linker
 FT misc_RNA 491..814
 FT /*tag= e
 FT /label= FRP5_light_chain_variable_domain
 FT mat_peptide 815..2155
 FT /*tag= f
 FT /label= phoA_coding_region
 PN EP-502812-A.
 PD 09-SEP-1992.
 PF 27-JAN-1992; 810056.
 PR 05-FEB-1991; EP-810079.
 PA (CIBA) CIBA GEIGY AG.
 PI Groner B, Hardman N, Harwerth I, Hynes NE, Wells WS;
 PI Zwickl M;
 DR WPI; 92-302096/37.
 DR P-PSDB; R26980.
 PT Recombinant antibodies directed to growth factor receptor C-erbB-2 -
 PT for diagnosing and treating tumours expressing C-erbB-2 e.g. breast
 PT or ovarian tumours
 PS Disclosure; Page 34-40; 67pp; English.
 CC The sequence given encodes the single chain recombinant antibody
 CC desiganted Fv(FRP5)-phoA. The alkaline phosphatase gene (phoA) was
 CC used as a marker gene so that E. coli transformed with the fusion gene
 CC could be identified. The fusion gene was expressed in E. coli and the
 CC antibody was extracted. This recombinant antibody can be used for the
 CC qualitative and quantitative determination of c-erbB-2. This can be
 CC used for monitoring or in-vivo localisation of tumours overexpressing
 CC c-erbB-2.
 SQ Sequence 2233 BP; 566 A; 573 C; 606 G; 488 T;

Initial Score = 257 Optimized Score = 260 Significance = 18.68
 Residue Identity = 81% Matches = 260 Mismatches = 58

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                ||  | ||||| |||
CCTCTGGCGGTGGCGGTTCTGGTGGCGGTGGCTCCGGCGGTGGCGGTTCTGACATCCAGCTGACCCAGTCTC
  450      460      470      480      490      500      510

  30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||||| |||| ||||| ||||| ||| ||||| ||||| ||||| ||||| ||||| |||||
ACAAATTCCTGTCCACTTCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGTATAATG
  520      530      540      550      560      570      580

 100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||| || ||||| ||||| ||||| || ||||| ||||| ||||| || ||||| || |||||
CTGTTGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTTCTGATTTACTCGGCATCCTCCCGGTACA
  590      600      610      620      630      640      650

 170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGGAGTCCCTTCTCGCTTCACTGGCAGTGGCTCTGGGCCGGATTTCACTTTCACCATCAGCAGTGTGCAGG
  660      670      680      690      700      710      720

 240      250      260      270      280      290      300      310
CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGC
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAACATTTTCGTACTCCATTACGTTCCGGCTCGGGGACAAAAT
  730      740      750      760      770      780      790      800

      X
TGGAGATC
|||||||
TGGAGATCAAAGCTCTAGAGCCTGTTCTGGAAAACCGGGCTGCTCAGGGCGATATTAC
  810      820      830      840      850
```

6. US-07-977-702-2 (1-318)

004592 Sequence encoding region of human carcinoembryonic

ID 004592 standard; DNA; 324 BP.
AC 004592;
DT 28-SEP-1990 (first entry)
DE Sequence encoding region of human carcinoembryonic light chain
DE antigen (CEA).
KW Carcinoembryonic antigen; CEA; Chelate-specific antigen; CHA;
KW tumor; cancer; serum sickness.
OS Homo sapiens.
PN EP-369566-A.
PD 23-MAY-1990.
PF 8-MAR-1989; 302313.
PR 17-NOV-1988; US-274105; EP-302313.
PA (HYBR-) Hybritech Inc.
PI Johnson MJ, Phelps JL;
DR WPI; 90-157695/21.
DR P-PSDB; R04936.
PT Bifunctional chimeric antibodies -
PT having variable regions which recognise different antigens and
PT metal chelates and human constant regions.
PS Claim 2; Page 24; 40pp; English.
CC Gene encodes portion of CEA light chain antigen, useful in
CC generating chimeric monoclonal antibody binding to CEA at a tumour
CC site and a metal chelate bonded to say a toxin or other drug.
SQ Sequence 324 BP; 85 A; 83 C; 77 G; 79 T;

Initial Score = 256 Optimized Score = 257 Significance = 18.60
 Residue Identity = 80% Matches = 257 Mismatches = 61
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
GACATTGTGATGACCCAGTCTCAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAAATGTTCTGACTGCTGTTGCCCTGGTATCAACAGAAACCAGGGCAGTCTCCTAAAGCACTGATT
      80      90     100     110     120     130     140

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTCACT
|||
TACTTGGCATCCAACCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTCTCACT
     150     160     170     180     190     200     210

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAAGGCTGAAGACCTGGCAGTTTATTTCTGTCTGAGGATTATAGCTCTCCGTAC
|||||
CTCACCATTAACCAATGTGCAATCTGAAGACCTGGCAGATTATTTCTGTCTGCAACATTGGAATTATCCGCTC
     220     230     240     250     260     270     280

290      300      310      X
ACGTTCTGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCTGGTGGGACCAAGCTGGAGCTGAAACGG
290      300      310      320

```

7. US-07-977-702-2 (1-318)

N90813 DNA encoding light chain variable region against c

ID N90813 standard; cDNA; 324 BP.
 AC N90813;
 DT 24-JAN-1990. (first entry)
 DE DNA encoding light chain variable region against carcinoembryonic antigen
 KW Carcinoembryonic antigen; immunogen; tumour; chimeric antibody.
 OS Murine (mouse) hybridoma CEM 231.6,7 (ATCC HB 9620).
 FH Key Location/Qualifiers
 FT CDS 1..324
 FT /*tag= a
 PN EP-332424-A.
 PD 13-SEP-1989.
 PF 08-MAR-1989; 302312.
 PR 09-MAR-1988; US-272577.
 PA (HYBR) Hybritech Inc.
 PI Beidler CB, Johnson MJ, Ludwig JR, Carlo DJ, David GS;
 DR WPI; 89-265635/37.
 DR P-PSDB; P91381.
 PT DNA constructs encoding light or heavy chain variable regions
 PT - chimeric monoclonal antibody, specific for human
 PT carcinoembryonic antigen, useful for diagnosis, imaging and
 PT treatment of tumours.
 PS Claim 2; page 18; 32pp; English.
 CC This region contained in a DNA construct with heavy chain variable
 CC and constant regions, light chain constant region, and 2 eukaryotic
 CC leader sequences. The chimeric monoclonal antibodies thus formed
 CC can be directed against CEA for immunoassay, and imaging and
 CC treatment of tumours, eg colorectal or breast carcinoma. The

constant regions are human-derived and so are less immunogenic
CC than entirely murine Abs.
SQ Sequence 324 BP; 85 A; 83 C; 77 G; 79 T;

Initial Score = 256 Optimized Score = 257 Significance = 18.60
Residue Identity = 80% Matches = 257 Mismatches = 61
Gaps = 0 Conservative Substitutions = 0

```
X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
GACATTGTGATGACCCAGTCTCAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAAATGTTCTGACTGCTGTTGCCCTGGTATCAACAGAAACCAGGGCAGTCTCCTAAAGCACTGATT
      80      90     100     110     120     130     140

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCCTACT
|||
TACTTGGCATCCAACCGGTACACTGGAGTCCCTGATCGCTTCAACAGGCAGTGGATCTGGGACAGATTTCCTACT
     150     160     170     180     190     200     210

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGGATTATAGCTCTCCGTAC
|||||
CTCACCATTACCAATGTGCAATCTGAAGACCTGGCAGATTATTTCTGTCTGCAACATTGGAATTATCCGCTC
     220     230     240     250     260     270     280

290      300      310      X
ACGTTCGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAACGG
290      300      310      320
```

8. US-07-977-702-2 (1-318)

027132 Light chain variable region contg. ompA leader pep

ID 027132 standard; DNA; 387 BP.

AC 027132;

DT 21-JAN-1993 (first entry)

DE Light chain variable region contg. ompA leader peptide.

KW Heavy; antibody; Fv; CEM231.6.7; VL; ss; chelator.

OS Synthetic.

PN EP-497585-A.

PD 05-AUG-1992.

PF 30-JAN-1992; 300775.

PR 30-JAN-1991; US-647901.

PA (ANDE/) ANDERSON L D.

PA (COOK/) COOK J A.

PA (DAVI/) DAVID G S.

PA (HOCH/) HOCHSCHWENDER S M.

PA (KASH/) KASHER M S.

PA (SMIT/) SMITH M C.

PA (STEM/) STEMMER W P C.

PI Anderson LD, Cook JA, David GS, Hochschwender SM, Kasher MS;

PI Smith MC, Stemmer WPC;

DR WPI; 92-261005/32.

PT Immobilisation and purification of molecules - using kinetically

PT inert immobilised metal-CP-protein complex useful in assay

PT system

PS Example 5; Page 37; 88pp; English.

CC Sequencing of cloned CER231.6.7. heavy and light chain variable
 CC regions along with the His-Trp-His-His-His fusion peptide was
 CC performed by standard procedures. This sequence shows the light
 CC chain variable sequence contg. the ompA leader peptide.
 CC See also Q27108-33.
 SQ Sequence 387 BP; 100 A; 100 C; 96 G; 91 T;

Initial Score = 256 Optimized Score = 257 Significance = 18.60
 Residue Identity = 80% Matches = 257 Mismatches = 61
 Gaps = 0 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                |||||
CTATCGGATCGCAGTGGCACTGGCTGGTTTCGCCACCGTGGCGCAGGCCGACATTGTGATGACCCAGTCTC
  20      30      40      50      60 X  70      80

  30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||| || ||| ||||| ||||| ||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGAATGTTCTGTA
  90     100     110     120     130     140     150

  100     110     120     130     140     150     160
ATGTAGCTTGGTACCAACAGAAAGCCAGGGCAGTCTCCTAAAGCTGCTGATATATTATGCATCCAATCGCTACA
||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGTTGCCTGGTATCAACAGAAACCAGGGCAGTCTCCTAAAGCACTGATTTACTTGGCATCCAACCGGTACA
  160     170     180     190     200     210     220

  170     180     190     200     210     220     230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGGAGTCCCTGATCGCTTCAACAGGCAGTGGATCTGGGACAGATTTCACTCTACCATTAACCAATGTGCAAT
  230     240     250     260     270     280     290     300

  240     250     260     270     280     290     300     310
CTGAAGACCTGGCAGTTTATTTCTGTCTGACAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGGACCAAGC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CTGAAGACCTGGCAGATTATTTCTGTCTGCAACATTGGAATTATCCGCTCACGTTCCGTTGCTGGGACCAAGC
  310     320     330     340     350     360     370

      X
TGGAGATC
|||||
TGGAGCTGAAATAG
  380
  
```

9. US-07-977-702-2 (1-318)

Q28256 Fv heavy chain/light chain variable domain fusion

ID Q28256 standard; DNA; 748 BP.
 AC Q28256;
 DT 11-FEB-1993 (first entry)
 DE Fv heavy chain/light chain variable domain fusion protein.
 KW Minigene; pMZ18/1; monoclonal antibody; kappa; light chain;
 KW variable region; pMW31; tumour; ss.
 OS Mus musculus.
 FH Key Location/Qualifiers
 FT CDS 5..731
 FT /*tag= a
 FT misc_RNA 9..365
 FT /*tag= b
 FT /label= FRP5_heavy_chain_variable_domain
 FT misc_RNA 99..113
 FT /*tag= c

FT /label= CDR1H 156..206
 FT /*tag= d
 FT /label= CDR2H
 FT misc_RNA 303..332
 FT /*tag= e
 FT /label= CDR3H
 FT misc_RNA 366..410
 FT /*tag= f
 FT /label= Linker
 FT misc_RNA 411..728
 FT /*tag= g
 FT /label= FRP5_light_chain_variable_domain
 FT misc_RNA 480..512
 FT /*tag= h
 FT /label= CDR1L
 FT CDS 558..578
 FT /*tag= i
 FT /label= CDR2L
 FT misc_RNA 675..701
 FT /*tag= j
 FT /label= CDR3L
 PN EP-502812-A.
 PD 09-SEP-1992.
 PF 27-JAN-1992; 810056.
 PR 05-FEB-1991; EP-810079.
 PA (CIBA) CIBA GEIGY AG.
 PI Groner B, Hardman N, Harwerth I, Hynes NE, Wels WS;
 PI Zwickl M;
 DR MPI; 92-302096/37.
 DR P-PSDB; R26979.
 PT Recombinant antibodies directed to growth factor receptor C-erbB-2 -
 PT for diagnosing and treating tumours expressing C-erbB-2 e.g. breast
 PT or ovarian tumours
 PS Disclosure; Page 31-33; 67pp; English.
 CC The sequence given encodes the Fv heavy chain/light chain variable
 CC domain fusion protein which binds to the extracellular domain of the
 CC growth factor receptor c-erbB-2. This recombinant antibody can be used
 CC for the qualitative and quantitative determination of c-erbB-2. This
 CC can be used for monitoring or in-vivo localisation of tumours
 CC overexpressing c-erbB-2.
 SQ Sequence 748 BP; 178 A; 190 C; 192 G; 188 T;

Initial Score = 256 Optimized Score = 259 Significance = 18.60
 Residue Identity = 81% Matches = 259 Mismatches = 59
 Gaps = 0 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                ||  | ||||| |||
CCTCTGGCGGTGGCGGTTCTGGTGGCGGTGGCTCCGGCGGTGGCGGTTCTGACATCCAGCTGACCCAGTCTC
   370       380       390       400       410       420       430

   30       40       50       60       70       80       90
CCAAATTCCTGCTTGTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACAAATTCCTGTCCACTTCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGTATAATG
   440       450       460       470       480       490       500

   100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||| || ||||| ||||| ||||| || ||||| ||||| ||||| || ||||| || ||||| || |||||
CTGTTGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTTCTGATTTACTCGGCATCCTCCCGGTACA
   510      520      530      540      550      560      570

   170      180      190      200      210      220      230

```

CTGGAGTCCCTGATCCCTTCACCTGGCAGTGGATATGGGACGGATTTCACCTTCACCATCAGCAGTGTGCAGG
|||||
CTGGAGTCCCTTCTCGCTTCACTGGCAGTGGCTCTGGGCCGGATTTCACCTTCACCATCAGCAGTGTGCAGG
580 590 600 610 620 630 640

240 250 260 270 280 290 300 310
CTGAAGACCTGGCAGTTTATTCTGTGCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGC
|||||
CTGAAGACCTGGCAGTTTATTCTGTGCAGCAACATTTTCGTAATCCATTACGTTCCGCTCGGGGACAAAAT
650 660 670 680 690 700 710 720

X
TGGAGATC
| |||||
TCGAGATCTAGCTGATCAAAGCTCTAGA
730 740

10. US-07-977-702-2 (1-318)

005557 Sequence encoding variable region of murine AHT 54

ID 005557 standard; DNA; 411 BP.
AC 005557;
DT 10-DEC-1990 (first entry)
DE Sequence encoding variable region of murine AHT 54 light chain.
KW Interleukin-2 receptor; IL-2; tumour necrosis factor; TNF; ss;
OS Mus sp.
FH Key Location/Qualifiers
FT CDS 58..411
FT /*tag= a
PN EP-380068-A.
PD 01-AUG-1990.
PF 24-JAN-1990; 101351.
PR 24-JAN-1989; US-301216.
PR 04-DEC-1989; US-441702.
PA (MOLE-) MOLECULAR THERAPEU.
PI Zerler B;
DR WPI; 90-232892/31.
DR P-PSDB; R06253.
PT Expression vectors for producing chimeric monoclonal antibodies -
PT which express human constant region and non-human variable region
PS Disclosure; p; English.
CC MAbs comprising mouse CH and CL constant regions with human
CC variable regions may be used to create mouse/human hybrid MAbs,
CC which have a longer serum half-life. Method can be used to produce
CC Abs against interleukin-2 receptor and tumour necrosis factor.
SQ Sequence 411 BP; 110 A; 94 C; 104 G; 103 T;

Initial Score = 255 Optimized Score = 259 Significance = 18.52
Residue Identity = 81% Matches = 260 Mismatches = 58
Gaps = 1 Conservative Substitutions = 0

X 10 20
AG-TATTGTGATGACCCAGACT
|| |||||
CAGACTCAGGTCTTTGTATACATGTTGCTGTGGTTGTCTGGTGGTGATGGAGACATTGTGATGACCCAGTCT
40 50 60 70 80 X 90 100

30 40 50 60 70 80 90
CCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAAT
| ||||| || |||||
CAAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGGTACT
110 120 130 140 150 160 170 180

100 110 120 130 140 150 160
GATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTGCATCCAATCGCTAC


```

120 130 140 150 160 170 180 190 200 210
GCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCAC
||||| || ||||| ||||| || ||||| || ||||| ||||| ||||| ||||| |||||
ACCAGGACAATCTCCTAAACTACTGATTTACTGGGCATCCACCCGGCACACTGGAGTCCCTGATCGCTTCAC
150 160 170 180 190 200 210

190 200 210 220 230 240 250 260
TGGCAGTGGATATGGGACGGATTTCACTTTCAACATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGCAGTGGATCTGGGACAGATTTCACTCTCACCATTAGCAATGTGCAGTCTGATGACTTGGCAGATTATT
220 230 240 250 260 270 280

270 280 290 300 310 X
CTGTCAAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGCTGGAGATC
||||| || || || || || ||||| || ||||| ||||| ||||| |||||
CTGTCAACAATATAGCGGTATCCTCTCACGTTCCGGTGCTGGGACCAAGCTGGAGCTGAAACGGGCTGATGC
290 300 310 320 330 340 X 350 360

TGCACCAACTGTATCCATCTTCCACCATCCAGTGA
370 380 390

```

12. US-07-977-702-2 (1-318)

004264 Encodes Colon Cancer monoclonal antibody CC83 ligh

ID 004264 standard; DNA; 685 BP.
AC 004264;
DT 13-SEP-1990 (first entry)
DE Encodes Colon Cancer monoclonal antibody CC83 light chain variable region
KW chimeric antibodies; TAG72; light chain variable region;
KW heavy chain variable region; ss
OS synthetic.
FH Key Location/Qualifiers
FT intron 136..313
FT /*tag= a
FT transit_peptide 76..325
FT /*tag= b
FT /note="intron is spliced out"
FT misc_feature 326..610
FT /*tag= c
FT /label= encodes variable segment
FT misc_feature 611..646
FT /*tag= d
FT /label=encodes J4 segment
PN EP-365997-A.
PD 02-MAY-1990.
PF 18-OCT-1989; 119361.
PR 19-OCT-1988;US-259943.
PA (DOWC) Dow Chemical Co.
PI Mezes P, Gourlie B, Rixon M;
DR MPI; 90-133521/18.
DR P-PSDB; R04387.
PT Chimeric antibodies against TAG72 and conjugate to provide imaging
PT markers and therapeutic tools
PS Disclosure; pp; English.
CC The polypeptide encoded by this sequence forms part of a chimera. The
CC other components are a heavy chain variable region and human-derived
CC constant light and heavy chain regions. The variable regions have
CC high affinity for TAG72. The constant regions reduce the side-effects
CC when administered to human patients because they are of human origin.
CC See also 004258-63 and 004265-9.
SQ Sequence 685 BP; 187 A; 138 C; 153 G; 207 T;

Initial Score = 250 Optimized Score = 253 Significance = 18.13
Residue Identity = 79% Matches = 254 Mismatches = 64
Gaps = 1 Conservative Substitutions = 0

```

X      10      20
AG-TATTGTGATGACCCAGACT
|| |||||
TATGTGTGAGTTTATACACATTATCTGTTTCTGTTTGCAGGTGTTGAAGGAGACATTGTGATGACCCAGTCT
280      290      300      310      320      X 330      340

30      40      50      60      70      80      90
CCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAAT
| ||||| || | |||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CACAAATTCATGTCCGCATCAGTGGGAGACAGGGTCAACATCACCTGCAAGGCCAGTCAGTATGTGGCTACT
350      360      370      380      390      400      410

100     110     120     130     140     150     160
GATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTAC
| ||||| |||| | || | |||| | ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GCTGTAGCCTGGTTTCAGCATAAACCAGGTCAGTCTCCTAAACTACTGATTACGGGGCATCCACCCGGCAC
420     430     440     450     460     470     480     490

170     180     190     200     210     220     230
ACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACCTTCACCATCAGCACTGTGCAG
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACTGGAGTCCCTGATCGCTTCAACAGGTCAGTGGATCTGGGACAGATTTCACCTCTCATCATTAGCAATGTGCAG
500     510     520     530     540     550     560

240     250     260     270     280     290     300
GCTGAAGACCTGGCAGTTTATTTCTGTGCAGCAGGATTATAGCTCTCCGTACACGTTCCGGAGGGGGACCAAG
||| ||| ||||| ||||| ||||| || || ||| ||| ||||| ||||| ||||| ||||| ||||| |||||
TCTGAGGACTTGGCAGATTATTTGTGTGCAGCATTATAGCGGCTATCCATTACGTTCCGGCTCGGGGACAAAG
570     580     590     600     610     620     630

310      X
CTGGAGATC
||| ||
TTGGAATAAAACGTAAGTAGACTTTTGCTCATTTACTTGTGACGTTTTGG
640      X 650      660      670      680

```

13. US-07-977-702-2 (1-318)

N40023 mRNA encoding kappa anti-carcinoembryonic antigen.

ID N40023 standard; mRNA; 882 BP.
AC N40023;
DT 01-DEC-1991 (first entry)
DE mRNA encoding kappa anti-carcinoembryonic antigen.
KW Immunoglobulin; ss mRNA; carcinoembryonic antigen.
FH Key Location/Qualifiers
FT CDS 1..673
FT /*tag= a
PN EP-125023-A.
PD 14-NDV-1984.
PF 06-APR-1984; 302368.
PR 08-APR-1983; US-483457.
PA (CITY) City of Hope.
PA (GETH) Genentech Inc.
PI Cabilly S, Holmes WE, Wetzel RB, Heyneker HL, Riggs AD.
DR WPI; 84-283749/46.
DR P-PSDB; P40031.
PT Immunoglobulin(s) produced by recombinant host cells - useful as
PT antibodies analogous to forms from mammals.
PS Disclosure; Fig. 3; 79pp; English.
CC The mRNA is the coding sequence of the cDNA fragment contained within
CC recombinant vector pK17G4 (see N40022). It encodes kappa anti-
CC carcinoembryonic antigen chain. Using the vector the immunoglobulin is
CC produced readily in pure monoclonal form. Genetic manipulations can be
CC used to produce chimeras of variants drawing their homology from species

CC differing from each other. Protein Manipulation is also possible.
SQ Sequence 882 BP; 231 A; 244 C; 194 G; 213 U;

Initial Score = 249 Optimized Score = 253 Significance = 18.06
Residue Identity = 59% Matches = 254 Mismatches = 64
Gaps = 1 Conservative Substitutions = 0

```

      X      10      20      30      40
      AG-TATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGC
      || ||||| ||||| ||||| ||||| |||||
GUUGCUGUGGUUGUCUGGUGUUGAAGGAGACAUUGUGAUGACCCAGUCUCACAAUUC AUGUCCACAUCAGU
      10      20      30      40      50      60      70

      50      60      70      80      90      100     110
AGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAA
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGAGACAGGGUCAGCAUACCCUGCAAGGCCAGUCAGGAUGUGGGUGUCGUAUAGCCUGGUAUACAGAA
      80      90      100     110     120     130     140

      120     130     140     150     160     170     180
GCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCAC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACCAGGACA AUCCUAAACUACUGAUUUACUGGGCAUCCACCCGGCACACUGGAGUCCUGAUCGCUUCAC
      150     160     170     180     190     200     210

      190     200     210     220     230     240     250     260
TGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTATTT
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGGCAGUGGAUCUGGGACAGAUUUCACUCACCAUUGCA AUGUGCAGUCUGAUGACUUGGCAGAUUUAUUU
      220     230     240     250     260     270     280

      270     280     290     300     310     X
CTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGGACCAAGCTGGAGATC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CUGUCAACAUAUAGCGGGUAUCCUCUCACGUUCGGUGCGUGGGACCAAGCUGCAGCUGAAACGGGCUGAUGC
      290     300     310     320     330     340     X 350     360

UGCACCAACUGUAUCCAUCUCCACCAGCCAGUGA
      370     380     390
```

14. US-07-977-702-2 (1-318)

Q25592 Encodes 4D5 Fab IgG antibody - recognises HER-2 re

ID Q25592 standard; DNA; 2178 BP.
AC Q25592;
DT 08-DEC-1992 (first entry)
DE Encodes 4D5 Fab IgG antibody - recognises HER-2 receptor.
KW humanised IgG antibody; human growth hormone; hGH; selection;
KW screening; ss.
OS Homo sapiens.
FH Key Location/Qualifiers
FT exon 1..712
FT /*tag= a
FT /product= light chain
FT exon 796..2178
FT /*tag= b
FT /product= heavy chain
PN WD09209690-A.
PD 11-JUN-1992.
PF 03-DEC-1991; U09133.
PR 03-DEC-1990; US-621667.
PR 10-APR-1991; US-683400.
PR 14-JUN-1991; US-715300.
PR 08-AUG-1991; US-743614.
PA (GETH) GENENTECH INC.

PI Bass S; Garrard LV; Greene R; Henner DJ; Lowman HB;
 DR WPI; 92-217069/26.
 DR P-PSDB; R24047.8.
 PT Selecting and enriching variant proteins - comprises fusing gene
 PT encoding e.g. growth hormone to part of M13 phage coat protein
 PT and mutagenising fusion prior to selection
 PS Claim 46; Fig 11; 102pp; English.
 CC This sequence encodes the Fab portion of the 4D5 humanised IgG
 CC antibody that recognises the HER-2 receptor. It was inserted into
 CC the plasmid pS0132, which had the DNA encoding human growth hormone
 CC excised from it. The plasmid was used to transform E. coli SR101.
 CC The sequence encodes two genes. The first encodes the variable and
 CC constant regions of the light chain, and with the st II signal
 CC sequence at its 5' end. The second contains four regions - the st II
 CC signal sequence at its 5' end, the variable domain of the heavy chain,
 CC the first domain of the heavy chain constant region, followed by the
 CC M13 gene III.
 SQ Sequence 2178 BP; 498 A; 572 C; 549 G; 559 T;

Initial Score = 234 Optimized Score = 237 Significance = 16.89
 Residue Identity = 74% Matches = 237 Mismatches = 81
 Gaps = 0 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                ||| ||||| ||||| |||
TTCTTCTTGCATCTATGTTTCGTTTTTCTATTGCTACAAACGGTACGCTGATATCCAGATGACCCAGTCCC
20      30      40      50      60      70      80      90

      30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
| | | ||| | | | ||| |||| |||| |||| |||| |||| |||| |||| |||| |||| ||||
CGAGCTCCCTGTCCGCCTCTGTGGGGATAGGGTCACCATCACCTGCCGTGCCAGTCAGGATGTGAATACTG
100     110     120     130     140     150     160

      100     110     120     130     140     150     160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||||| ||||| ||||| ||||| | |||| |||| |||| ||| | ||||| | ||||
CTGTAGCCTGGTATCAACAGAAACCAGGAAAAGCTCCGAAACTACTGATTACTCGGCATCCTTCCTCTACT
170     180     190     200     210     220     230

      170     180     190     200     210     220     230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||||| ||||| |||| ||| ||||| ||||| ||| ||||| ||| |||||
CTGGAGTCCCTTCTCGCTTCTGTGGATCCAGATCTGGGACGGATTTCACTCTGACCATCAGCAGTCTGCAGC
240     250     260     270     280     290     300

      240     250     260     270     280     290     300     310
CTGAAGACCTGGCAGTTTATTTCTGTGAGGATTATAGTCTCCGTACACGTTCCGAGGGGGACCAAGC
| ||||| | ||| ||||| ||||| ||||| |||| ||||| ||||| ||||| |||||
CGGAAGACTTCGAACTTATTACTGTGAGCAACATTATACTACTCTCCACGTTCCGACAGGGTACCAAGG
310     320     330     340     350     360     370

      X
      TGGAGATC
      |||||
      TGGAGATCAAACGAACTGTGGCTGCACCATCTGTCTTCATCTTCCGCCATCTGATGA
380     390     400     410     420     430
  
```

15. US-07-977-702-2 (1-318)
 Q28747 Anti-CEA specific light chain variable region DNA.

ID Q28747 standard; DNA; 387 BP.
 AC Q28747;

DT 01-MAR-1993 (first entry)
 DE Anti-CEA specific light chain variable region DNA.
 KW Human; carcinoembryonic antigen; heavy chain; light chain; variable;
 KW region; diagnostic; tumour; markers; targetting; ss.
 OS Mus musculus.
 FH Key Location/Qualifiers
 FT sig_peptide 1..60
 FT /*tag= a
 FT mat_peptide 61..387
 FT /*tag= b
 PN J04234987-A.
 PD 24-AUG-1992.
 PF 28-DEC-1990; 408810.
 PR 28-DEC-1990; JP-408810.
 PA (MITU) MITSUBISHI KASEI CORP.
 DR WPI; 92-327631/40.
 DR P-PSDB; R27054.
 PT New DNA fragments encoding variable regions of ABS specific for
 PT human CEA - for diagnosing and monitoring tumours, as tumour
 PT markers and for treatment of tumours
 PS Claim 1; Fig 2; 7pp; Japanese.
 CC The anti-CEA murine monoclonal antibody light chain variable region
 CC was obtd. by screening a cDNA library prepd. from mRNA obtd. from
 CC hybridomas producing anti-CEA-specific antibodies with a probe
 CC based on the constant region of the L-chain. The antibodies reacts
 CC specifically with human CEA and are useful as a diagnostic agents,
 CC as tumour markers for digestive organs, for diagnosis of malignant
 CC tumours; for monitering after cancer operations, to follow up bloodless
 CC therapy or as therapeutic agents in passive immune therapy and
 CC targetting therapy. See also 028744-6.
 SQ Sequence 387 BP; 105 A; 92 C; 95 G; 95 T;

Initial Score = 227 Optimized Score = 257 Significance = 16.34
 Residue Identity = 80% Matches = 260 Mismatches = 58
 Gaps = 4 Conservative Substitutions = 0

```

                                X      10      20
                                AG-TATTGTGATGACCCAGACT
                                || ||||| ||||| ||
CAGACTCAGGTCTTTCTATACATCTTGCTGTGGTTGTCTGGTGTGATGGAGACATTGTGATGACCCAGTCT
10      20      30      40      50      60      70      80

      30      40      50      60      70      80      90
CCCAAATTCCTGCTTGTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAAT
| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CAAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGGTACT
90      100     110     120     130     140     150

      100     110     120     130     140     150     160
GATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTAC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AATGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGCACTGATTAAGTGGCATCTACCGGTAC
160     170     180     190     200     210     220

      170     180     190     200     210     220     230
ACTGGAGTCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTACCATCAGCACTGTGCAG
| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
AGTGGAGTCCCTGATCGCTTCAAGGCAGTGGATCTGGGACAGATTTCACTCTACCATCAGCAATGTGCGG
230     240     250     260     270     280     290

      240     250     260     270     280     290     300
GCTGAAGACCTGGCAGTTTATTTCTGTGACGAGGATTATAGCT---CTCCGTACACGTTCCGAGGGGGGACC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TCTGAAGACTTGGCAGAGTATTTCTGTGACGAATATAACAGCTATCCTCTCTACACATTCCGAGGGGGGACC
300     310     320     330     340     350     360
  
```

310
 AAGCTGGAGATC
 || ||||| ||
 AACCTGGAAATAAACGG
 370 380

> 0 <
 0| 0 IntelliGenetics
 > 0 <


FastDB - Fast Pairwise Comparison of Sequences
 Release 5.4

Results file us-07-977-702-2.res made by shears on Tue 15 Jun 93 11:04:41-PDT.

Query sequence being compared:US-07-977-702-2 (1-318)
 Number of sequences searched: 125798
 Number of scores above cutoff: 4066

Results of the initial comparison of US-07-977-702-2 (1-318) with:
 Data bank : EMBL-NEW 3, all entries
 Data bank : GenBank 75, all entries
 Data bank : GenBank-NEW 3, all entries
 Data bank : UEMBL 34_75, all entries

100000-
 -
 N -
 U50000-
 M -
 B -
 E - ***
 R - *
 - *
 D -
 F10000-
 - *
 S - * *
 E 5000-
 Q -
 U - *
 E -*
 N -
 C - *
 E -
 S 1000- *
 - *
 500-
 - *
 - *
 - *
 - **
 - *
 100* *
 - * * * * *



PARAMETERS

| | | | |
|---------------------|---------|-----------------|----|
| Similarity matrix | Unitary | K-tuple | 4 |
| Mismatch penalty | 1 | Joining penalty | 30 |
| Gap penalty | 1.00 | Window size | 32 |
| Gap size penalty | 0.33 | | |
| Cutoff score | 0 | | |
| Randomization group | 0 | | |

| | | | |
|--------------------------|----|--------------------|----|
| Initial scores to save | 40 | Alignments to save | 15 |
| Optimized scores to save | 0 | Display context | 50 |

SEARCH STATISTICS

| Scores: | Mean | Median | Standard Deviation |
|---------|------|--------|--------------------|
| | 27 | 27 | 11.35 |

| Times: | CPU | Total Elapsed |
|--------|-------------|---------------|
| | 00:28:23.05 | 00:58:37.00 |

| | |
|--------------------------------|-----------|
| Number of residues: | 150464018 |
| Number of sequences searched: | 125798 |
| Number of scores above cutoff: | 4066 |

Cut-off raised to 21.
 Cut-off raised to 26.
 Cut-off raised to 29.
 Cut-off raised to 32.
 Cut-off raised to 34.
 Cut-off raised to 36.
 Cut-off raised to 39.
 Cut-off raised to 41.
 Cut-off raised to 43.
 Cut-off raised to 46.
 Cut-off raised to 49.
 Cut-off raised to 52.
 Cut-off raised to 56.

The scores below are sorted by initial score.
 Significance is calculated based on initial score.

A 100% identical sequence to the query sequence was not found.

The list of best scores is:

| Sequence Name | Description | Length | Score | Score | Init. Opt. | Sig. | Frame |
|---|-------------------------------|--------|-------|-------|------------|------|-------|
| **** 23 standard deviations above mean **** | | | | | | | |
| 1. MUSOHP57K | Mus musculus mRNA for Ig kapp | 322 | 298 | 300 | 23.87 | 0 | |
| 2. S63304 | Vk28 VkJk [not specified, Gen | 322 | 295 | 297 | 23.61 | 0 | |
| 3. MUSSCETK | Mus musculus DNA for Ig kappa | 322 | 295 | 297 | 23.61 | 0 | |
| 4. MMIGRF28 | Murine MRL-RF28L mRNA for IgM | 398 | 295 | 298 | 23.61 | 0 | |
| 5. MUSIGKCPF | Mouse Ig active kappa-chain (| 938 | 290 | 293 | 23.17 | 0 | |
| 6. MMIGKL | Mouse mRNA for Ig C.C58 M75 k | 938 | 290 | 293 | 23.17 | 0 | |
| **** 22 standard deviations above mean **** | | | | | | | |
| 7. S60946 | mAb BA.N4:4.57 V kappa region | 300 | 287 | 289 | 22.91 | 0 | |
| 8. MMVL105 | Mouse mRNA for kappa-immunogl | 321 | 287 | 290 | 22.91 | 0 | |
| 9. MUSIGKVM | Mouse Ig germline kappa-chain | 1816 | 280 | 294 | 22.29 | 0 | |
| 10. S60873 | Ab2 kappa chain V region mA | 300 | 278 | 279 | 22.11 | 0 | |
| **** 21 standard deviations above mean **** | | | | | | | |
| 11. MMNPCRLB6 | M.musculus NPCRLB6 mRNA for i | 321 | 273 | 275 | 21.67 | 0 | |
| 12. MUSIGKCNK | Mouse Ig rearranged kappa-cha | 456 | 272 | 275 | 21.58 | 0 | |
| 13. MMNPCRLB1 | M.musculus NPCRLB1 mRNA for i | 321 | 271 | 273 | 21.50 | 0 | |
| 14. MUSIGKVN | Mouse Ig germline kappa-chain | 2002 | 270 | 284 | 21.41 | 0 | |
| 15. MUSIGKCKP | Mouse Ig kappa-chain mRNA V-r | 341 | 269 | 272 | 21.32 | 0 | |
| 16. MUSIGLAFF | Mouse Ig kappa-chain mRNA V r | 318 | 268 | 271 | 21.23 | 0 | |
| 17. S51704 | hybridoma antibody kappa-chai | 313 | 266 | 266 | 21.06 | 0 | |
| 18. MUSIGKAF0 | Mouse Ig active kappa-chain m | 313 | 266 | 266 | 21.06 | 0 | |
| 19. MUSIGLAFD | Mouse Ig kappa-chain mRNA V r | 315 | 266 | 266 | 21.06 | 0 | |
| 20. MUSIGKAL | Mouse Ig active kappa gene: M | 739 | 266 | 269 | 21.06 | 0 | |
| **** 20 standard deviations above mean **** | | | | | | | |
| 21. MMVL3190 | Mouse mRNA for kappa-immunogl | 321 | 264 | 264 | 20.88 | 0 | |
| 22. MUSIGKCSR | Mouse Ig active kappa-chain m | 321 | 262 | 265 | 20.70 | 0 | |
| 23. MUSIGKAAV | Mouse Ig rearranged kappa-cha | 363 | 262 | 270 | 20.70 | 0 | |
| 24. MUSIGKAO | Mouse Ig kappa active gene: k | 765 | 261 | 263 | 20.61 | 0 | |
| 25. S51746 | hybridoma antibody kappa-chai | 276 | 260 | 261 | 20.53 | 0 | |
| 26. MUSIGKAFV | Mouse Ig active kappa-chain m | 275 | 259 | 260 | 20.44 | 0 | |
| 27. MMBV1745L | M.musculus light chain variab | 324 | 259 | 261 | 20.44 | 0 | |
| 28. MUSIGKAJ | mouse ig kappa mna from mopc | 943 | 259 | 262 | 20.44 | 0 | |
| 29. MMIGK9 | Messenger RNA for mouse immun | 943 | 259 | 262 | 20.44 | 0 | |
| 30. MUSIGKAJA | Mouse Ig kappa active mRNA fr | 462 | 258 | 261 | 20.35 | 0 | |
| 31. MUSNC41 | Mus musculus NC41 mRNA, parti | 324 | 257 | 260 | 20.26 | 0 | |
| 32. MMIGKV | Mouse mRNA for immunoglobulin | 462 | 257 | 259 | 20.26 | 0 | |
| 33. M245877S1 | anti-human erbB-2 receptor bi | 894 | 257 | 260 | 20.26 | 0 | |
| 34. MUSIGKAE0 | Mouse Ig active kappa chain m | 321 | 256 | 258 | 20.17 | 0 | |
| 35. MUSIGLAA | Mouse rearranged light chain | 354 | 256 | 260 | 20.17 | 0 | |
| 36. HUMIGLIA | Human Ig light chain VJ regio | 618 | 256 | 258 | 20.17 | 0 | |
| 37. S115039 | immunoglobulin light chain va | 411 | 255 | 259 | 20.09 | 0 | |
| **** 19 standard deviations above mean **** | | | | | | | |
| 38. MUSIGKCNM | Mouse Ig active kappa chain m | 321 | 254 | 259 | 20.00 | 0 | |
| 39. MUSIGLAB | Mouse rearranged light chain | 357 | 254 | 260 | 20.00 | 0 | |
| 40. MUSIGLAFE | Mouse Ig kappa-chain mRNA V r | 303 | 253 | 257 | 19.91 | 0 | |

1. US-07-977-702-2 (1-318)

MUSOHP57K Mus musculus mRNA for Ig kappa chain precursor.

LOCUS MUSOHP57K 322 bp ss-mRNA ROD 11-NOV-1992
 DEFINITION Mus musculus mRNA for Ig kappa chain precursor.
 ACCESSION D12733
 KEYWORDS Ig kappa chain; steroid specific antibody; variable region.
 SOURCE Mus musculus (strain BALB/c) hybridoma cell line OHP57.G6.1 mRNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Mammalia; Rodentia; Muridae.
 REFERENCE 1 (bases 1 to 322)
 AUTHORS Sawada,J., Mizusawa,S., Terao,T., Naito,M. and Kurosawa,Y.

TITLE Molecular characterization of monoclonal anti-steroid antibodies:
 primary structures of the variable regions of seven antibodies
 specific for 17alpha-hydroxyprogesterone or 11-deoxycortisol and
 their pH-reactivity profiles
JOURNAL Mol. Immunol. 28, 1063-1072 (1991)
STANDARD full automatic
COMMENT Submitted (27-JUL-1992) to DDBJ by: Jun-ichi Sawada
 Dept. of Biochem. and Immunochem.
 National Institute of Hygienic Sciences
 1-18-1 Kamiyoga
 Setagaya, Tokyo 158
 Japan
 Phone: 03-3700-1141 x240
 Fax: 03-3707-6950.
FEATURES Location/Qualifiers
 mat_peptide 1..>322
 /product="Ig kappa chain"
 /codon_start=1
 /note="VJ region (1-322)"
 CDS <1..>322
 /product="Ig kappa chain precursor"
 /codon_start=1
 /translation="SIVMTQTPKFLIRAGDRVMTCKASQ SARNGVAVYQQKPGQSP
 KLLIYYTSDRYTGVPDRFTGSGYGTDFFTISTVQAEDEVAVYFCQQVYSSPYTFGGGT
 KLEIK"
BASE COUNT 86 a 76 c 84 g 76 t
ORIGIN

Initial Score = 298 Optimized Score = 300 Significance = 23.87
 Residue Identity = 94% Matches = 300 Mismatches = 18
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTATAAGAGCAGGAGACAGGGTCACCATGACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAGTGCGAGAAATGGTGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
      80      90     100     110     120     130     140

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTACT
|| |||
TACTATACATCCGATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTACT
     150     160     170     180     190     200     210

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTAC
|||||
TTCACCATCAGCACTGTGCAGGCTGAAGACGTGGCAGTTTATTTCTGTGTCAGCAGGTTATAGTTCTCCGTAC
     220     230     240     250     260     270     280

290      300      310      X
ACGTTCTGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCTGGAGGGGGGACCAAGCTGGAATAAAAC
290      300      310      320
  
```

2. US-07-977-702-2 (1-318)

S63304 VkJ28 VkJk [not specified, Genomic, 322 nt]

LOCUS S63304 322 bp DNA 03-JAN-1992
 DEFINITION Vk28 VkJk [not specified, Genomic, 322 nt]
 ACCESSION S63304
 KEYWORDS .
 SOURCE not specified
 ORGANISM Unclassified.
 Unclassified.
 REFERENCE 1 (bases 1 to 322)
 AUTHORS Sawada,J., Mizusawa,S., Terao,T., Naito,M. and Kurosawa,Y.
 TITLE Molecular characterization of monoclonal anti-steroid antibodies:
 primary structures of the variable regions of seven antibodies
 specific for 17 alpha-hydroxyprogesterone or 11-deoxycortisol and
 their pH-reactivity profiles.
 JOURNAL Mol. Immunol. 28, 1063-1072 (1991)
 STANDARD full automatic
 COMMENT This entry [NCBI gibbsq 63304] was created by the journal scanning
 component of NCBI/GenBank at the National Library of Medicine.
 This sequence comes from Fig 5.
 FEATURES
 CDS
 Location/Qualifiers
 1..322
 /partial
 /note="Description: Vk28 VkJk; kappa chain variable and
 joining region; For the protein sequence (NCBI gibbsq
 63309): Method: conceptual translation with partial
 peptide sequencing. This sequence comes from Fig 6."
 /product="monoclonal antibody SCET.M8.1"
 /codon_start=1
 /translation="SIVMT@TPKFLHVSVGDRVTITCKAS@SVRNAVVWY@QKTGLSP
 RLLIYYASNRYTGVPDRFTGSGYGTDFLTIRSVEAEDLAVYFC@NFKSPYTFGGGT
 KLEIK"
 BASE COUNT 87 a 72 c 84 g 79 t
 ORIGIN

Initial Score = 295 Optimized Score = 297 Significance = 23.61
 Residue Identity = 93% Matches = 297 Mismatches = 21
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCATGTATCAGTAGGAGACAGGGTTACCATAACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAGTGTGAGGAATGCTGTAGTTTGGTACCAACAGAAGACAGGGCTGTCTCCTAGACTGCTGATA
      80      90     100     110     120     130     140

      150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACT
|| |||||
TACTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACT
      150     160     170     180     190     200     210

      220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTCAGCAGGATTATAGCTCTCCGTAC
|||||
CTCACCATCAGAAGTGTGGAGGCTGAAGACCTGGCAGTTTATTTCTGTCAGCAGAAATTTAAGTCTCCGTAC
      220     230     240     250     260     270     280

      290     300     310     X
ACGTTCGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCGGAGGGGGGACCAAGCTGGAATAAAAC
      290     300     310     320

```

3. US-07-977-702-2 (1-318)

MUSSCETK Mus musculus DNA for Ig kappa chain precursor.

LOCUS MUSSCETK 322 bp ds-DNA ROD 11-NOV-1992
 DEFINITION Mus musculus DNA for Ig kappa chain precursor.
 ACCESSION D12737
 KEYWORDS Ig kappa chain; steroid specific antibody; variable region.
 SOURCE Mus musculus (strain BALB/c) hybridoma cell line SCET.M8.1.1 DNA.
 ORGANISM Mus musculus
 Eukaryota; Animalia; Chordata; Mammalia; Rodentia; Muridae.
 REFERENCE 1 (bases 1 to 322)
 AUTHORS Sawada,J., Mizusawa,S., Terao,T., Naito,M. and Kurosawa,Y.
 TITLE Molecular characterization of monoclonal anti-steroid antibodies:
 primary structures of the variable regions of seven antibodies
 specific for 17alpha-hydroxyprogesterone or 11-deoxycortisol and
 their pH-reactivity profiles
 JOURNAL Mol. Immunol. 28, 1063-1072 (1991)
 STANDARD full automatic
 FEATURES Location/Qualifiers
 mat_peptide 1..>322
 /product="Ig kappa chain"
 /codon_start=1
 /note="VJ region (1-322)"
 CDS <1..>322
 /product="Ig kappa chain precursor"
 /codon_start=1
 /translation="SIVMTQTPKFLHVSVDRTITCKASQSVRNAVVWYQ@KTLSP
 RLLIYYASNRYTGVPDRFTGSGYGTDFLTIRSVEAEDLAVYFC@QNFKSPYTFGGGT
 KLEIK"
 BASE COUNT 87 a 72 c 84 g 79 t
 ORIGIN

Initial Score = 295 Optimized Score = 297 Significance = 23.61
 Residue Identity = 93% Matches = 297 Mismatches = 21
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGATGTATCAGTAGGAGACAGGGTTACCATAACCTGCAAG
X      10      20      30      40      50      60      70

```

```

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAGTGTGAGGAATGCTGTAGTTTGGTACCAACAGAAGACAGGGCTGTCTCCTAGACTGCTGATA
      80      90     100     110     120     130     140

```

```

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCAC
||
TACTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCAC
     150     160     170     180     190     200     210

```

```

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTAC
|||||
CTCACCATCAGAAGTGTGGAGGCTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATTAAGTCTCCGTAC
     220     230     240     250     260     270     280

```

```

290      300      310      X
ACGTTCTGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCTGGAGGGGGGACCAAGCTGGAAATAAAC

```

4. US-07-977-702-2 (1-318)

MMIGRF28 Murine MRL-RF28L mRNA for IgM (kappa)-light chain

LOCUS MMIGRF28 398 bp RNA ROD 04-AUG-1992
 DEFINITION Murine MRL-RF28L mRNA for IgM (kappa)-light chain V(kappa)28, J(kappa) 1
 ACCESSION X14622
 KEYWORDS autoantibody; Ig kappa light chain; Ig light chain; IgM; immunoglobulin; variable region.
 SOURCE mouse
 ORGANISM Mus musculus
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia; Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 398)
 AUTHORS Kofler, R.
 TITLE Direct Submission
 JOURNAL Submitted (07-MAR-1989) Kofler R., General and Experimental Pathology, University of Innsbruck, Fritz-Pregl-Str.3, A-6020 Innsbruck, Austria.
 STANDARD full automatic
 REFERENCE 2 (bases 1 to 362)
 AUTHORS Kofler, R., Duchosal, M.A. and Dixon, F.J.
 TITLE Complexity, polymorphism, and connectivity of mouse V-kappa gene families
 JOURNAL Immunogenetics 29, 65-74 (1989)
 STANDARD full automatic
 COMMENT *source: strain=MRL/Mp-lpr/lpr;
 *source: haplotype=Ig(kappa)(a);
 *source: tissue=spleen;
 *source: cell_type=hybridoma;
 *source: cell_line=MRL-RF28;
 Data kindly reviewed (24-jul-1989) by Kofler R.
 FEATURES
 CDS
 18..>398
 /note="IgM; (kappa)-light chain precursor"
 /codon_start=1
 /translation="MKSQTQVFIFLLLCVSGAHGSIVMTQTPKFLPVSAGDRVMTCKASQSVGNVVAWYQKPGQSPKLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVEDLAVYFCQGHYSSPWTFGGGTKLEIK"
 CDS
 18..77
 /note="signal peptide; (AA -20 to -1)"
 /codon_start=1
 /translation="MKSQTQVFIFLLLCVSGAHG"
 CDS
 78..>398
 /note="mature IgM; (kappa)-light chain (AA 1-107)"
 /codon_start=1
 /translation="SIVMTQTPKFLPVSAGDRVMTCKASQSVGNVVAWYQKPGQSPKLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVEDLAVYFCQGHYSSPWTFGGGTKLEIK"
 BASE COUNT 102 a 97 c 100 g 99 t
 ORIGIN
 Initial Score = 295 Optimized Score = 298 Significance = 23.61
 Residue Identity = 93% Matches = 298 Mismatches = 20
 Gaps = 0 Conservative Substitutions = 0

X 10 20
 AGTATTGTGATGACCCAGACTC
 |||||
 AGACCCAGGTCTTCATATTTCTACTGCTGTGTGCTGGTGCTCATGGAGTATTGTGATGACCCAGACTC
 30 40 50 60 70 80 90


```

30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||| ||| ||||||||||||||||||| ||||||||||||||||||| |||
CCAAATTCCTGCTGTATCAGCAGGAGACAGGGTTACCATGACCTGCAAGGCCAGTCAGAGTGTGGGTAATA
100      110      120      130      140      150      160      170

100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||||| ||||||||||||||||||| ||||||||||||||||||| |||||||||||||||||||
ATGTAGCCTGGTACCAACAGAAGCCAGGACAGTCTCCTAAACTGCTGATATACTATGCATCCAATCGCTACA
180      190      200      210      220      230      240

170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||| ||||||||||||||||||| ||||| ||||||||||||||||||| |||||||
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTTCACTTTCACCATCAGCAGTGTGCAGG
250      260      270      280      290      300      310

240      250      260      270      280      290      300      310
CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGC
||||| ||||||||||||||||||| ||||||||||| ||||| ||| |||||
TTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGCATTATAGCTCTCCGTGGACGTTCCGTGGAGGCACCAAGC
320      330      340      350      360      370      380

X
TGGAGATC
||| |||
TGGAAATCAAA
390 X

```

5. US-07-977-702-2 (1-318)

MUSIGKCPF Mouse Ig active kappa-chain (V-J-C) mRNA from C.C5

```

LOCUS      MUSIGKCPF      938 bp ss-mRNA      ROD      15-SEP-1989
DEFINITION Mouse Ig active kappa-chain (V-J-C) mRNA from C.C58 m75 myeloma.
ACCESSION  M12177
KEYWORDS   constant region; immunoglobulin light chain; immunoglobulin-kappa;
           joining region; processed gene; variable region.
SOURCE      Mouse C.C58 m75 myeloma cDNA to mRNA, clone p9.
ORGANISM    Mus musculus
           Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
           Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
REFERENCE   1 (bases 1 to 938)
AUTHORS     Goldrick,M.M., Boyd,R.T., Ponath,P.D., Lou,S.Y. and Gottlieb,P.D.
TITLE       Molecular genetic analysis of the VkSer group associated with two
           mouse light chain genetic markers
JOURNAL     J. Exp. Med. 162, 713-728 (1985)
STANDARD    full automatic
FEATURES     Location/Qualifiers
             sig_peptide      36..95
                               /codon_start=1
                               /note="Ig kappa chain (V-J-C) signal peptide"
             mat_peptide      96..737
                               /codon_start=1
                               /note="Ig kappa chain (V-J-C) mature peptide"
             misc_recomb      380..381
                               /note="V region end/J region start"
             misc_recomb      416..417
                               /note="J region end/C region start"
             CDS               36..739
                               /partial
                               /note="Ig kappa chain; (V-J-C)"
                               /codon_start=1
                               /translation="MKSQTQVFIFLLLCVSGAHGSIVHTQTPKFLPVSAGDRVNTCK
                               ASQSVGNVVAWYQGGKPGQSPKLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVED

```

LAVIFCGQHTTSPPTFGGKLEINRADAAPTIVSIFPPSSEGLTSGGASVVCFLNNFY
 PKDINVKWKIDGSRQNGVLNSWTDQDSKDYSSSTLTLTKEVERHNSYTCEATH
 KTSTSPIVKSFNRNECX"

BASE COUNT 248 a 260 c 206 g 224 t
 ORIGIN

Initial Score = 290 Optimized Score = 293 Significance = 23.17
 Residue Identity = 92% Matches = 293 Mismatches = 25
 Gaps = 0 Conservative Substitutions = 0

X 10 20
 AGTATTGTGATGACCCAGACTC

|||||

AGACCCAGGTCTTCATATTTCTACTGCTCTGTGTCTGGTGCTCATGGGAGTATTGTGATGACCCAGACTC

50 60 70 80 90 X 100 110

30 40 50 60 70 80 90

CCAAATTCCTGCTTGTTCACGAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG

|||||

CCAAATTCCTGCTGTATCAGCAGGAGACAGGGTTACCATGACCTGCAAGGCCAGTCAGAGTGTGGGTAATA

120 130 140 150 160 170 180

100 110 120 130 140 150 160

ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA

|||||

ATGTAGCCTGGTACCAACAGAAGCCAGGACAGTCTCCTAAATTGCTGATATACTATGCATCCAATCGCTACA

190 200 210 220 230 240 250 260

170 180 190 200 210 220 230

CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG

|||||

CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTTCACTTTCACCATCAGCACTGTGCAGG

270 280 290 300 310 320 330

240 250 260 270 280 290 300 310

CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGACCAAGC

|||||

TTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAACATTATACCTCTCCTCCGACGTTCCGTTGGAGGCACCAAGC

340 350 360 370 380 390 400

X

TGGAGATC

|||

TGGAAATCAATCGGGCTGATGCTGCACCAACTGTATCCATCTTCCACCATCCAGTGA

410 X 420 430 440 450 460

6. US-07-977-702-2 (1-318)

MMIGKL Mouse mRNA for Ig C.C58 M75 kappa light chain (VK)

LOCUS MMIGKL 938 bp RNA ROD 07-MAY-1992
 DEFINITION Mouse mRNA for Ig C.C58 M75 kappa light chain (VK Ser-group)
 ACCESSION X02816 M12177
 KEYWORDS constant region; Ig light chain; immunoglobulin; joining region;
 signal peptide; variable region.
 SOURCE mouse
 ORGANISM Mus musculus
 Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
 Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 REFERENCE 1 (bases 1 to 938)
 AUTHORS Goldrick,M.M., Boyd,R.T., Ponath,P.D., Lou,S.Y. and Gottlieb,P.D.
 TITLE Molecular genetic analysis of the VkSer group associated with two
 mouse light chain genetic markers
 JOURNAL J. Exp. Med. 162, 713-728 (1985)
 STANDARD full automatic
 COMMENT BALB/C mice germline V(K1) region see MMIG25, C(K) region see

Data kindly reviewed (24-FEB-1986) by P.D. Gottlieb.

```

FEATURES             Location/Qualifiers
     misc_feature     165..197
                       /note="put. CDR1"
     misc_feature     243..263
                       /note="put. CDR2"
     misc_feature     360..380
                       /note="put. CDR3"
     misc_feature     381..382
                       /note="CC is TG in germline J(K1) of BALB/ C"
     misc_feature     416
                       /note="T is A in germline J(K1) of BALB/C"
     misc_feature     710
                       /note="C is T in germline C(K) of BALB/C"
     CDS               36..737
                       /note="(K)L-chain precursor"
                       /codon_start=1
                       /translation="MKSQTQVFIALLCVSGAHGSIVMTQTPKFLPVSAGDRVTMTCK
ASQSVGNVAVYQKPGQSPKLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVED
LAVYFCQHHYTSPTFGGGTKLEINRAAAPTVSIFPPSSEQLTSGGASVVCFLNNFY
PKDINVKWKIDGSEKQNGVLNSWTDQDSKDYSTYMSSTLTLTKEYERHNSYTCEATH
KTSTSPIVKSFNREC"
     CDS               36..95
                       /note="signal peptide; (aa -20 to -1)"
                       /codon_start=1
                       /translation="MKSQTQVFIALLCVSGAHG"
     CDS               96..737
                       /note="mature; (K)L-chain (aa 1-214)"
                       /codon_start=1
                       /translation="SIVMTQTPKFLPVSAGDRVTMTCKASQSVGNVAVYQKPGQSP
KLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVEDLAVYFCQHHYTSPTFGGGT
KLEINRAAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSEKQNGVL
NSWTDQDSKDYSTYMSSTLTLTKEYERHNSYTCEATHKTSTSPIVKSFNREC"
     CDS               96..380
                       /note="V region"
                       /codon_start=1
                       /translation="SIVMTQTPKFLPVSAGDRVTMTCKASQSVGNVAVYQKPGQSP
KLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVEDLAVYFCQHHYTSP"
     CDS               381..416
                       /note="J region"
                       /codon_start=1
                       /translation="PTFGGGTKLEIN"
     CDS               417..737
                       /note="C region"
                       /codon_start=1
                       /translation="RAAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKID
GSEKQNGVLNSWTDQDSKDYSTYMSSTLTLTKEYERHNSYTCEATHKTSTSPIVKSF
NRREC"

```

BASE COUNT 248 a 260 c 206 g 224 t
ORIGIN

Initial Score = 290 Optimized Score = 293 Significance = 23.17
Residue Identity = 92% Matches = 293 Mismatches = 25
Gaps = 0 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                |||
AGACCCAGGTCTTCATATTCTACTGCTCTGTGTCTGGTGCTCATGGGAGTATTGTGATGACCCAGACTC
 50      60      70      80      90      X 100      110

 30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
|||||

```

```

120      130      140      150      160      170      180
CCAAATTCCTGCTGATACGACAGGAGACAGGGTTACCATGACCTGCAAGGCCAGTCAGAGTGTGGGTAATA

100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||||| |||||||||||||||||| |||||||||| |||||||||| |||||||||| ||||||||||
ATGTAGCCTGGTACCAACAGAAGCCAGGACAGTCTCCTAAATTGCTGATATACTATGCATCCAATCGCTACA
190      200      210      220      230      240      250      260

170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||| |||||||||||||||||| ||||| |||||||||| |||||||||| |||||||
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTTCACTTTCACCATCAGCAGTGTGCAGG
270      280      290      300      310      320      330

240      250      260      270      280      290      300      310
CTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGGACCAAGC
||||| |||||||||||||||||| ||||| ||||| ||||||| || || |||||
TTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAACATTATACCTCTCCTCCGACGTTCCGTGGAGGCACCAAGC
340      350      360      370      380      390      400

X
TGGAGATC
|||||
TGGAAATCAATCGGGCTGATGCTGCACCAACTGTATCCATCTTCCCAACCATCCAGTGA
410 X 420 430 440 450 460

```

7. US-07-977-702-2 (1-318)

S60946 mRNA BA.N4:4.57 V kappa region [mice, B cell hybrid

```

LOCUS      S60946      300 bp      mRNA      ROD      08-JAN-1992
DEFINITION mAb BA.N4:4.57 V kappa region [mice, B cell hybridoma, BALB/c,
            mRNA, 300 nt]
ACCESSION  S60946
KEYWORDS   .
SOURCE     mice BALB/c B cell hybridoma
ORGANISM   Unclassified.
            Unclassified.
REFERENCE  1 (bases 1 to 300)
AUTHORS    Carlsson,L., Andersson,A. and Holmberg,D.
TITLE      Germ-line origin of functional idiotypic interactions:
            identification of two idiotypically connected, natural antibodies
            that are encoded by germ-line gene elements.
JOURNAL    Eur. J. Immunol. 21, 2285-2288 (1991)
STANDARD   full automatic
COMMENT     This entry [NCBI gibbsq 60946] was created by the journal scanning
            component of NCBI/GenBank at the National Library of Medicine.
            This sequence comes from Fig.2.
FEATURES   Location/Qualifiers
            misc_feature 1..300
                        /note="This feature applies to a gene which lacks a coding
                        region feature. Description: mAb BA.N4:4.57 V kappa
                        region"
BASE COUNT 74 a 69 c 77 g 77 t 3 others
ORIGIN

```

Initial Score = 287 Optimized Score = 289 Significance = 22.91
Residue Identity = 96% Matches = 289 Mismatches = 11
Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
||||| |||||||||||||| |||||||||| |||||||||| |||||||||| |||||||
AGTATTGTGATGACCCAGACTCCNNAATTCCTGCTTGTATCAGCAGGAGAGAGGGTTACCATAACCTGCAAG
X      10      20      30      40      50      60      70

```

```

      80      90      100      110      120      130      140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGAGTGTGAGTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
      80      90      100      110      120      130      140

      150      160      170      180      190      200      210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTACT
||
TACTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTACT
      150      160      170      180      190      200      210

      220      230      240      250      260      270      280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTGAGCAGGATTATAGCTCTCCGTAC
|||||
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGNAGTTTATTTCTGTGAGCAGGATTATAGCTCTCCGTGG
      220      230      240      250      260      270      280

290      X      310
ACGTTTCGGAGGGGGACCAAGCTGGAGATC
|||||
ACGTTTCGGTGGGA
290      300

```

8. US-07-977-702-2 (1-318)

MMVL105 Mouse mRNA for kappa-immunoglobulin light chain V-

```

LOCUS      MMVL105      321 bp      RNA      ROD      04-AUG-1992
DEFINITION Mouse mRNA for kappa-immunoglobulin light chain V-J region (cell
line 105-2H)
ACCESSION  X51852
KEYWORDS   Ig kappa light chain; Ig light chain; immunoglobulin;
joining region; variable region.
SOURCE      mouse
ORGANISM    Mus musculus
Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
REFERENCE  1 (bases 1 to 321)
AUTHORS     Reininger,L.
TITLE       Direct Submission
JOURNAL     Submitted (16-FEB-1990) Reininger L., Dept of Pathology , Centre
Medical Universitaire, 1 rue michel servet, CH-1211 Geneve 4,
Switzerland.
STANDARD   full automatic
REFERENCE  2 (bases 1 to 321)
AUTHORS     Reininger,L., Shibata,T., Ozaki,S., Shirai,T., Jaton,J.C. and
Izui,S.
TITLE       Variable region sequences of pathogenic anti-mouse red blood cell
autoantibodies from autoimmune NZB mice.
JOURNAL     Eur. J. Immunol. 20, 771-777 (1990)
STANDARD   full automatic
COMMENT     *source: strain=New Zealand black; *source: cell_type=hybridoma B;

*source: cell_line=105-2H.
FEATURES
  CDS
    <1..321
    /note="kappa-Ig light chain (107 AA)"
BASE COUNT  81 a      72 c      82 g      78 t      8 others
ORIGIN

```

```

Initial Score      =      287  Optimized Score      =      290  Significance = 22.91
Residue Identity   =      91%  Matches              =      291  Mismatches   =      26
Gaps               =           1  Conservative Substitutions      =           0

```

```

      10          20          30          40          50          60          70
AGTATTGTGATGACCCAGACTCCCAAATTCTGCTTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAA
|| |||||| | ||||||| ||||||| |||| ||||||| ||||||| ||||||| ||||||| |||||||
GAG-ATTGTGTTGACCCAGACTCCNNAATTCTGCTTGTA TCAGTAGGAGACAGGGTTACCATAACCTGCNA
X           10           20           30           40           50           60           70

      80          90          100         110          120          130          140
GGCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGAT
||||| ||||||| ||||||| | ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
GGCCAGTCAGAGTGTGAAGAATGATGTTGGNTGGTACCAACAGNAGCCAGGGCAGTCTCCTAAATTGCTGAT
      80          90          100         110          120          130          140

      150         160         170         180         190         200         210
ATATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCAC
|| | ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| |||||||
ATACTATGCATCCAATCGCTACACTGGAATCCCTGATCGCTTCACTGGCAGTGGACATGGGACGGATTTCAC
      150         160         170         180         190         200         210

      220         230         240         250         260         270         280
TTTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTCAGCAGGATTATAGCTCTCCGTA
||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||| |||||||
TTTCACCATCAGCACTGTGCAGGCTGAAGACCTGGNNGTTTATTTCTGTCAGCAGGATNATACCTCTCCGTG
      220         230         240         250         260         270         280

      290          300          310          X
CACGTTCGGAGGGGGACCAAGCTGGAGATC
 ||||||| || ||||||| |||||
GACGTTCGGTGGAGGGACCAAGCTGAAATAAAA
      290          300          310          320

```

9. US-07-977-702-2 (1-318)

MUSIGKVM Mouse Ig germline kappa-chain V-region gene V-Ser.

| | | | | |
|-------------|---|----------------|-----|-------------|
| LOCUS | MUSIGKVM | 1816 bp ds-DNA | ROD | 30-JUN-1987 |
| DEFINITION | Mouse Ig germline kappa-chain V-region gene V-Ser. | | | |
| ACCESSION | M14360 | | | |
| KEYWORDS | constant region; germline; immunoglobulin-kappa; variable region. | | | |
| SOURCE | Mouse (Balb/c) liver DNA, clone EM3.BALB-1. | | | |
| ORGANISM | Mus musculus | | | |
| | Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria; | | | |
| | Eutheria; Rodentia; Myomorpha; Muridae; Murinae. | | | |
| REFERENCE | 1 (bases 1 to 1816) | | | |
| AUTHORS | Boyd,R.T., Goldrick,M.M. and Gottlieb,P.D. | | | |
| TITLE | Structural differences in a single gene encoding the V-k-Ser group of light chains explain the existence of two mouse light-chain genetic markers | | | |
| JOURNAL | Proc. Natl. Acad. Sci. U.S.A. 83, 9134-9138 (1986) | | | |
| STANDARD | full automatic | | | |
| FEATURES | Location/Qualifiers | | | |
| exon | <916..964 | | | |
| | /number=1 | | | |
| | /note="Ig kappa-chain precursor V-Ser" | | | |
| sig_peptide | join(916..964,1179..1189) | | | |
| | /codon_start=1 | | | |
| | /note="Ig kappa-chain signal peptide" | | | |
| sig_peptide | 916..964 | | | |
| | /codon_start=1 | | | |
| | /note="Ig kappa-chain signal peptide" | | | |
| intron | 965..1178 | | | |
| | /note="IgK intron A" | | | |
| exon | 1179..>1474 | | | |
| | /number=2 | | | |
| | /note="Ig kappa-chain precursor V-Ser" | | | |
| sig_peptide | 1179..1189 | | | |
| | /codon_start=1 | | | |

```

mat_peptide 1190..1474
              /note="Ig kappa-chain signal peptide"
              /partial
              /codon_start=1
              /note="Ig kappa-chain"
idNA         1475..>1816
              /note="V-J intervening DNA (5' end +/- 1 bp)"
CDS          join(916..964,1179..1473)
              /partial
              /partial
              /note="Ig kappa-chain precursor V-Ser"
              /codon_start=1
              /translation="MKSQTQVFVFLLCVSGAHGSIVMTQTPKFLLVSAGERVTITCK
ASQSVSNDAWYQKPGQSPKLLIYYASNRYTGVDPDRFTGSGYGTDFTFITISTVQAE
LAVYFCQQDYSSP"
BASE COUNT   482 a    385 c    354 g    595 t
ORIGIN       1297 bp upstream of KpnI site; chromosome 6.

```

```

Initial Score = 280 Optimized Score = 294 Significance = 22.29
Residue Identity = 92% Matches = 301 Mismatches = 17
Gaps = 9 Conservative Substitutions = 0

```

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                |||||
GTGTAAATGTGTATCCTCATTATTTATCTCTGATTGCAGGTGCTCATGGGAGTATTGTGATGACCCAGACTC
1140      1150      1160      1170      1180      1190      1200      1210

      30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
|||||
CCAAATTCCTGCTTGTATCAGCAGGAGAGAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGAGTAATG
1220      1230      1240      1250      1260      1270      1280

      100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
|||||
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATACTATGCATCCAATCGCTACA
1290      1300      1310      1320      1330      1340      1350

      170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
|||||
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
1360      1370      1380      1390      1400      1410      1420

      240      250      260      270      280      290      300
CTGAAGACCTGGCAGTTTATTCTGTGTCAGCAGGATTATAGCTCTCCGTACAC-GTTC-GGAG-GGGGGAC-C
|||||
CTGAAGACCTGGCAGTTTATTCTGTGTCAGCAGGATTATAGCTCTCCTCCACAGTGCTTCAGCCTCCTACAC
1430      1440      1450      1460      1470      1480      1490

      310      X
AA----GCTGGAGA-TC
||  || ||| ||
AAACCTCCTTGAGAGTCTCACAGCTGTGGCCTTGACAGTTCCTCCCTCTGCCTGGAGCAGCGATTCA
1500      1510      1520      1530      1540      1550      1560

```

10. US-07-977-702-2 (1-318)

S60873 Ab2 kappa chain V region | mAb F {V/J junction} [m

```

LOCUS       S60873      300 bp      mRNA           ROD      08-JAN-1992
DEFINITION  Ab2 kappa chain V region | mAb F {V/J junction} [mice, MLR-lpr/lpr,
              mRNA Partial, 300 nt]
ACCESSION   S60873

```

KEYWORDS .
 SOURCE mice MLR-lpr/lpr
 ORGANISM Unclassified.
 Unclassified.
 REFERENCE 1 (bases 1 to 300)
 AUTHORS Koizumi,T., Puccetti,A., Migliorini,P., Barrett,K.J. and
 Schwartz,R.S.
 TITLE Molecular heterogeneity of auto-anti-idiotypic antibodies in
 MLR-lpr/lpr mice.
 JOURNAL Eur. J. Immunol. 21, 2185-2193 (1991)
 STANDARD full automatic
 COMMENT This entry [NCBI gibbsq 60873] was created by the journal scanning
 component of NCBI/GenBank at the National Library of Medicine.
 This sequence comes from Fig.6.

FEATURES Location/Qualifiers
 misc_feature 1..300
 /note="This feature applies to a gene which lacks a coding
 region feature. Description: Ab2 kappa chain V region |
 mAb F"

BASE COUNT 74 a 77 c 71 g 76 t 2 others
 ORIGIN

Initial Score = 278 Optimized Score = 279 Significance = 22.11
 Residue Identity = 93% Matches = 279 Mismatches = 21
 Gaps = 0 Conservative Substitutions = 0

X 10 20 30 40 50 60 70
 AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
 |||||
 AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATGACCTGCAAG
 X 10 20 30 40 50 60 70

80 90 100 110 120 130 140
 GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
 |||||
 GCCAGTCAGAGTGTGGGTAATAATGTAGCTTGGTACCAACAGAAGCCAGGACAGTCTCCTAANCTGCTGATA
 80 90 100 110 120 130 140

150 160 170 180 190 200 210
 TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTCACT
 |||||
 TACTATGCATCCAATCGCTACACTGGNGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTCTCACT
 150 160 170 180 190 200 210

220 230 240 250 260 270 280
 TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGGATTATAGCTCTCCGTAC
 |||||
 TTCACCATCAGCAGTGTGCAGGTTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGCATTATAGCTCTCCATT
 220 230 240 250 260 270 280

290 X 310
 ACGTTCGGAGGGGGGACCAAGCTGGAGATC
 |||||
 ACGTTCGGCAGC
 290 300

11. US-07-977-702-2 (1-318)

MMNPCRLB6 M.musculus NPCRLB6 mRNA for immunoglobulin light c

ID MMNPCRLB6 standard; RNA; ROD; 321 BP.
 XX
 AC X70097; X51612;
 XX
 DT 19-MAR-1993 (Rel. 35, Created)
 DT 19-MAR-1993 (Rel. 35, Last updated, Version 1)

XX
 DE M.musculus NPCRLB6 mRNA for immunoglobulin light chain, variable
 DE region
 XX
 KW immunoglobulin light chain variable region.
 XX
 OS Mus musculus (mouse)
 DC Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
 DC Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
 XX
 RN [1]
 RP 1-321
 RA Izui S.;
 RT ;
 RL Submitted (05-FEB-1993) on tape to the EMBL Data Library by;
 RL S. Izui, Dept. of Pathology, Centre Medical Universitaire, 1, Rue
 RL Michel Servet, CH-1211, geneva 4, SWITZERLAND
 XX
 CC *source: strain=C57BL/6;
 CC *source: tissue=lymphoid;
 CC *source: cell_type=hybridoma;
 CC *source: cell_line=CB6;
 CC *source: is_germline=N;
 XX
 FH Key Location/Qualifiers
 FH
 FT CDS <1..>321
 FT /codon_start=1
 FT /product="immunoglobulin light chain, variable region"
 XX
 SQ Sequence 321 BP; 88 A; 80 C; 78 G; 75 T; 0 other;

Initial Score = 273 Optimized Score = 275 Significance = 21.67
 Residue Identity = 86% Matches = 275 Mismatches = 43
 Gaps = 0 Conservative Substitutions = 0

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG
|||||
GACATTGTGATGACCCAGTCTCACAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAG
X      10      20      30      40      50      60      70

      80      90     100     110     120     130     140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
|||||
GCCAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATT
      80      90     100     110     120     130     140

     150     160     170     180     190     200     210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTCACT
|||
TACTCGGCATCCTACCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACGGATTCTCACT
     150     160     170     180     190     200     210

     220     230     240     250     260     270     280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTGTCAGCAGGATTATAGCTCTCCGTAC
|||||
TTCACCATCAGCAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTGTCAGCAACATTATAGTACTCCGTAC
     220     230     240     250     260     270     280

     290     300     310     X
ACGTTCGGAGGGGGGACCAAGCTGGAGATC
|||||
ACGTTCGGAGGGGGGACCAAGCTGGAATAAAA
     290     300     310     320
  
```

12. US-07-977-702-2 (1-318)
MUSIGKCNK Mouse Ig rearranged kappa-chain mRNA, clone AN12K.

LOCUS MUSIGKCNK 456 bp ss-mRNA ROD 15-MAR-1990
DEFINITION Mouse Ig rearranged kappa-chain mRNA, clone AN12K.
ACCESSION M19914 J03832
KEYWORDS constant region; immunoglobulin light chain; immunoglobulin-kappa;
processed gene.
SOURCE Mouse (BALB/c) mature B cell, cDNA to mRNA, clone AN12K.
ORGANISM Mus musculus
Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
REFERENCE 1 (bases 1 to 56)
AUTHORS Rule,G.S.
JOURNAL Unpublished (1988) Stanford U., Chem. Dept., Stanford CA 94305.
STANDARD full automatic
REFERENCE 2 (bases 1 to 456)
AUTHORS Leahy,D.J., Rule,G.S., Whittaker,M.M. and McConnell,H.M.
TITLE Sequence of 12 monoclonal anti-dinitrophenyl spin-label anti-bodies
for NMR studies
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 85, 3661-3665 (1988)
STANDARD full automatic
COMMENT Draft entry and computer-readable sequence [2] kindly submitted by
G.Rule, 20-JUL-1988.

FEATURES Location/Qualifiers
sig_peptide 19..90
/codon_start=1
/note="Ig kappa-chain signal peptide"
mat_peptide 91..456
/partial
/codon_start=1
/note="Ig kappa-chain"
CDS 19..455
/partial
/partial
/note="Ig kappa-chain precursor"
/codon_start=1
/translation="MGIKHESQIQVFVFVFLWLSGVDGDIVMTQSHKFMSTSVGDRVS
ITCKASQDVSTAVAWYQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSV
QAEDLAVYYCHQHYSSPYTFGGGTKLEIKRADAAPTVSIFPPSX"
BASE COUNT 118 a 114 c 108 g 116 t
ORIGIN

Initial Score = 272 Optimized Score = 275 Significance = 21.58
Residue Identity = 86% Matches = 276 Mismatches = 42
Gaps = 1 Conservative Substitutions = 0

```

                                     X      10      20
                                     AG-TATTGTGATGACCCAGACT
                                     || ||||| ||||| ||
CAGATTCAGGTCTTTGTATTCTGTTCTCTGGTTGTCTGGTGTGACGGAGACATTGTGATGACCCAGTCT
40      50      60      70      80      90      100     110

      30      40      50      60      70      80      90
CCCAAATTCCTGCTTGTGTTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAAT
| ||||| || ||||| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
CACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGAGTACT
120     130     140     150     160     170     180

100     110     120     130     140     150     160
GATGTAGCTTGGTACCAACAGAACCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTAC
| ||||| ||||| ||||| || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GCTGTAGCCTGGTATCAACAAAAACAGGACAATCTCCTAAACTACTGATTTACTCGGCATCTACCGGTAC
190     200     210     220     230     240     250
```

```

170      180      190      200      210      220      230
ACTGGAGTCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACCTTCACCATCAGCACTGTGCAG
|||||
ACTGGAGTCCTGATCGCTTCACTGGCAGTGGATCTGGGACGGATTTCACCTTCACCATCAGCACTGTGCAG
260      270      280      290      300      310      320

240      250      260      270      280      290      300
GCTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGGATTATAGCTCTCCGTACACGTTCCGAGGGGGGACCAAG
|||||
GCTGAAGACCTGGCAGTTTATTACTGTCTATCAACATTATAGTTCTCCGTACACGTTCCGAGGGGGGACCAAG
330      340      350      360      370      380      390

310      X
CTGGAGATC
|||||
CTGGAATAAAACGGGCTGATGCTGCACCAACTGTATCCATCTTCCCACCATCCAGT
400      410      420      430      440      450

```

13. US-07-977-702-2 (1-318)

MMNPCRLB1 M.musculus NPCRLB1 mRNA for immunoglobulin light c

```

ID  MMNPCRLB1 standard; RNA; ROD; 321 BP.
XX
AC  X70095; X51612;
XX
DT  19-MAR-1993 (Rel. 35, Created)
DT  19-MAR-1993 (Rel. 35, Last updated, Version 1)
XX
DE  M.musculus NPCRLB1 mRNA for immunoglobulin light chain, variable
DE  region
XX
KW  immunoglobulin light chain variable region.
XX
OS  Mus musculus (mouse)
OC  Eukaryota; Animalia; Metazoa; Chordata; Vertebrata; Mammalia;
OC  Theria; Eutheria; Rodentia; Myomorpha; Muridae; Murinae.
XX
RN  [1]
RP  1-321
RA  Izui S.;
RT  ;
RL  Submitted (05-FEB-1993) on tape to the EMBL Data Library by:
RL  S. Izui, Dept. of Pathology, Centre Medical Universitaire, 1, Rue
RL  Michel Servet, CH-1211, geneva 4, SWITZERLAND
XX
CC  *source: strain=C57BL/6;
CC  *source: tissue=lymphoid;
CC  *source: cell_type=hybridoma;
CC  *source: cell_line=CB1;
CC  *source: is_germine=N;
XX
FH  Key          Location/Qualifiers
FH
FT  CDS          <1..>321
FT              /codon_start=1
FT              /product="immunoglobulin light chain, variable region"
XX
SQ  Sequence 321 BP; 87 A; 81 C; 77 G; 76 T; 0 other;

```

```

Initial Score   =   271  Optimized Score   =   273  Significance = 21.50
Residue Identity =   85%  Matches           =   273  Mismatches   =   45
Gaps            =       0  Conservative Substitutions   =       0

```

```

X      10      20      30      40      50      60      70
AGTATTGTGATGACCCAGACTCCCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAG

```

```

|||||
GACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTTGGAGACAGGGTCAGCATCACCTGCAAG
X      10      20      30      40      50      60      70

      80      90      100      110      120      130      140
GCCAGTCAGAGTGTGACTAATGATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATA
||||| ||||| || || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
GCCAGTCAGGATGTGAGTACTGCTGTAGCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATT
      80      90      100      110      120      130      140

      150      160      170      180      190      200      210
TATTATGCATCCAATCGCTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTCTCACT
|| | ||||| | || ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TACTCGGCATCCTACCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACGGATTCTCACT
      150      160      170      180      190      200      210

      220      230      240      250      260      270      280
TTCACCATCAGCACTGTGCAGGCTGAAGACCTGGCAGTTTATTTCTGTACAGCAGGATTATAGCTCTCCGTAC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
TTCACCATCAGCAGTGTGCAGCCTGAAGACCTGGCAGTTTATTACTGTACGAACATTATAGTACTCCGTAC
      220      230      240      250      260      270      280

290      300      310      X
ACGTTCCGAGGGGGGACCAAGCTGGAGATC
||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
ACGTTCCGAGGGGGGACCAAGCTGGAAATAAAA
290      300      310      320

```

14. US-07-977-702-2 (1-318)

MUSIGKVN Mouse Ig germline kappa-chain V-region gene V-Ser.

LOCUS MUSIGKVN 2002 bp ds-DNA ROD 30-JUN-1987

DEFINITION Mouse Ig germline kappa-chain V-region gene V-Ser.

ACCESSION M14361

KEYWORDS constant region; germline; immunoglobulin-kappa; variable region.

SOURCE Mouse (C.58) liver DNA, clones EMC58-[5,7,10].

ORGANISM Mus musculus

Eukaryota; Animalia; Chordata; Vertebrata; Mammalia; Theria;
Eutheria; Rodentia; Myomorpha; Muridae; Murinae.

REFERENCE 1 (bases 1 to 2002)

AUTHORS Boyd,R.T., Goldrick,M.M. and Gottlieb,P.D.

TITLE Structural differences in a single gene encoding the V-k-Ser group
of light chains explain the existence of two mouse light-chain
genetic markers

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 83, 9134-9138 (1986)

STANDARD full automatic

FEATURES Location/Qualifiers

exon <1071..1119

/number=1

/note="Ig kappa-chain precursor V-Ser"

sig_peptide join(1071..1119,1335..1346)

/codon_start=1

/note="Ig kappa-chain signal peptide"

sig_peptide 1071..1119

/codon_start=1

/note="Ig kappa-chain signal peptide"

intron 1120..1334

/note="IgK intron A"

exon 1335..1630

/number=2

/note="Ig kappa-chain precursor V-Ser"

sig_peptide 1335..1346

/codon_start=1

/note="Ig kappa-chain signal peptide"

mat_peptide 1347..1630

```

partial
/codon_start=1
/note="Ig kappa-chain"
iDNA 1631..>2002
/note="V-J intervening DNA (5' end +/- 1 bp)"
CDS join(1071..1119,1335..1629)
/partial
/partial
/note="Ig kappa-chain precursor V-Ser"
/codon_start=1
/translation="MKSQTQVFIFLLLCVSGAHGSIVMTQTPKFLPVSAGDRVMTCK
ASQSVGNVAVYGGQKPGQSPKLLIYYASNRYTGVPDRFTGSGSGTDFTFTISSVQVED
LAVYFCQQHYSSP"

```

BASE COUNT 533 a 421 c 376 g 672 t
 ORIGIN 1 bp upstream of EcoRI site; chromosome 6.

Initial Score = 270 Optimized Score = 284 Significance = 21.41
 Residue Identity = 88% Matches = 291 Mismatches = 27
 Gaps = 9 Conservative Substitutions = 0

```

                                X      10      20
                                AGTATTGTGATGACCCAGACTC
                                |||||
GTGTAAATGTGTATCCTCATTATTTATCTCTGATTGCAGGTGCTCATGGGAGTATTGTGATGACCCAGACTC
1300      1310      1320      1330      1340      1350      1360

      30      40      50      60      70      80      90
CCAAATTCCTGCTTGTTCAGCAGGAGACAGGGTTACCATAACCTGCAAGGCCAGTCAGAGTGTGACTAATG
||||| ||| |||||
CCAAATTCCTGCTGATCAGCAGGAGACAGGGTTACCATGACCTGCAAGGCCAGTCAGAGTGTGGGTAATA
1370      1380      1390      1400      1410      1420      1430

      100      110      120      130      140      150      160
ATGTAGCTTGGTACCAACAGAAGCCAGGGCAGTCTCCTAAACTGCTGATATATTATGCATCCAATCGCTACA
||||| |||||
ATGTAGCCTGGTACCAACAGAAGCCAGGACAGTCTCCTAAACTGCTGATATACTATGCATCCAATCGCTACA
1440      1450      1460      1470      1480      1490      1500      1510

      170      180      190      200      210      220      230
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATATGGGACGGATTTCACTTTCACCATCAGCACTGTGCAGG
||||| |||||
CTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACAGATTTCACTTTCACCATCAGCACTGTGCAGG
1520      1530      1540      1550      1560      1570      1580

      240      250      260      270      280      290      300
CTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGGATTATAGCTCTCCGTACAC-GTTC-GGAG-GGGGGAC-C
||||| ||||| ||| || ||
TTGAAGACCTGGCAGTTTATTTCTGTCTCAGCAGCATTATAGCTCTCCTCCACAGTGCTTCAGCCTCCTACAC
1590      1600      1610      1620      1630      1640      1650

      310      X
AA----GCTGGAGA-TC
|| || ||| ||
AAACCTCCTTGAGAGTCTCACAGCTGCCTGTCTACATACAGCTGTGGCCTTGACACTTCCCCCTC
1660      1670 X 1680      1690      1700      1710      1720

```

15. US-07-977-702-2 (1-318)

MUSIGKCKP Mouse Ig kappa-chain mRNA V-region (VJ), from hybr

LOCUS MUSIGKCKP 341 bp ss-mRNA ROD 15-MAR-1989
 DEFINITION Mouse Ig kappa-chain mRNA V-region (VJ), from hybridoma
 A003-40/5G7k.
 ACCESSION M17161 J02815
 KEYWORDS immunoglobulin light chain; immunoglobulin-kappa; joining region;
 variable region.

